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ABSTRACT 
 
Human immunodeficiency virus type 1 (HIV-1) is the cause of acquired immune deficiency 
syndrome (AIDS). HIV-1 is a worldwide epidemic that currently affects over 35 million people 
worldwide, and continues to spread at an appalling rate. A universal HIV-1 preventive vaccine is 
considered to be the optimal solution in achieving the ultimate goal of AIDS eradication. 
Regretfully, most endeavors thus far of developing a prophylactic vaccine have been largely 
disappointing. Highly Active Anti-Retroviral Therapy (HAART) has been shown to reduce the 
plasma HIV-1 RNA level to below the detection limit of clinical assays (50 copies/ml); it 
combines three or more antiretroviral drugs which belong to at least two different classes – 
targeting distinct steps in the viral life cycle, and inhibiting viral replication. However, unless the 
infection is eradicated, strict adherence to a lifelong treatment regimen is required. HAART is 
limited by its high cost, drug availability, complicated administration schedules, serious side 
effects, and the potential that the virus will ultimately develop drug resistance. A more plausible 
approach lies in therapeutic vaccines that provide immunity to partially control viral 
replication postinfection – delaying or minimizing ART, and offering “drug holidays”.   
 
The primary goal of a therapeutic vaccine is to effectively induce HIV-1 specific cytotoxic T 
lymphocyte (CTL) responses, which plays a critical role in control of viral proliferation. 
Dendritic cells (DCs)-based therapeutic vaccines have been showing the most promising results. 
However, the therapeutic efficacy of DCs based vaccines is limited. This is partially due to the 
fact that DCs induced CD8+ T cell responses are largely CD4+ T cell dependent, while HIV-1 
infection usually renders the immune system very “helpless” from CD4+ T cells. In addition, 
infection, impaired function, and physical depletion of DCs are often reported during the early 
stage. Furthermore, DCs are often found to be inflammatory and immunosuppressive, which is 
mainly mediated by the interaction between HIV-1 Env gp120 and DC receptors. Thus, the search 
for a novel therapeutic vaccine strategy is warranted. 
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Using T-APC (T cells-antigen-presenting cells) as a novel T cell-based vaccine has emerged as a 
potential candidate for a HIV-1 therapeutic vaccine, which aims at boosting HIV-specific CTL 
responses. Our previous work demonstrated that CD4+ and CD8+ T cells derived from ovalbumin 
(OVA)-specific T cell receptor (TCR) transgenic OT II and OT I mice via co-culture with 
OVA-pulsed DCs (DCOVA) can be activated, acquiring pMHC I, pMHC II, and costimulatory 
molecules, thus act as CD4+ T helper-antigen-presenting cells (Th-APCs) and CD8+ cytotoxic 
T-antigen-presenting cells (Tc-APCs). We also elucidated that DC-derived exosomes (EXO), 
which are 50- to 90-nm diameter vesicles containing antigen-presenting, tetraspan, adhesion, and 
costimulatory molecules, can transfer the antigen-presenting activity of DCs to activated CD4+T 
cells through EXO uptake. EXOOVA-targeted activated CD4+T (aTexo) cells can (1) stimulate 
more efficient central memory CD8+ CTL responses and T cell memory than EXOOVA or DCOVA, 
(2) activate CD8+ CTL responses independent of CD4+Th cells, and (3) counteract 
CD4+25+regulatory T (Tr) cell-mediated immune suppression. These results formed the new 
concept of novel EXO-targeted CD4+ T cell vaccines. 
 
In this study, we tailored EXO-targeted T cells vaccine by using polyclonal activated CD8+ T 
cells instead of CD4+ T cells, as CD4+ T cells served as the primary target for HIV-1 infection. 
We showed that (1) OVA-specific exosome-targeted CD8+ T cell-based vaccine (OVA-Texo) 
can stimulate efficient OVA-specific CD8+ CTL and memory responses, inducing sufficient 
antitumor immunity against OVA-expressing tumor cells in mouse models. (2) This 
exosome-targeted CD8+ T cell-based vaccine strategy could be applied to HIV-1-Gag protein, 
provoking effective Gag-specific CD8+ CTL, T cell memory, and antitumor immunity against 
Gag-expressing tumor cells. (3) Engineering Gag-Texo with up-regulated 4-1BBL (APC derived 
costimulatory molecule) expression could improve the performance of Gag-Texo vaccine. (4) 
OVA-Texo is able to evoke a successful immune response in bystander chronic infection, 
converting CD8+ T cell exhaustion, restoring effector functions of exhausted CD8+ T cells. 
Moreover, combination of OVA-Texo vaccine with PD-L1 blockage in a dual treatment could 
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result in a synergistic effect in rescuing CTLs exhaustion in chronic infection. Those desired 
features make EXO-targeted CD8+ T cells vaccine an appealing novel strategy in HIV-1 
infection. The EXO-targeted CD8+ T cells vaccine may be applicable to therapeutic HIV 
treatment through the use of autologous T cells with uptake of EXOs derived from engineered 
DCs. 
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CHAPTER 1  LITERATURE REVIEW 
 
1.1 Immune system 
 
The immune system is a defense system that many organisms utilize to fight pathogenic 
infections mostly caused by virus/bacterial/fungi/parasites, as well as harmful matters, with the 
help of a variety of immune cells and the molecules they produce in particular organs. Ranging 
from very simple to highly complex, the immune system is comprised of the biological structures 
and processes that stave off disease. Humans have a very intricate immune system[1], which can 
effectively identify and protect against non-self pathogens from the massive number of objects 
we encounter daily; initially through innate immunity, then through adaptive immunity for more 
severe infections.  
 
1.1.1 Innate immunity 
 
The innate immune system is the first line of defense microorganisms would face if they made it 
through the physical barrier – such as skin for external invasions or mucous membranes for 
internal exposed surface (respiratory tract, alimentary tract and genitourinary tract)[2]. It is an 
ancestral and broad response characterized by non-specificity and instantaneity, and can be 
traced to many ancient life forms and found in all modern animals and plants[3].  
 
Most cell components in the innate immune system are derived from the common myeloid 
progenitor, including granulocytes (neutrophil, eosinophil, and basophil), mast cells, 
macrophages, and majority of dendritic cells (DC). The exception lies with nature killer cells as 
they are derived from the common lymphoid progenitor. Nevertheless, their lack of antigen 
specificity makes them part of the innate immunity.  
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When an infection happens, an inflammatory response is triggered[4], during which 
macrophages at the site would recognize, engulf and kill microorganisms. In addition, cytokines 
are released at the site increasing blood vessel permeability causing more proteins and fluid to 
flow into the tissues. The chemokines released via this process attract neutrophils and more 
monocytes to leave bloodstream[5], migrating to the site. The collection of these processes 
working together is responsible for the characteristic symptoms of inflammation: redness, heat, 
swelling and pain. 
 
Neutrophils, macrophage and dendritic cells are the three major phagocytes. They take up 
pathogens through phagocytosis and eliminate them via degradative enzymes and antimicrobial 
substances within the lysosome[6]. Mature dendritic cells are well known by another crucial 
function - the ability to process and present antigens in forms that can be recognized by T 
lymphocytes. Thus they carry another title as antigen-presenting cells (APCs) for their key role 
in activating T lymphocytes and initiating the adaptive immune response[7, 8]. Macrophages can 
also function as APCs in addition to their versatile jobs of activating other immune cells and 
signaling more of them to join the fight, and serving as general scavengers[9].  
 
Eosinophils and basophils are involved in fighting parasites that are usually too large for 
phagocytosis, by the means of producing enzymes and antimicrobial chemicals upon activation 
by antibodies[10]. They are well known for their involvement in allergic reactions along with 
mast cells, where they actually do more harm than good. Mast cells express high-affinity IgE 
antibody receptors on the cell surface. Antigens binding to IgE activate mast cells to release 
inflammatory mediators such as histamine, triggering an allergic response[11]. Nature killer cells 
are important in early stage defense against intracellular infections caused by virus and killing 
abnormal cells such as tumor cells[12]. 
 
The complement system is a major humoral component in the innate immune response[13]. It is 
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an enzyme activated cascade reaction that involves serials of proteases. Each protease’s 
activation depends on the cleavage of its precursor by the upstream enzyme. The active form can 
serve as a protease acting on the next one’s precursor[14]. There are three different pathways to 
trigger a complement reaction: the classic pathway, lectin pathway, and alternative pathway[15]. 
Each pathway is initiated by a distinct set of proteins existing broadly in tissues and body fluids. 
These proteins trigger the cascade by either directly binding to pathogen surface components or 
binding to the antigen/antibody complexes, and thus link the innate and adaptive immune 
response. The three pathways joint at a same point which eventually lead to the generation of the 
same group of active effector molecules[16]. Complement effectors can opsonize pathogens – 
facilitating their uptake by phagocytes; attract inflammatory molecules – augmenting the 
immune response; and directly kill pathogens by forming holes in their membrane. 
 
Innate immune cells recognize microorganisms via pattern recognition receptors (PRRs). These 
receptors can be expressed on both the cell surface or intracellular endosome membranes[17]. 
They are of limited diversity - each receptor can detect a pathogen structural component rather 
than one specific kind of pathogen, and every cell of the same cell type has the same group of 
receptors. Toll-like receptors (TLRs) are the most well studied family of PRRs because of their 
extensive involvement in the innate immune response[18]. Ten TLRs have been identified so far 
in humans[19]. The components recognized by PRRs are often repeated molecules or common 
patterns that are shared by a group of microbes but not self cells, collectively known as 
pathogen-associated molecular patterns (PAMPs). One such example of a PAMP is lipoteichoic 
acid (LTA) which constitutes the cell wall of Gram-positive bacteria can be detected by TLR2. 
Another example is the lipopolysaccharide (LPS) of Gram-negative bacteria detected by TLR4. 
TLR3 recognizes virus originated double-stranded RNA. Bacterial unmethylated CpG DNA is 
detected by TLR-9[20, 21].  
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1.1.2 Adaptive immunity 
 
The role of adaptive immunity comes into play when the innate response is insufficient to 
eradicate an infection. It represents a more evolved mechanism that can only be found in humans 
and other vertebrates[1]. This response usually requires many days and is highly specific. Most 
importantly, it is capable of creating immunological memory that can last for years even a 
lifetime. Thus the foundation to vaccine design and application lies in understanding the adaptive 
immune response. Unlike the innate response which responds the same way to repetitive 
infections, the adaptive response adapts its form to different nature of infections, develops 
quicker and stronger response each successive time to the same pathogen. 
 
Antigen specific lymphocytes including B cells and T cells are the core components of adaptive 
immunity. They are both derived from common lymphoid progenitors; differentiating at bone 
marrow and thymus, respectively[22]. These two sites are referred to as the primary lymphoid 
organs. Naïve lymphocytes that have not been stimiulated by their cognate antigens either 
circulate in the bloodstream or reside in the secondary lymphoid organs (spleen, lymph nodes, 
and mucosal lymphoid organs).  
 
The most important feature of lymphocytes is that each of them bears a unique set of cell surface 
receptors specialized in recognizing a specific antigen. There are no identical receptors shared by 
any two lymphocytes when they are generated[23]. Since each lymphocyte only carries one kind 
of receptor, there has to be an immense lymphocyte pool to provide enormous variety required 
by the adaptive response so that at any time point a proper adaptive immune response could be 
provoked against any antigen a person is likely to encounter. This is made possible by an 
intricate genetic mechanism known as somatic gene segment rearrangements[24]. Briefly, the 
genes responsible for encoding the variable region of a B-cell or T-cell receptor exist as groups 
of gene segments. Randomly selected gene segment from each group undergo recombination to 
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form a DNA sequence that could be translated into a fragment of polypeptides, and this unique 
amino acid arrangement is corresponding to the antigen binding specificity. The diversity of 
receptors is further magnified by introducing changes at the joint point between segments, 
random pairing of heavy chain and light chain, and somatic hypermutation that only occurs for 
B-cell receptors[25]. In total, there are 1011 possibilities in the structure of each receptor. 
Adopting this strategy, the immune system focuses resources and energy on pathogens that 
manage to bypass innate immunity – only lymphocytes with the matching specificity being 
activated to proliferate and their daughter cells inheriting the same receptors forming a big army 
of effector T cells. 
 
B-cell receptors can either be transmembrane or be secreted post activation as an antibody[26]. 
Each has a different immunological effector function regarding pathogen defense. T-cell 
receptors on the other hand are only transmembrane and their function is exclusively to bind to 
the matching antigen on APCs and targeting cells[27]. Another major difference between B-cell 
and T-cell receptors is that instead of recognizing epitopes (molecular features on an antigen 
surface) directly, T-cell receptors only respond to antigens presented in the form of 
peptide-fragments:MHC molecule complexes on APCs and infected cells[28]. The different 
mechanisms of the receptor’s activation reflect the distinct effector functions of B-cells and 
T-cells. Activated B-cells differentiate into effector plasma cells, of which the sole mission is to 
secret antibodies that directly bind to extracellular antigens. In comparison, there are three major 
types of effector T-cells[29]. Cytotoxic T cells kill cells that are infected with intracellular 
pathogens (primarily viruses and intracellular bacteria); helper T cells offer assistance in B cell 
activation by providing additional signal; regulatory T cells are found responsible for immune 
regulation - limiting the damage when an immune response gets out of hand.  
 
Immature dendritic cells consistently sample the peripheral environment through phagocytosis 
and macropinocytosis - engulfing large volume of fluid in a receptor independent manner. 
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Whenever dendritic cells uptake a pathogen, they migrate to secondary lymphoid tissue where 
they become mature dendritic cells able to display antigens in the specific manner as well as 
providing additional signals – all of which requisites for successful T cell activation[30]. The 
three key signals involved in T-cell activation are: 1.antigen-peptide:MHC molecule complex 
binding with TCR comprising the initial activation signal; 2.co-stimulatory molecules displayed 
on mature APCs binding with their ligands on T cells, driving clone expansion and survival; and 
3.cytokines secreted by activated APCs, which often determine the fate of T cells[31]. 
Depending on the type, effector T cells could either migrate to the site of infection or stay in the 
secondary lymphoid organs to activate B cells. Upon activation, a small portion of plasma cells 
(activated B cells) stay in the secondary lymphoid organs, while majority of them migrate to the 
bone marrow, from where they send antibodies out to enter the blood stream[32]. 
 
In addition to dendritic cells and macrophages, mature naïve B cell could also be induced to 
express co-stimulatory molecules and thus act as APCs[33]. Once B-cell receptors (BCRs) on the 
surface of naïve B cells recognize and bind to a specific pathogen, the formed complexes will be 
internalized by B cells, split into peptides by lysosome, and then presented to the corresponding 
T cells.  
 
After successfully eliminating an infection, most effector lymphocytes die through apoptosis. 
Roughly 5% of them survive and become memory cells. Memory T-cells and B-cells are the 
pillar of immune memory. Upon reencountering with the same antigen, memory cells are able to 
differentiate into effector cells in a much shorter amount of time, and elicit a stronger and more 
efficient secondary response to ensure the rapid elimination of invading pathogens.    
 
1.1.2.1 Humoral immunity 
 
Humoral and cellular immunity are the two arms of adaptive immune response. Humoral 
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immunity refers specifically to antibody mediated immune responses. The humoral response is 
named aptly due to its components exiting in blood plasma and bodily fluids. Antibodies 
comprise the immunoglobulin group of biochemistry molecules[26]. They structurally resemble 
the letter ‘Y’, composed of two identical heavy chains and two identical light chains[34]. Each 
arm of antibody carries one antigen epitope binding site, constituted by the top quarter of the 
heavy chain and the top half of the light chain. Those sections are the variable regions that bear 
almost infinite diversity. The remaining three quarters of the heavy chain and the bottom half of 
the light chain constitute the constant region of antibody[35]. The bottom half of the two heavy 
chain form the antibody stem. The constant regions are of very limited variety. One of five forms 
is chosen for an existing antibody - referred to as an isotype. Instead of determining the antigen 
recognizing specificity, the constant region control antibodies’ functional properties[36].  
 
Antibodies are engaged in three distinct immune mechanisms regarding host defense: 
neutralization, opsonization and complement activation[37]. Neutralization is the direct binding 
of small size extracellular pathogens by antibodies, preventing them from entering cells or 
causing further damage. It is mostly effective against viruses and bacterial toxins. However, for 
bigger size pathogens like bacteria and parasites, direct binding is not enough to weaken them. 
This is where opsonization comes into play. Opsonization is the coating of antibodies on 
pathogens. In this case, antibody binding facilitates the recognition and engulfing of pathogens 
by phagocytic cells. This is induced by the binding of surface receptors on phagocytotic cells to 
the stem part of antibody. Another immune mechanism that can be activated by antigen:antibody 
complexes is the complement system. Upstream protease members bind to the pathogen surface 
of the complexes, triggering downstream activities.  
      
1.1.2.2 Cellular immunity 
 
Pathogens that manage to invade host cells, or replicate inside infected cells are less vulnerable 
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to humoral immunity. The help from T lymphocyte mediated immune responses is required in 
this case, forming the concept of cellular immunity. The two major classes of effector T cells- 
cytotoxic T cells and helper T cells carry distinct surface function markers. These markers are 
CD8 and CD4 respectively. Naïve CD4+ T cells can further differentiate into several main 
subtypes of helper T cells: TH1, TH2, TH17 and regulatory T cells[38]. TH 1 cells have dual 
functions. Aside from producing essential co-stimulation signals for B cell activation, TH1 cells 
are also involved in helping macrophages with combating mycobacteria infection[39]. Certain 
intracellular bacteria reside inside sub-cellular vesicles of macrophages. They possess the ability 
to prevent dwelling vesicles from merging with lysosome, stopping further degradation. TH1 
cells bearing receptors for those bacteria activate infected macrophages enabling the fusion, thus 
clearing the infection with lysosomal enzymes and antimicrobial substances. TH2 cells, on the 
other hand, are specialized in the process of B cell activation for antibodies production[40]. TH17 
cells are important in recruiting neutrophils for assisting defense against extracellular pathogens 
at early stage of adaptive immune responses[41].   
 
1.1.2.2.1 Primary T cell response 
 
The activation of CD4+ and CD8+ T cells require two kinds of MHC molecules along with the 
processed antigen peptide to interact with TCR as the first signal (signal one)[42]. The loading of 
the peptide occurs during the synthesis and assembly of the MHC molecule on the endoplasmic 
reticulum (ER) in the cytosol. The complexes are then transported and displayed on the cell 
surface. The two kinds of MHC molecules have very different preference for peptide origin, 
which in turn, tailor the targeting of CD4+ and CD8+ T cells[43]. MHC Class I molecules carry 
peptides derived from proteins that are synthesized in the host cells. The proteins are broken 
down by proteasome in the cytosol. Therefore all the self-peptides and foreign peptides that are 
made with the host cell’s protein-making machinery will be presented. Self-peptides usually do 
not provoke an immune response, whereas all viruses replicate inside the host cells will be 
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exposed, inducing naïve CD8+ T cell activation. These CD8+ T cells then differentiate into 
effector cytotoxic T cells, destroying infected cells[44]. MHC Class II molecules bind to peptide 
originating from extracellular antigens internalized by phagocytic APCs. Those peptides are 
processed in intracellular vesicles, and then loaded on to MHC class II molecules[45]. The 
peptide: MHC II complex is detected by naïve CD4+ T cells, stimulating their differentiation into 
effector helper T cells. These helper T cells go on to assist macrophage functions as well as B 
cell activation. Given this fine division of responsibility, it follows that MHC Class I molecules 
are found on virtually all nucleated cells, whereas MHC Class II molecules are normally 
expressed only on major APCs. The physical interactions between CD4/CD8 and MHC 
molecules are the first step in the activation of the first signal. They are thus known as 
co-receptors of T cells.  
 
The three signals essential for the priming of T cells are generally provided by the same APC. 
The second signal (signal two) is indispensable for T cell activation. Without this signal, T cells 
migrate into an opposite fate; either being targeted for deletion or moving to a non-responsive 
state called anergy or tolerance[46]. The most common co-stimulators are the B7 molecules on 
DC, including B7.1 (CD80) and B7.2 (CD86). The ligand for it is CD28, which is present on the 
surface of all naïve T cells[47]. Several additional co-stimulators expressed by DCs and activated 
T cells are involved in modifying signal two. CD40 molecules on DC are members of the tumor 
necrosis factor receptor family (TNFR). The binding between CD40 and its ligand CD40L on T 
cells promote the activation of T cells, further enhancing the expression of B7 molecules[48]. 
Another pair of co-stimulators that belongs to the TNF receptor family is 4-1BB (CD137) on the 
T cells and 4-1BBL from APCs, which also sends mutual beneficial signals. However, some 
co-stimulators are found to induce the opposite effect. CTLA-4 (CD152) is a CD28 related 
surface protein. The binding of it with B7 delivers an inhibitory signal, hindering further 
expansion of T cells[49-51]. PD-1 on activated T cells binds PD-L1 from APCs leading to 
down-regulation of T cell response [52, 53]. Those inhibitory signals are of great importance for 
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preventing overstimulation of the immune system. The most crucial function of signal two is the 
induction of activated T cells to start synthesizing interleukin-2 (IL-2). IL-2 enables activated T 
cell to enter a robust proliferation phase, which generates thousands of progeny cells possessing 
the same specificity within 4 to 5 days. This process is known as clone expansion. Moreover, 
IL-2 promotes the activated progeny T cells to differentiate into effector T cells.  
 
1.1.2.2.2 Effector CD8+ T cells induce CTL responses 
 
CD8+ T cell mediated cytotoxic T-cell responses are highly important in combating virus 
induced intracellular infection[54]. Once CD8+ T cells become cytotoxic lymphocytes (CTLs), 
they are able to deliver their killing effect on all virus infected target cells. They do so without 
the requirement for co-stimulator signals, inducing target cells to undergo apoptosis[55]. The 
killing effect of CLTs is achieved by releasing cytotoxic granules that contain effector proteins 
including perforin, granzymes and granulysin[56]. A well-ordered immunological synapse is 
built between CTLs and target cells, which helps direct the cytotoxic effector molecules towards 
the target cells in a highly polarized way[57]. CTLs can induce apoptosis of target cells in a 
cytotoxic granules-independent manner[58]. Fas, another TNF family member, is expressed by 
target cells including activated lymphocytes. Its corresponding ligand FasL is found on effector 
CTLs. The interaction of Fas and FasL leads to the recruitment of Fas-associated death domain 
(FADD), eventually activating the caspase pathway. This mechanism is commonly used for 
regulating lymphocyte proliferation after a successful clearance of pathogens, as well as 
promoting self-antigen tolerance[59]. CTLs also secrete effector cytokines like IFN-γ, TNF-α 
and LT-α. They can directly interfere with viral replication, increase the expression of MHC 
Class I molecules on infected cells, as well as enhance macrophage activation[60]. The quality 
and quantity of the CTL response is affected by a number of factors. These include the nature of 
the antigen, inflammatory stimuli, duration of the infection, and so on. 
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1.1.2.2.3 Memory T cell response 
 
The most significant outcome of a primary response is the establishment of immunological 
memory. Once the infection is resolved, 90%-95% of effector CTLs are lost through apoptosis - 
named the contraction phase of the CTL response[61]. The small surviving population is 
composed of long-lived memory cells, which lay the foundation of potentially lifelong immune 
protection[62]. IL-7 and IL-15 are crucial for maintaining long-term survival of CD8+ memory T 
cells[63]. There are two kinds of memory T cells – each with distinct activation 
characteristics[64]. Effector memory T cells express comparatively low levels of lymph node 
homing cytokine receptors CCR7 and CD62L, but are abundant in inflammatory chemokines 
receptors like CCR3, CCR5. They swiftly differentiate into effector T cells upon restimulation. 
On the contrary, central memory T cells are CCR7+CD62Lhigh. They are often found resting in 
peripheral lymphoid tissues, taking longer to mature into effector T cells. The mechanism that 
drives the differentiation of effector cells into either one of those two memory cell phenotypes is 
still under exploration.   
 
1.2 HIV-1 and AIDS 
 
HIV stands for Human Immunodeficiency Virus. It has been identified as the pathogen 
responsible for Acquired Immune Deficiency Syndrome (AIDS)[65-67], which is arguably the 
most extreme case of immune dysfunction. Spread of HIV occurs by contact with bodily fluids - 
commonly through blood, semen, and breast milk. HIV-1 infection is characterized by a 
progressive loss of immune function, increased susceptibility to opportunistic infections and 
cancers. Most HIV-1 infected patients progress to AIDS within 10 years without treatment. After 
AIDS diagnosis, life-expectancy shortens to around 1 year. In 2013, it was estimated that around 
35 million people were living with HIV globally – with 2.1 million new cases arising that year. 
Over 36 million people have died due to HIV-1 infection since its discovery in the 1980’s. 
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1.2.1 HIV-1 virology 
 
HIV-1 is categorized as a type of retrovirus. Retroviruses contain RNA as their genetic material 
and encode for a reverse transcriptase that enables the formation of a dsDNA provirus upon entry 
into a target cell. It falls into a subgroup known as lentiviruses, which are distinguished by their 
long and variable incubation periods[68] and the presence of additional regulatory genes.  
 
1.2.1.1 Structure of HIV-1 
     
The viral particle is roughly spherical in shape[69], with a diameter of approximately 100 
nanometers. It is enclosed by a viral envelope comprised of two layers of phospholipids, taken 
from the host cell plasma membrane during the budding process. Protein Env, which plays a 
central role in the virus entering phase, is embedded in the envelope spiking through the surface. 
Three glycoproteins (gp120) compose the cap of Env, while three gp41 compose the stem part. 
Between the viral envelope and the viral core is matrix protein p17. Two single strands of 
positive sense HIV genomic RNA are surrounded by the conical-shaped viral core, which is 
made of viral capsid protein gag p24.  
 
HIV-1 has a more complicated genome structure than most retroviruses. It contains 9 reading 
frames encoding three standard structure proteins including gag, pol and env, as well as six 
additional regulatory proteins: vif, vpr, tat, rev, vpu, and nef. The HIV-1 primary transcript is 
further spliced, forming an mRNA pool containing more than 25 mRNA. Those mRNA can be 
divided into three classes according to size: the full-length 9Kb mRNA, which will be translated 
into Gag and Gag-Pol proteins, the single-spliced 4Kb mRNA encoding Env, Vif, Vpr and Vpu 
proteins, and the double-spliced 2Kb mRNA generating Tat, Rev and Nef proteins.  
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Vif has been proven to be responsible for preventing antiviral host defense proteins from the 
APOBEC3 family (apolipoprotein B mRNA-editing enzyme catalytic 
polypeptide-like)[70]from being incorporated in virions. APOBEC3 enzymes are DNA cytidine 
deaminases, which induce hypermutation on viral cDNA during reverse transcription to rendering 
HIV-1 non-viable[71]. Nef[71, 72] and Vpu[73] interact with the cytoplasmic tail of CD4 to 
decrease its surface expression, facilitating evasion of immune recognition[74]. Another 
important function of Vpu is counteracting B cell stromal factor 2 (BST-2)[75, 76], also known 
as tetherin – which blocks the releasing of mature viral particles from the host cell surface. 
Vpr[73] possesses the ability to arrest infected cells in the G2 phase of the cell cycle, possibly 
due to the fact that virus replication is more active in the G2 phase. Those four viral proteins are 
usually referred to as “accessory proteins”. Tat proteins accelerate transcription and Rev proteins 
help shuttle unspliced viral mRNA from the nucleus to the cytoplasm. Reverse transcriptase, 
integrase and protease are three enzymes that exist in the viral core. They are crucial for HIV-1 
replication after viral entry. 
 
Based on the genetic heterogeneity, HIV-1 viruses are commonly divided into 3 phylogenetic 
groups: M (major), N (non-M/non-O), and O (outlier)[77]. Group M is predominate and 
responsible for over 90% of HIV-1 cases. There are at least 10 clades within the M group, 
according to their geographically distinct genomes[78]. Clade A is common in central and 
eastern Africa; clade B is found dominantly in Europe, North American, Australia and Thailand; 
clade C is mostly found in China, India, and some parts of Africa[78].  
 
Recombination events between clades are frequently reported, termed as “circulation 
recombinant forms”[79]. Those hybrid forms are attributed to dual infection - individuals 
infected with more than one HIV-1 strain[80]. Two types of dual infections are described: 
1. Coinfection. Infection of two distinct strains happens simultaneously, or within a short 
frame - the second infection happens during acute phase of initial infection.  
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2. Superinfection. Acquiring of the second strain takes place when infection with the initial 
strain is established, presumably after seroconversion but rarely in chronic phase[81].  
It has been suggested by several studies that the immune responses elicited by the initial 
infection are not capable of preventing the second infection[82, 83]. Dual infection is associated 
with more severe disease progression, decrease in CD4+ T cell count, and higher chance of drug 
resistance[84-87].  
 
1.2.1.2 HIV-1 replication cycle 
    
There are generally six steps in the replication cycle of HIV-1[88]. The first step is viral entry 
into the target host cells. The mechanism by which this occurs consists of the binding between 
viral gp120 molecules and CD4 molecules on the cell surface. This triggers a conformational 
change in gp120, enabling a secondary interaction between gp120 and cell surface 
co-receptors[89]. The viral envelope and the cell membrane then fuse, and the viral core is 
essentially injected into the cell[90]. In the next step, HIV-1 reverse transcriptase converts viral 
RNA into DNA using host nucleotides in the cytoplasm of the cell[91]. After that, viral integrase 
carries the newly synthesized dsDNA into nucleus, inserting the viral DNA into the host cell 
chromosome. From here on, viral DNA becomes part of the host genomic DNA. Using host cell 
machinery, both encoding mRNA as well as genomic RNA is transcribed. The encoding 
sequences are then translated into long chains of viral proteins and enzymes. Eventually, all the 
viral components are assembled at the inner surface of the cellular membrane and form an 
immature viral particle, which buds off the host cell. Viral proteases digest the poly-protein chain 
into individual parts. Thus a mature infectious virion is created. This last step marks the 
completion of the entire viral replication cycle for HIV.  
 
1.2.2 HIV-1 pathology 
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HIV-1 targets the most crucial cells in the immune system such as CD4+ helper T cells, dendritic 
cells, and macrophages [92]. This leads to the depletion of CD4+ T lymphocytes and the 
dysfunction of DC, depriving the ability of immune system to fight natural infections – paving 
the way for life-threatening opportunistic infections and malignant tumors. 
 
HIV-1’s entry of the target cell requires the recognition of cell surface receptor CD4 by viral Env 
gp120 and co-receptor CXCR4 for T-tropic strains or CCR5 for M-tropic strains [93, 94]. These 
co-receptors naturally serve as targets for chemokines. CXCR4 is the receptor for the chemokine 
SDF-1 [95, 96], while CCR5 acts as a receptor for the chemokines MIP-1 α and β as well as 
RANTES [97]. The optimal replication of HIV-1 in CD4+ helper T cells requires cell activation. 
An increased level of transcription factors such as NF-κB leads to more effective transcription, 
as well as a higher nucleotide pool in these activated cells allows for more efficient reverse 
transcription[98]. This offers one explanation as to why reverse transcription is not completed in 
quiescent cells[99]. 
 
At the early stage of an infection, DCs in mucosal tissues capture HIV-1 via DC-SIGN[100], 
carrying the virus from mucosal tissues to draining lymph nodes where DC-SIGN promotes HIV 
infection by delivering the virus to CD4+ T cells as well as macrophage/monocyte cells. Thus 
HIV uses DCs as a Trojan horse. HIV-1 induces the killing of infected CD4+ T cells in at least 
three manners: apoptosis of uninfected bystander cells[101], direct killing, and virus specific 
CTL responses of infected cells[102]. 
 
1.2.3 Courses of HIV-1 infection 
 
HIV-1 infection can generally be broken down into four distinct stages. The acute infection stage 
consists of the first 2 to 4 weeks post infection. Most patients experience influenza-like 
symptoms. During this stage, an abundance of virus is generated, primarily in the peripheral 
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circulatory system. From there, it is spread throughout the body with an emphasis on the 
lymphoid organs. The number of CD4+ cells drops profoundly in this phase. However, in the 
next phase, the count of CD4+ T cells rebounds close to ordinary levels, owing to the adaptive 
immune response fighting back with cytotoxic T cells and humoral antibodies – drastically 
reducing viral titers. The infection then enters the clinical latency period. This stage lasts 
anywhere between 6 months to over 20 years and appears quiescent despite the fact that HIV-1 
replicates persistently in the lymphoid organs and CD4+ T cell count continually declines. The 
immune system is eventually damaged to such a degree that the human body is unable to fight 
off other infections. The HIV-1 load in the blood considerably increases while the number of 
CD4+ T cells drops to dangerously low levels. HIV-1-infected patients are diagnosed with AIDS 
when they have one or more opportunistic infections and/or fewer than 200 CD4+ T cells per 
milliliter of blood. 
 
1.2.4 HIV-1 treatment 
 
There is currently no universal effective vaccine or cure for HIV-1. Current therapies for the 
treatment of HIV-1 infection are aimed at developing reagents that interfere with distinct steps in 
the viral life cycle – inhibiting viral replication. Six mechanistic classes of drugs have been 
licensed so far for HIV-1 treatment.  
1. Entry inhibitors (or fusion inhibitors) interfere with viral binding, fusion and entry[103] 
by blocking either gp41 of HIV to form an inactive bundle. An example of this is T20 
(Enfuvirtide). Other drugs such as Maraviroc target co-receptor CCR5 on CD4+ T cells. 
2. Nucleoside-analog Reverse Transcriptase (RT) inhibitors (NRTIs)[104] act as 
competitive substrate inhibitors. They prevent other nucleosides from being incorporated 
because of they lack a 3’OH (hydroxyl) group – thus terminating viral DNA chain 
elongation. Examples of drugs in this class include zidovudine, dideoxyinosine, and 
dideoxycytidine. 
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3. Non-nucleoside-analog RT inhibitors (NNRTIs)[105] on the other hand act as 
non-competitive inhibitors. They bind to a hydrophobic cavity adjacent to the 
polymerase active site of RT, disturbing the handling of substrate nucleotides by the 
enzyme. Examples of drugs in this class are nevirapine, and rilpivirine. 
4. Integrase inhibitors inhibit the enzyme activity of integrase. This is a relatively new class 
of drug and includes Elvitegravir, and Dolutegravir[106]. 
5. Protease inhibitors[107] block encapsidation of precursor proteins into mature viral 
capsids. Drugs in this class include Darunavir, and Atazanavir. 
6. Maturation inhibitors[108-110] target the protease substrate Gag polyprotein precursors 
instead of the enzyme itself. An example of a drug in this category is Bevirimat [99]. 
 
Antiretroviral drugs are commonly used in combination of 3 or more drugs belonging to at least 
two different classes. This is referred to as Highly Active Anti-Retroviral Therapy 
(HAART)[111]. HAART is considered the greatest success in combating HIV[112, 113]. It 
virtually converts HIV infection from a “death sentence” to a long-term chronic infection. 
Unfortunately, drug resistance to most of these agents have been reported due to the rapid 
evolution of HIV in vivo[114, 115]. HARRT has been very effective in reducing viral titers to 
below detection limit and partial recovery of CD4+ T cell levels. However, it is limited by its 
high cost, drug availability, complicated administration schedules, serious side effects, and the 
potential that the virus will ultimately develop drug resistance[116, 117]. It neither cures the 
patient nor does it completely eradicate HIV infection. HIV-1 viral loads rebound quickly if 
treatment ceases[112, 118].  
 
1.2.5 HIV-1 latency and chronic infection  
 
HARRT effectively reduces plasma HIV-1 RNA level from over 10,000 to below 50 copies/ml, 
which is well under the detection limit of clinical assays. However, a stable latent reservoir 
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composed of latently infected resting CD4+ T cells persists despite decades of non-interrupted 
treatment[119, 120]. The latent reservoir is established during primary HIV-1 infection prior to 
the treatment[121]. Although less than one per million resting CD4+ T cells harbor latent 
provirus, they represent the major barrier to the achievement of either a sterilizing cure or a 
functional cure for HIV-1. Naïve CD4+ T cells and memory CD4+ T cells are the two major 
latent reservoir hosts. Latency can be established in both naïve and memory CD4+ T cells 
through direct infection[122]. This is inefficient due to the restrictive host environment (low 
CCR5 expression, limited nucleoside)[99, 123] and the presence of host restriction factors like 
APOBEC3G (low-molecular-mass complex, active form)[124], and SAMHD1 (sterile alpha 
motif (SAM) and histidine/aspartic acid (HD) domain-containing protein 1)[125]. As a result, 
viral DNA is generated in the cell without integration. This is known as pre-integration latency. 
It is unstable and decays rapidly[126, 127]. Post-integration latency mostly happens through 
infection of activated CD4+ T cells, which allows integration of viral dsDNA in the host cell 
genome[128]. The small fraction of activated CD4+ T cells becomes resting memory CD4+ T 
cells, which carry stable provirus that can be reversed upon encountering their cognate antigen. 
Current strategies for purging viral latency are focused on reactivating of provirus without 
inducing global T cell activation. This alone does not eliminate latent reservoir owing to 
defective viral cytopathic effects (CPE) and the host CTL response[129]. Priming of effective 
HIV-1 specific CTL response becomes a pre-requisite[130]. However, CTL exhaustion induced 
by chronic HIV-1 infection complicates the situation[131].  
 
Chronic infection related antigen-specific T cells exhaustion has been intensively studied since 
the early documentations more than a decade ago[132]. Chronic infection with HIV-1[131, 133], 
lymphocytic choriomeningitis virus (LCMV)[134], or adenovirus[135] does not lead to the 
generation of a highly polyfunctional memory T cell pool. Instead, CTLs adopt “exhausted 
phenotypes”, and display an array of dysfunctions in a gradual and orderly manner[136]. Early 
stage dysfunction compromises IL-2 secretion, proliferative capacity, and cytolytic ability. This 
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is followed by decrease in TNF-α production, and then IFN-γ production. In extreme 
circumstances, virus-specific CTLs could be physically deleted[137]. T cell exhaustion is also 
associated with increased and prolonged expression of surface inhibitory receptor molecules, 
such as PD-1, PD-L1, LAG-3, TIM-3, CTLA-4, 2B4 and many others[138]. An increased 
abundance of antigen, increased level of inhibitory receptor expression, lack of help from CD4+ 
T cells, and a longer duration of infection correlate with the severity of exhaustion. The 
PD-1/PD-L1 pathway stands in the spotlight of research due to its great importance in exhaustion 
regulation[139]. In vivo blockage of PD-1/PD-L1 restores effector function of virus-specific 
CD8+ T cells, enhancing virus control during chronic LCMV infection[140]. In HIV-specific 
CTLs, PD-1 expression is related to T cell dysfunction and disease progression[141-143]. In 
vitro targeting of the PD-1/PD-L1 pathway in HIV-infected cells enhanced effector function and 
proliferation[142, 144]. The maintenance of exhausted CD8+ T cells in chronic infection is very 
distinct from that of memory CD8+ T cells in acute infection. They show decreased level of 
homeostatic cytokine receptors CD62L and IL-7R[145], and rely on the presence of their cognate 
antigen for long-term survival[146]. This makes functional recovery of HIV-specific CTLs 
possible after efficient treatments or early epitope escape mutation[147]. Plenty of strategies 
have been exploited to rescue exhausted CD8+ T cells. A dual in vivo treatment combining 
agonist anti-4-1BB Abs with PD-L1 blockage resulted in a vigorous boost in LCMV-specific 
CTL response, and enhanced viral control during chronic LCMV infection[148]. The 
co-stimulator CD40/CD40L pathway has been found to be indispensable for anti-PD-L1 
treatment[149]. Moreover, agonistic anti-CD40 Abs could suppress PD-1 induction and restore 
CTL function[150]. 
 
1.2.6 HIV-1 vaccine and cure 
 
A universal HIV-1 preventive vaccine is considered to be the optimal solution to achieve the 
ultimate goal of AIDS eradication. The ideal characteristics of a prophylactic vaccine should 
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evoke both overall and sterilizing immunity to block infection, prevent the establishment of a 
persistent infection, and finally impede its transmission. April 2015 marks the 31st anniversary 
of the discovery of HIV. The following obstacles are usually held responsible for preventing the 
development of an effective HIV vaccine:  
1. Lack of broad neutralizing Abs: The conserved neutralizing epitopes of Env glycoprotein 
are masked by variable carbohydrates, and only transiently exposed during viral entry. 
The non-neutralizing domain stimulated B cell responses become immunodominant[151]. 
Furthermore, another factor hindering Ab induction is host tolerance deletion, as a result 
of autoreactivity with non-HIV antigens[152, 153]. 
2. Targeting the most essential immune cells: Activated CD4+ T cells are fully permissive to 
viral replication. In other words, the key mediators of both humoral and cellular 
immunity that are currently fighting the infection are the ideal viral targets[154]. 
3. Establishment of viral latency: Once the retroviral genome is integrated into that of 
resting CD4+ T cells, the provirus enters a stage where it is replication-competent but 
transcriptionally quiescent[155]. Latently infected memory CD4+ T cells represent the 
biggest viral reservoir. They cannot be detected by the immune system and serve as the 
major source of viral rebound[156, 157]. 
4. High levels of genetic diversity: HIV is a rapidly evolving virus – it has an extremely 
high mutation rate.  In contrast to the high fidelity of mammalian DNA polymerase α  
(typical error rate 10-4 to 10-5), HIV-1 RT does not correct errors by exonucleolytic 
proofreading, shows relatively high efficiency both regarding misincorporation and 
subsequent extension of mispaired primers. The frequency of nucleotide-substitution 
introduced by HIV-1 RT could reach from 1/2000 to 1/4000[158], which could be 
interpreted as amaximum of 10 mutations per HIV-l genome each round of replication 
considering the process of RNA-ssDNA-dsDNA in the retroviral life cycle. In addition, 
the frequent recombination events and the fast replication cycle - approximately 1010 
virions being produced every day, are contributing to HIV genetic variation[159-161]. 
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5. Direct cell-to-cell transmission: Besides the classic cell-free transmission method, HIV 
infected cells can form virological synapses with uninfected cells to directly spread viral 
particles[162]. This may protect the virus from several biophysical, kinetic, and immune 
effector barriers[163, 164]. 
 
There are a handful of examples where a patient is cured of HIV. The “Berlin patient”[165] who 
suffered from both leukemia and HIV, received a bone marrow stem cell transplant from a donor 
homozygous for a 32-base pair deletion in the HIV-1 coreceptor CCR5, which is naturally 
resistant to HIV infection with R5 tropism[166]. Following transplantation, no persistent HIV 
could be detected – even after the cease of HAART treatment. This is the first and probably the 
only sterilizing cure of established HIV infection[167]. Another case is the “Mississippi baby”, 
who was born infected in 2010, and received early, aggressive HAART treatment for 18 
months[168]. The HIV level remained undetectable within the following one year after HAART 
interruption. The baby was believed to have been cured of HIV until rebound viremia was 
reported after an additional year of follow-up. For functional cure, which is defined as the 
establishment of effective host immunity that provides permanent suppression of HIV replication 
in the absence of ART, rather than a complete eradication, there are elite controllers[169], 
long-term nonprogressors[170], and post-treatment controllers[171]. Post-treatment controllers 
represent a small percentage of patients who were treated early during acute infection[172]. 
 
The above cure examples are considered invaluable for HIV-1 research; unfortunately, they 
cannot be applied to all 35 million HIV patients worldwide. A more realistic approach is to 
develop therapeutic vaccines that provide immunity to partially control viral replication post 
infection. Two major strategies represent the main principle of current HIV-1 therapeutic 
vaccine design: inducing protective neutralizing antibodies to interrupt viral entry via a humoral 
immune response – mostly targeted at Env gp120, and eliciting an HIV-1-specific CTL 
response via a cellular immune response – commonly tested in replication-incompetent viral 
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vectors or autologous DC. 
 
1.3 Therapeutic vaccine for HIV-1 treatment 
 
Therapeutic vaccines seem to be more feasible than prophylactic ones in terms of strategy 
execution and efficacy evaluation. Therapeutic vaccines impose less ethical issues, requiring 
much shorter and more affordable proof-of-concept efficacy assessments. In addition, they are 
more efficient at narrowing down pathogenic epitopes and relevant immune responses that 
should be examined. They could be used in combination with HAART as treatment 
intensification, helping with the purging of the viral reservoir, or as treatment substitution if 
desired efficacy is attained. 
 
1.3.1 Overview of therapeutic vaccine strategies  
 
Traditional approaches for vaccine development include the use of live-attenuated vaccines (oral 
polio, mumps and yellow fever), whole inactivated viruses (hepatitis A, influenza), and 
recombinant proteins (hepatitis B). These approaches have either been considered or tested for 
HIV-1 therapeutic vaccine design. Live-attenuated HIV-1 viruses are considered too risky due to 
the possibility of reverting to virulence via its high mutation rate[150]. Remune, a whole, 
inactivated HIV-1 immunogen lacking protein Env, was unable to induce an enhanced CTL 
response, increase CD4+ T cell count, or diminish viral loads[173, 174]. Recombinant HIV-1 
protein or peptide vaccines such as Env[175-177], Tat[178-180], and Gag p24-like 
peptides[181-183] were exhibiting promising outcomes including improvement of antigen related 
CD4+ and CD8+ T cell responses. Even so, they failed to deliver clinical efficacy or consistent 
immunogenicity. More innovative approaches are based on DNA vectors, recombinant viral 
vectors and DCs. DNA vaccines relying on bacterial plasmids encoding HIV-1 genes were able to 
evoke moderate level of HIV-specific CTL responses. However, there was little indication that 
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they restrained viral replication or had any effect on CD4+ T cell counts[184-186]. Vaccines based 
on live recombinant viral or bacterial vectors have superior efficacy as they create natural 
intercellular infections that provoke an immune response against HIV-1 antigens. Their 
limitations are competition of antigen presentation between engineered HIV-1 proteins and the 
multitude of the vector’s own proteins[187], and pre-existing immunity against the microbe from 
which the vectors are derived – either through endemic infection or vaccination[188]. Virtually 
every viral system, from which molecularly cloned vectors have been developed, has been probed 
for their potential usage as HIV-1 vaccine candidate. Poxvirus vectors are among the best 
characterized viral vectors[189]. The most commonly studied replication deficient poxvirus 
vectors are the Modified Vaccinia Virus Ankara (MVA), NYVAC, canarypox (ALVAC) and 
fowlpox (FPV). The QUEST study was based on ALVAC carrying HIV-1 gene sequence 
epitopes of env, gag, nef and pol[190]. The results were disappointing as there was no change in 
viral rebound, or reduction in viral replication[191]; it was found to be poorly immunogenic[192]. 
FPV vaccine expressing gag/pol and IFN-γ demonstrated improved control of viral replication, 
albeit with no difference regarding CTL responses[193]. MVA inserted with nef[194] or gag 
p24[195] maintained viral load post treatment interruption and increased effector cytokine IFN-γ 
production[196]. Replication deficient recombinant adenovirus type 5 (rAd5) is well known for 
its application in HIV-1 prophylactic vaccine clinical trials[197-199]. In a therapeutic context, 
patients with stable treatment were given rAd5 gag expressing vaccine. In these tests, a significant 
drop in plasma viral load was observed after treatment interruption, however, the impact on viral 
rebound kinetics was modest, and the level of significance was limited[200]. 
 
1.3.2 DC vaccine 
 
DCs, as the most powerful APC initiating both innate and adaptive immune responses, have been 
heavily exploited for HIV-1 vaccine development[201]. The approaches for loading HIV-1 
associated antigens to DC in vitro are quite versatile: pulsing with peptides, recombinant proteins 
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or apoptotic infected cells, or transfecting with antigen-encoding DNA, mRNA or viral vectors. 
Many groups have adequately reported their feasibility. Autologous DC pulsed with HIV-1 
peptides and proteins were safe and brought a stronger HIV-1 specific immune response[202]. A 
recent study using DCs loaded with HIV-1 lipopeptides increased the breadth of immune response 
and effector cytokines, generating polyfunctional CD4+ and CD8+ T cells[203]. The drawbacks of 
this strategy are limited coverage over epitopes, and HLA polymorphism. Several DC 
immunotherapy clinical trials using autologous DC vaccines pulsed with autologous inactive 
HIV-1 virus exhibiting inconsistent levels of CTL response was able to partially reduce viral load 
in distinct scenarios[204-206]. A later study conducted in patients with high CD4+ T cell counts 
with the same heat-inactivated HIV-1 pulsed DC vaccine significantly decreased plasma viral 
loads. This reduction in viral load is associated with an increased HIV-1 specific T cell 
response[207]. The shortcomings are potential risk of infection due to incomplete inactivation, 
and difficulty with standardization. DCs infected with ALVAC carrying HIV-1 genes prior to 
administration showed no difference in viral load rebound[208]. DCs electroporated with cDNA 
or mRNA enhanced antigen specific immunological response, CTL proliferation, and viral 
control[209-211]. Direct in vivo targeting of DCs, through HIV-1 antigens conjugated with 
antibodies of DC membrane molecules such as DC-SIGN or DC205, has been tested in animal 
models[212, 213]. Overall, only five out of thirteen DC based HIV-1 clinical trials elicited 
virological responses[214, 215]. The limited therapeutic efficacy of a DC based vaccine is 
partially due to the following reasons: DC induced CD8+ T cell responses are largely CD4+ T cell 
dependent (HIV-1 infection usually renders the immune system “helpless” from CD4+ T 
cells)[216, 217]; infection, impaired function, and physical depletion of DCs are abundantly 
reported during early stage of HIV infection[218-220]; DCs are often inflammatory and 
immunosuppressive[221, 222], and these responses are mediated by the interaction between 
HIV-1 Env gp120 and DC receptors[223]. 
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1.3.3 T-APC vaccine: a new concept 
 
1.3.3.1 Forming of T-APC via immunological synapse 
 
The concept of T cell-antigen-presenting cells (T-APC) was first raised by Xiang et al. through 
the examination of the transfer of APC associated membrane molecules from APCs to T cells 
during the process of T cell priming[224]. Antigen-peptide:MHC (pMHC) complexes (signal one) 
and co-stimulatory molecules (signal two) of mature APCs cluster in membrane lipid raft 
microdomains[225, 226]. In order to activate T cells, APCs connect with cognate T cell bearing 
TCRs and co-stimulatory molecule ligands. A stable APC-T cell junction forms via this 
interaction, known as an immunological synapse. Immunological synapse is a nanometer scale 
gap comprising two concentric rings. The central supramolecular activation cluster contains 
signal 1 and 2 molecules (pMHC complexes-TCR, APC CD80/86-T cell CD28), and the 
peripheral supramolecular activation cluster contains adhesion molecule ICAM-1 (CD54) of 
APC, which is a major ligand for the integrin leukocyte function-associated antigen-1 (LFA-1) 
on T cells[227, 228]. Consequently, APC-derived surface molecules are transferred to the T cells, 
and subsequently displayed on T cell surfaces by virtue of TCR-mediated internalization 
followed by recycling[229, 230]. This phenomenon is biologically significant – potentially 
changing T cell homing, effector functions, and above all, allowing T cells to act as APCs[231]. 
CD4+ T cells acquire the synapse-composed antigen-presenting machinery (pMHC class I and II, 
costimulatory molecules CD54 and CD80) from APCs and act as CD4+ Th-APCs capable of 
stimulating CTL responses in vitro and in vivo[224]. CD8+ T cells are competent in the same 
manner  - illustrating the concept of CD8+ Tc-APC[232]. 
 
1.3.3.2 A novel exosome-targeted T cell vaccine 
 
In addition to direct interaction, the membrane material of APCs can be transferred to T cells 
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through shedding vesicles. Exosomes are 50-90 nm membrane nanovesicles secreted by virtually 
all types of cells including DCs[233], and formed through the direct fusion between the 
endosome external membrane and plasma membrane. The biological function of exosome 
release was initially proposed as an obsolete mechanism for discarding cellular molecules[234, 
235]. Later their essential role in intercellular communication drew growing attention since they 
can effectively transfer biological active molecules, proteins and RNAs[236]. Exosomes are 
enriched in MHC, costimulatory molecules, adhesion molecules, heat shock proteins (e.g., 
HSP70, HSP90) and tetraspanins. Transfer of exosomes to naïve DCs potentially amplifies 
cellular immune responses[237]. The potential immune function of exosomes derived from 
APCs has been confirmed in many studies[238-240]. DC derived exosomes (Dex) trigger CD4+ 
and CD8+ T cell activation, priming an in vivo CTL response, eradicating established murine 
tumor growth[241]. DC exosome based cancer therapeutic vaccines have been tested in phase I 
and II clinical trials[242]. Exosomes are highly involved in HIV-1 infection. Exosomes 
originating from HIV-1 infected cells contain viral Gag[243] and Nef[244, 245] proteins. The 
exosomal host intrinsic defense protein APOBEC3G confers HIV-1 resistance to exosome 
recipient cells[246]. Exosomes purified from CD8+ T cells mediate noncytotoxic antiviral 
activity by suppressing HIV-1 transcription in both acute and chronic infection models[247]. 
 
Different approaches have been compared in order to maximize the immunogenicity of APC 
derived exosomes. Indirect loading of desired antigens via DC pulsing onto exosomes seems to 
increase their potency in inducing immune responses, compared to direct loading with peptides 
or proteins[248]. Mature DCs are superior to immature DCs since mature DCs release higher 
amount of exosomes. Such exosomes express increased level of immunostimulatory molecules 
pMHC class I and II, CD40, CD80, CD86, ICAM-1, and so on[249, 250]. Furthermore, in many 
studies, exosomes exhibit enhanced immunity when taken up by recipient cells – promoting T 
cell activation leading to tumor eradication[251, 252]. Hao et al. showed that DC acquiring 
exosomes derived from antigen pulsed DCs express high level of exosomal pMHC I, 
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costimulatory molecules, and stimulate antigen specific CTL responses and CD8+ T cell 
memory[253]. T cells can take up Dex as well – although with lower efficiency compared to 
direct cell-to-cell interaction in terms of the amount of membrane immunostimulatory molecules 
transferred[254]. Therefore, Ag-presenting activity of DCs could be acquired by T cells through 
EXO[255]. Activated non-specific T cells adopting antigen-specific Dex are equipped with all 
the exosomal molecules, and become T-APC. EXOOVA-targeted activated CD4+T (aTEXO) cells 
can (1) stimulate more efficient central memory CD8+CTL responses and T cell memory than 
EXOOVA or DCOVA, (2) activate CD8+CTL responses independent of CD4+Th cells, and (3) 
counteract CD4+25+regulatory T (Tr) cell-mediated immune suppression. These results formed 
the new concept of a novel EXO-targeted CD4+ T cell vaccine[256, 257].  
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1.4 Rationale, hypothesis and objectives 
 
HIV-1 infection is a worldwide epidemic that is spreading at an appalling rate. It lays serious 
social and economical impact upon public health. Infection with HIV-1 fails to evoke protective 
immunity in the large majority of the population. The immune response is able to compromise 
the rate of replication but does not eliminate the infection. The acknowledgement that therapeutic 
vaccines can be a more plausible approach has been gaining growing attention in recent years. 
While the induction of broad neutralizing antibodies is typically a key element of prophylactic 
vaccines, therapeutic vaccines generally rely more on provoking cellular immunity. Consistent 
with this principle, Barouch et al. recently revealed their results of a SIV (simian 
immunodeficiency virus) prophylactic vaccine study, elucidating that protective immunity is 
mediated mostly by humoral anti-env antibodies, whereas post infection restraining of viral 
replication is mainly provided by cellular anti-gag response[258]. There exists an abundance of 
evidence supporting the critical role of HIV-1 specific CTLs in control of viral replication[259, 
260]. Of note, up-regulated CTL activity mediated by CD8+ effectors is associated with natural 
resistance to HIV-1 infection among a group of elite controllers[261]. Therefore, many attempts 
have been made or are ongoing for improving the HIV-specific CTL response. 
 
T-APC as a novel T cell based vaccine has emerged as a potential candidate for HIV-1 
therapeutic vaccines, aiming at boosting HIV-specific CTL responses. It provides distinct signals 
for CD8+ T cells priming: exosomal pMHC I complex (signal 1), exosomal costimulatory CD80, 
CD40L (signal 2) and IL-2 cytokine secretion (signal 3)[232]. Exosome targeted T-APCs 
possess unique attributes, such as the stimulation of efficient antigen specific CD8+ CTL 
responses in the absence of CD4+ Th cells, and breaking CD4+25+ Tr cell-mediated immune 
tolerance, which makes EXO-targeted T cells vaccine an appealing novel strategy in HIV-1 
infection. It is worth exploring if EXO-targeted T cells vaccine is applicable therapeutically for 
HIV patient treatment by using autologous T cells with uptake of EXOs derived from engineered 
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DCs[262, 263]. 
 
In this study, we tailored EXO-targeted T cells vaccine by using polyclonal activated CD8+ T 
cells instead of CD4+ T cells. CD4+ T cells served as the primary target for HIV-1 infection[264]. 
Therefore, depletion of CD4+ T cells is the hallmark of disease progression[265, 266]. We 
surmised that (1) OVA-specific exosome-targeted CD8+ T cell-based vaccine (OVA-Texo) can 
stimulate efficient OVA-specific CD8+ CTL and memory responses, inducing sufficient 
antitumor immunity against OVA-expressing tumor cells in mouse model. (2) This 
exosome-targeted CD8+ T cell-based vaccine strategy could be applied to HIV-1- Gag protein, 
provoking effective Gag-specific CD8+ CTL responses, T cell memory, and antitumor immunity 
against Gag-expressing tumor cells. (3) Engineering Gag-Texo with up-regulated 4-1BBL (APC 
derived costimulatory molecule) expression could improve the performance of Gag-Texo 
vaccine. (4) OVA-Texo is able to evoke a successful immune response in bystander chronic 
infection, converting CD8+ T cell exhaustion, restoring effector functions of exhausted CD8+ T 
cells.  
 
In order to test the above hypotheses, the objectives of each corresponding study are as follows. 
In part one: 
1. Generation and characterization of CD8+ OVA-Texo vaccine.  
2. Assessing the ability of CD8+ OVA-Texo vaccine to stimulate OVA-specific CD4+ and CD8+ 
T cell response. 
3. Evaluation of CD8+ OVA-Texo vaccine in stimulating of antitumor immunity and long-term 
memory against BL6-10OVA in C57BL/6 mice. 
In part two: 
1. Generation and characterization of Gag-specific exosome-targeted CD8+ T cell (Gag-Texo) 
vaccine.  
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2. Assessment of Gag-Texo vaccine in stimulating of Gag-specific CD8+ CTL response and 
antitumor immunity against BL6-10Gag in C57BL/6 mice. 
3. Examination of Gag-Texo vaccine in stimulating of protective and therapeutic antitumor 
immunity against BL6-10Gag/A2 in transgenic HLA-A2 mice. 
In part three: 
1. Generation and phenotype analysis of OVA-Texo vaccine with 4-1BBL transgene 
expression. 
2. Investigate if OVA-Texo/4-1BBL vaccine can stimulate enhanced OVA-specific CD8+ effector 
CTL responses and long-term recall memory responses. 
3. Assessment of OVA-Texo/4-1BBL vaccine stimulated therapeutic and long-term antitumor 
immunity against BL6-10OVA in C57BL/6 mice. 
4. Evaluate if Gag-Texo/4-1BBL vaccine exhibits improved antitumor immunity against 
BL6-10Gag/A2 in transgenic HLA-A2 mice. 
 
In part four: 
1. Assessment of CTL exhaustion caused by Adenovirus-OVA induced long-term chronic 
infection in C57BL/6 mice.  
2. Evaluation of immune dysfunction induced by Adenovirus-LacZ long-term chronically 
infected C57BL/6 mice, and the counteraction ability of an OVA-Texo vaccine in bystander 
chronic infection.  
3. Examining if OVA-Texo vaccine can convert exhausted CTLs in Adenovirus-OVA induced 
long-term chronic infected C57BL/6 mice. 
4. Assessing if a dual treatment of OVA-Texo vaccine and PD-L1 blockage can result in a 
synergistic effect in rescuing CTLs from exhaustion in chronic infection. 
5. Investigate if a Gag-Texo vaccine can stimulate antitumor immunity against BL6-10Gag/A2 in 
chronic infected transgenic HLA-A2 mice. 	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2.1 Abstract 
 
The limitations of highly active anti-retroviral therapy (HAART) have necessitated the 
development of alternative therapeutics. In this study, we generated ovalbumin (OVA)-pulsed 
and pcDNAgp120-transfected dendritic cell (DC)-released exosomes (EXOova and EXOgp120) 
and ConA-stimulated C57BL/6 CD8+ T cells. OVA- and Gp120-Texo vaccines were generated 
from CD8+ T cells with uptake of EXOova and EXOgp120, respectively. We demonstrate that 
OVA-Texo stimulates in vitro and in vivo OVA-specific CD4+ and CD8+ cytotoxic T 
lymphocyte (CTL) responses leading to long-term immunity against OVA-expressing 
BL6-10OVA melanoma. Interestingly, CD8+ T cell responses are DC and CD4+ T cell independent. 
Importantly, Gp120-Texo also stimulates Gp120-specific CTL responses and long-term 
immunity against Gp120-expressing B16 melanoma. Therefore, this novel HIV-1-specific 
EXO-targeted Gp120-Texo vaccine may be useful in induction of efficient CTL responses in 
AIDS patients with DC dysfunction and CD4+ T cell deficiency.   
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2.2 Introduction 
 
Acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type-1 
(HIV-1)-infected patients is a rapidly expanding global pandemic, which causes millions of 
death each year. In AIDS patients, severe immune suppression and dysfuction have been found. 
For example, viral Gp120 causes CD4+ T cell death and depletion [1] and dysfunctional dendritic 
cells (DCs) [2] through its binding to CD4 and C-type lectin DC-SIGN, respectively. Highly 
active antiviral therapy (HAART) suppresses viral replication and significantly improve the 
prognosis [3]. However, it does not restore immunity to HIV-1 [4]. Treatment in acute phase of 
human immunodeficiency virus type 1 (HIV-1) infection preserves CD4+ T cells [5], but limits 
CD8+ T cell responses [6], whereas treatment in chronic phase does not restore CD4+ T cells [4, 
5] and CD8+ effector T cells decay with virus [7] leading to  proviral latent reservoirs in AIDS 
patients with chronic infection [8, 9]. New immunotherapeutic strategies [10] are expected to be 
developed to enhance virus control, help to attenuate disease progression during treatment 
interruptions, and limit further usage of HAART, minimizing their toxicity and cost [11].  
 
Neutralization antibodies (Abs) binding to the virus envelope can prevent a virus from entering 
cells. However, in the case of HIV-1 infections, the envelope proteins, which are the primary 
target for neutralization, have evolved multiple pathway to escape elimination by Abs [12]. As 
such, efforts to develop envelop-based HIV-1 vaccines that elicit high and sustained titers of 
broadly cross-neutralizing Abs have been unsuccessful [13, 14]. More and more evidence have 
shown that CD8+ cytotoxic T lymphocytes (CTLs) play a critical role in control of HIV-1 
proliferation [15-17]. Furthermore, CD8+ CTLs appear to work against a wide array of variants, 
selectively targeting and destroying cells that the virus has managed to infect. Therefore, cellular 
immunity plays an important role in controlling the acute phase of infection and disease 
progression even in the absence of neutralizing Abs [18, 19]. Therefore, how to stimulate 
efficient CD8+ CTL responses to clean the entire latent reservoir becomes one of the major 
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challenges in AIDS patients with HAART.  
 
DCs are the most potent antigen-presenting cells (APCs) that can stimulate CD4+ T 
cell-dependent CD8+ CTL responses [20]. DC vaccine for induction of antitumor immune 
responses has been well documented [21]. Late structural proteins such as Gp120 are the major 
targets for HIV-1 vaccines. In the context of DC-based immunotherapy, DCs expressing HIV-1 
antigens (Ags) have also been shown to stimulate HIV-1-specific CD8+ CTL responses both in 
vitro [22, 23] and in vivo in animal models [24-27]. In addition, HIV-1-specific DC vaccine has 
also been applied to clinical trials in AIDS patients [28-31]. However, its therapeutic efficiency 
was very low, possibly due to lacking of functional CD4+ T cells. DCs also process Ags in 
endosomal compartments which can fuse with plasma membrane, thereby releasing Ag 
presenting vesicles called "exosomes" (EXO) [32]. Recently, we have demonstrated that Con 
A-stimulated nonspecific CD4+ T cells with uptake of ovalbumin (OVA) Ag-specific 
DC-released EXO can be used as vaccine capable of inducing CD4+ T cell-independent 
OVA-specific CD8+ CTL responses and antitumor immunity [33]. However, whether CD8+ T 
cells with cytokine profile distinct from CD4+ T cells can be used as vaccine to stimulate 
Ag-specific CD8+ CTL responses after they uptake Ag-specific DC-released EXO is unknown. 
 
In this study, we constructed an expression vector pcDNAgp120 expressing HIV-1 Gp120. We 
generated DCgp120 and BL6-10gp120 cell lines expressing gp120 by transfection of DC cell 
line (DC2.4) and B16 melanoma cell line (BL6-10) with pcDNAgp120, respectively. We then 
generated OVA-pulsed DC (DCova)- and DCgp120-released EXO (EXOova and EXOgp120) 
and ConA-activated polyclonal CD8+ T (ConA T) cells of C57BL/6 mice. By incubation of 
CD8+ ConA T cells with EXOova and EXOgp120, we further generated EXO-targeted T 
(OVA-Texo and Gp120-Texo) cells with uptake of exosomal molecules of EXOova and 
EXOgp120 for vaccination. We demonstrated that OVA-Texo vaccine is capable of stimulating 
DC- and CD4+ T cell-independent OVA-specific CD8+ CTL responses leading to long-term 
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antitumor immunity against OVA-expressing B16 melanoma (BL6-10ova). Importantly, 
Gp120-Texo vaccine also stimulates efficient Gp120-specific CTL responses and long-term 
immunity against Gp120-expressing B16 melanoma (BL6-10gp120). 	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2.3 Materials and methods 
 
2.3.1 Reagents, cell lines and animals.  
 
Ovalbumin (OVA) was obtained from Sigma (St. Louis, MO). OVAI (SIINFEKL) specific for 
H-2Kb and Mut1 (FEQNTAQP) peptide specific for H-2Kb of an irrelevant 3LL lung carcinoma 
were synthesized by Multiple Peptide Systems (San Diego, CA). Biotin-labeled or fluorenscein 
isothiocyanate (FITC)-labeled antibodies (Abs) specific for H-2Kb, Iab, CD8, CD11c, CD25, 
CD40, CD54, CD80, LFA-1, LAMP-1, FITC-conjugated avidin, PE-anti-IFN-γ and 
ECD-anti-CD44 Abs were all obtained from BD Biosciences (Mississauga, Ontario, Canada). 
The goat anti-gp120 polyclonal Ab was obtained from Cedarlane Lab Ltd, Burlington, Ontario, 
Canada. The anti-H-2Kb/OVA I complex (pMHC I) Ab was obtained from Dr. Germain 
(National Institute of Health, Bethesda, MD) [33]. The 5-carboxy-fluorescein diacetate 
succinimidyl ester (CFSE) was obtained from Molecular Probes, Eugene, OR. Expression vector 
pcDNAgp120 expressing HIV-1 Gp120 was constructed by cloning Gp120 gene from 
PConBgp120 vector (NIH AIDS Research and Reference Reagent Program, Bethesda, MD) into 
pcDNA (Invitrogene, Carlsbad, CA) by recombinant DNA technology. OVA gene-transfected 
BL6-10 (BL6-10OVA) melanoma cell line was previously generated in our laboratory [34]. 
BL6-10 tumor cell line was also transfected with pcDNAgp120 or pcDNA to form HIV-1 
Gp120-expressing BL6-10gp120 or BL6-10null by Lipofectamine 2000 (Invitrogene). Female 
C57BL/6 and OVA-specific T cell receptor (TCR)-transgenic OT I and OT II mice and 
diphtheria toxin receptor (DTR)-CD11c transgenic (Tg) mice on a C57BL/6 background were 
obtained from the Jackson Laboratory (Bar Harbor, MA). Dendritic cells of DTR-CD11c Tg 
mice expressing DTR under CD11c promoter can be completely depleted by a single dose of 
diphtheria toxin (DT) treatment (1.5 µg/kg mouse body weight) [35, 36]. All mice were treated 
according to animal care committee guidelines of the University of Saskatchewan. 
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2.3.2 Dendritic cell and exosome preparation.  
 
The wild-type C57BL/6 mouse dendritic cell (DC) line DC2.4 obtained from Dr. K. Rock 
(Dana-Farber Cancer Institute, Boston, Mass) was cultured in DMEM plus 10% fetal calf serum 
(FCS) and IFN-γ (20 ng/ml) and pulsed with OVA (0.5 mg/ml) for overnight. OVA-pulsed 
DC2.4 (DCOVA)-released exosomes (EXOOVA) were purified from its culture supernatants by 
differential ultracentrifugation [33]. To generate CFSE-labeled EXOs, DC2.4 cells were stained 
with 0.5 µM CFSE at 37oC for 20 minutes [37] and then CFSE-labeled EXO (EXOCFSE) were 
harvested and purified from its culture supernatants by differential ultracentrifugation [34]. The 
pcDNAgp120- and the control pcDNA-transfected DC2.4 cells were termed DCgp120 and 
DCnull, respectively. EXOs released by DCgp120 were termed EXOgp120. 
 
2.3.3 RT-PCR analysis 
 
Total RNA was obtained from DCnull and DCgp120 cells or BL6-10null and BL6-10gp120. The 
first-strand cDNA synthesis was performed as described. Two sets of PCR primers were used, 
including the sense (5’ tgatg cactc cttca actgc 3’) and anti-sense primer (5’ tcctg ccaca tgttg atgat 
3’) for gp120 gene, and the sense (5’ ttcgt tgccg gtcca ca 3’) and anti-sense primer (5’ accag 
ggcag cgata tcg 3’) for the control gene β-actin. The protocol employed for amplification of both 
mRNA species comprised: 1 cycle of 94oC (5 min), 52oC (1 min) and 72oC (1 min); and 25 
cycles of 94oC (1 min), 52oC (1 min) and 72oC (1 min). All PCR reaction products were resolved 
using ethidium bromide stained 1% agarose gels[38].  
 
2.3.4 Electron microscopic analysis. 
 
EXOs were fixed in 4% paraformaldehyde. The pellets were then loaded onto carbon-coated 
formvar grids. After incubation in a moist atmosphere for 20 min, the samples were washed 
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twice in PBS and then fixed for 5 min in 1% glutaraldehyde. After washes for three times, the 
EXO sample-loaded grids were stained for 10 min with saturated aqueous uranyl. EXO samples 
were then examined with a JEOL 1200EX electron microscope at 60kV[39]. 
 
2.3.5 Western blot analysis. 
 
EXO samples (10 µg/lane) were loaded onto 12% acrylamide gels, subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and subsequently transferred onto 
nitrocellulose membrane (Millipore, Bedford, MA). The membrane was blocked by incubation 
for 2 hrs at room temperature with ODYSSEY blocking buffer (LI-COR Bioscience, Lincoln, 
NE) and immunoblotted with a panel of Abs specific for gp120, CD54, CD80, LAMP-1 and 
Calnexin at 4 °C for overnight. After washes for three times with PBS containing 0.05% (V/V) 
Tween 20, the membrane was further incubated with goat anti-rat/mouse IRDyeR800CW and 
scanned using ODYSSEY instrument according to manufacture’s instruction (LI-COR 
Bioscience)[39]. 
 
2.3.6 T cell preparation.  
 
Naïve CD8+ or CD4+ T cells were isolated from OVA-specific TCR transgenic OT I or OT II 
mouse spleens, enriched by passage through nylon wool columns (C&A Scientific, Manassas, 
VA), and then purified by negative selection using anti-mouse CD4 or CD8 paramagnetic beads 
(DYNAL Inc, Lake Success, NY) to yield populations that were >98% CD4+/Vα2Vβ5+  or 
CD8+/Vα2Vβ5+ [40]. To generate active CD8+ T cells, the spleen cells from naïve C57BL/6 mice 
were cultured in RPMI1640 medium containing IL-2 (20 U/ml) and ConA (1 µg/ml) for 3 
days[41]. ConA-activated CD8+ T cells were then purified from these activated T cells as 
described above to yield T cell populations that were >98% CD8+ T (ConA T) cells. The culture 
supernatant of ConA CD8+ T cells was used for measurement of cytokine secretion using 
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cytokine ELISA kits (R&D Systems Inc, Minneapolis, MN).   
 
2.3.7 Uptake of EXO by CD8+ T cells.  
 
For assessment of EXO uptake, CD8+ ConA T cells were incubated with different amounts of 
EXOCFSE at 37°C for 1-6 hrs and then analyzed for CFSE expression by flow cytometry and 
confocal microscopy [33]. In another set of experiments, CD8+ T cells were co-cultured with 
EXOCFSE in presence or absence of blocking reagents such as anti-LFA-1 and anti-CD28 Ab (20 
µg/ml), and then analyzed by confocal microscopy[39].  
 
2.3.8 In vitro T cell proliferation assay.  
 
To assess the functional effect of OVA-Texo cells, we performed T cell proliferation assay. The 
irradiated (3,000 rad) OVA-Texo or ConA T (0.6×105 cells/well) cells, DCOVA (0.3×105 
cells/well), and their 2-fold dilutions were cultured with a constant number of naïve OT I CD8+ 
or OT II CD4+ T cells (1×105 cells/well) in a 96-well plate. After culturing for 3 days, 
3H-thymidine incorporation was determined by liquid scintillation counting [33]. 
 
2.3.9 Flow cytometric analysis.  
 
Six days after the immunization, one hundred microliter of blood was taken from the mice with 
i.v. immunization of irradiated (4,000 rad) DCova (1×106 cells/mouse), ConA  T cells, 
OVA-Texo (1×106 cells/mouse), respectively. The blood samples harvested from immunized 
mice at different times after the immunization were then stained with FITC-conjugated anti-CD4 
(FITC-CD4) or anti-CD8 Ab (FITC-CD8) and PE-conjugated Iab/OVAII (OVA265-280) tetramer 
(NIH tetramer facility, Bethesda, MD) and PE-conjugated H-2Kb/OVAI (OVA257-264) tetramer 
(Beckman Coulter, Mississauga, Ontario, Canada), respectively, for 30 min at room temperature 
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and analyzed by flow cytometry [37]. To assess Gp120-Texo-stimulated CTL responses, the 
blood samples harvested from mice immunized with irradiated DCgp120, ConA T and 
Gp120-Texo (1×106 cells/mouse) 6 days after the immunization were stained with PE-conjugated 
anti-CD8 Ab (PE-CD8) and ECD-conjugated anti-CD44 Ab (ECD-CD44) and analyzed by flow 
cytometry. In another set of experiments, the blood samples were first stained with PE-anti-CD8 
Ab and the T cells were then fixed and cell membranes were permeabilized with 
Cytofix/Cytoperm solution (BD Biosciences) and stained with ECD-conjugated anti-IFN-γ Ab 
and then analyzed by flow cytometry[42]. 
 
2.3.10 Cytotoxicity assay.   
 
The in vivo cytotoxicity assay was performed as previously described. Briefly, splenocytes were 
harvested from naive mouse spleens and incubated with either high (3.0 µM, CFSEhigh) or low 
(0.6 µM, CFSElow) concentrations of CFSE, to generate differentially labeled target cells. The 
CFSEhigh cells were pulsed with OVAI peptide, whereas the CFSElow cells were pulsed with 
Mut1 peptide and served as internal controls. These peptide-pulsed target cells were washed 
extensively to remove free peptides, and then i.v. co-injected at 1:1 ratio into OVA-Texo 
immunized mice six days after the immunization. Sixteen hrs later, the residual CFSEhigh and 
CFSElow target cells remaining in the recipients' spleens were analyzed by flow cytometry. 
 
2.3.11 Animal studies.  
 
To examine the antitumor protective immunity conferred by OVA-Texo or Gp120-Texo vaccine, 
wild-type C57BL/6 mice (n=8) or Iab-/- or H-2Kb-/- KO mice were injected i.v. with DCova or 
DCgp120 (1×106 cells/mouse), the control ConA-stimulated CD8+ T (ConA T) and OVA-Texo or 
Gp120-Texo (1×106 cells/mouse) cells, respectively. The mice injected with PBS were used as 
another control. The immunized mice were challenged i.v. with 0.5×106 BL6-10ova or 
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BL6-10gp120 cells six days or two months subsequent to the immunization. The mice were 
sacrificed 3 weeks after tumor cell injection, and the lung metastatic tumor colonies were 
counted in a blind fashion. Metastases on freshly isolated lungs appeared as discrete black 
pigmented foci that were easily distinguishable from normal lung tissues and confirmed by 
histological examination. Metastatic foci too numerous to count were assigned an arbitrary value 
of >100[33]. 
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2.4 Results  
 
2.4.1 Characterization of DC-released exosomes  
 
C57BL/6 mouse bone-marrow cell-derived DC cell line DC2.4 was in vitro cultured in DMEM 
plus 10% FCS and IFN-γ (20 ng/ml) and pulsed overnight with OVA (0.5 mg/ml) and subjected 
to flow cytometric analysis. As shown in Figure 2.1A, OVA-pulsed DCs (DCova) expressed 
CD11c, MHC II (Iab), CD40 and CD80, indicating that they are mature DC. In addition, they 
also displayed MHC class I (H-2Kb), adhesion molecule CD54 and pMHC I complexes. 
DCova-released EXO (EXOova) were purified from DCova culture supernatants by differential 
ultracentrifugation and subjected to electron microscopic, flow cytometric and Western blotting 
analysis. As shown in Figure 2.1B, EXOOVA had a typical exosomal characteristic of “saucer” or 
round shape with a diameter between 5- to 90 nm. EXOova were then stained with a panel of 
antibodies (Abs) and analyzed by flow cytometry calibrated with microbeads (3.8 µm in 
diameter) (Figure 2.1C). As shown in Figure 2.1D, EXOova displayed expression of all DCova 
molecules including CD80 and pMHC I complexes, but at a lower extent than DCOVA. EXOova 
also displayed EXO-associated proteins such as LAMP-1, CD54 and CD80, but not apoptotic 
body marker Calnexin [43] by Western blot analysis (Figure 2.1E).  
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Figure 2.1 Phenotypic analysis of DCova and DCova-released EXOova.  
(A) DCOVA were stained with a panel of Abs (solid lines) or isotype-matched irrelevant Abs (dotted lines) and 
analyzed by flow cytometry. (B) Electron micrograph of EXO. Bar, 100 nm. (C & D) Flow cytometric analysis of 
EXOs stained with a panel of Abs and microbeads (3.8 µm in diameter). EXOs stained with a panel of FITC-Abs 
(solid lines) or isotype-matched irrelevant FITC-Abs (dotted lines) were sorted (in circle) and analyzed by flow 
cytometry. (E) Western blot analysis of EXOova and EXOgp120 using a panel of Abs. One representative 
experiment of two is shown. 
 
2.4.2 Acquisition of exosomal molecules by CD8+ T cells via LFA-1  
 
Active CD8+ T cells were in vitro generated from naïve CD8+ T cells purified from C57BL/6 
mouse spleen T cells, which were then cultured with ConA for activation and expansion. 
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Activated T cells were then subjected to flow cytometric analysis. As shown in Figure 2.2A, 
these ConA-stimulated T cells expressed CD8, CD25 (T cell activation marker), CD54 and 
LFA-1, indicating that they are active CD8+ T cells. In addition, these CD8+ T cells secreted IL-2 
(2.4 ng/ml/l06 cells/24 hr) and IFN-y (2.6 ng/ml/l06 cells/24 hr), but no IL-4 and IL-l 0 in their 
culture supernatants, indicating that they are type 1 CD8+ T cells. To explore the potential uptake 
of EXOs by T cells, these ConA-stimulated CD8+ T cells were incubated with CFSE-labelled 
EXOs (EXOCFSE) derived from CFSE-labelled DCs (DCCFSE), and then analyzed by flow 
cytometry.  CFSE dye was detectable on EXOCFSE (panel a, Figure 2.2B) and CD8+ T cells 
with incubation of EXOCFSE (panel b, Figure 2.2B), indicating that EXOCFSE could be uptaken 
by CD8+ T cells. The uptake of EXOCFSE by CD8+ T cells increased with the amount of EXOCFSE 
(Figure 2.2C) and with the length of the incubation time (Figure 2.2D). A maximal level of 
EXOCFSE uptake was reached when 1×106 T cells were incubated with 10 µg EXOCFSE for 4 hrs 
which was visualized by confocal microscopy (Figure 2.2E). T cells can absorb DC EXO via 
TCR or CD28 [44] and LFA-l [1, 20]. To assess the molecular mechanism for EXO uptake by 
CD8+ T cells, we added blocking reagents to the above mixture of T cells and EXOCFSE. We 
found that anti-LFA-l Ab, but not anti-CD28 Ab significantly inhibited the uptake of EXOCFSE 
by CD8+ T cells (p<0.05) (Figure 2.2F), indicating that the CD54/LFA-l interaction mediates 
CD8+ T cell's absorption of DC EXO. To assess uptake of exosomal molecules, we performed 
flow cytometric analysis. Similar to CFSE dye transfer, some exosomal molecules such as CD80 
and pMHC I (the critical component in stimulation of OVA-specific CD8+ CTL responses) [40] 
were also transferred onto CD8+ T cells (Figure 2.2A).  
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Figure 2.2 Exosome uptake by ConA-stimulated CD8+ T cells. 
(A) ConA-stimulated CD8+ T cells and OVA-Texo were stained with a panel of Abs (solid lines) or isotype-matched 
irrelevant Abs (dotted lines), and then analyzed by flow cytometry. (B) EXOCFSE (solid line) and EXO (dotted line) 
(a) or ConA T cells after (solid line) and before (dotted line) incubation with EXOCFSE (b) were analyzed by flow 
cytometry. (C) ConA-stimulated CD8+ T (ConA T) cells were incubated with different doses of EXOCFSE for 4 hrs. 
CFSE-positive T cells were detected by confocal microscopy. (D) ConA T cells were incubated with EXOCFSE (10 
µg/1×106 T cells) for different times. (E) CFSE-positive T cells were detected under differential interference 
contrast (DIC) by confocal microscopy. (F) The blocking reagents (anti-H-2Kb or anti-LFA-1 Ab, 20 µg/ml) were 
added to the mixture of ConA T cells and EXOCFSE. After 4 hrs of incubation, CFSE-positive T cells were detected 
by confocal microscopy. One representative experiment of two is shown. 
 
2.4.3 OVA-Texo stimulates in vitro OVA-specific CD4+ and CD8+ T cell proliferation  
 
Since EXO harbor many immune molecules including pMHC complexes and costimulatory 
molecules, CD8+ aTexo with acquired exosomal molecules may thus have potent effect in 
stimulation of T cell responses. We performed in vitro OVA-specific CD4+ and CD8+ T cell 
proliferation assays. We demonstrated that OVA-Texo stimulated in vitro OVA-specific OT II 
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CD4+ (Figure 2.3A) and OT I CD8+ (Figure 2.4A) T cell proliferation by 3H-thymidine 
incorporation.  
	  
Figure 2.3 OVA-Texo induces OVA-specific CD4+ T cell responses. 
(A) Naive OT II mouse CD4+ T cells (0.5×105 cells/well) were incubated with irradiated DCOVA and OVA-Texo 
(0.25×105 cells/well) and their 2 fold dilutions in a 3H-thymidine uptake assay. The ConA-stimulated C57BL/6 
CD8+ T (ConA T) cells were used as a control. (B) The immunized mouse tail blood samples harvested at different 
days after the immunization of OVA-Texo were stained with PE-Iab/OVA II peptide tetramer and FITC-anti-CD4 
Ab, and then analyzed by flow cytometry. The value in each panel represents the percentage of OVA-specific 
(tetramer-positive) CD4+ T cells vs the total CD4+ T cell population. The value in parenthesis represents the 
standard deviation (SD). One representative experiment of three is shown. 
 
2.4.4 OVA-Texo stimulates in vivo functional OVA-specific CD4+ and CD8+ T cell 
responses  
 
To assess whether OVA-Texo can also stimulate T cell proliferation in vivo, we performed 
tetramer staining assays. As shown in Figure 2.3B, OVA-Texo stimulated PE-Iab/OVA265-280 
tetramer-positive CD4+ T cell responses with a peak time at day 3 subsequent to the 
immunization, which accounted for 0.56% of the total CD4+ T populations in the mouse blood. 
In addition, OVA-Texo also stimulated H-2Kb/OVA257-264 tetramer-positive CD8+ T cell 
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responses with a peak time at day 6 subsequent to immunization (Figure 2.4B), which accounted 
for 1.13% of the total CD8+ T cell populations in the mouse blood (Figure 2.4C). Next, we 
assessed the ability of OVA-Texo to induce the differentiation of stimulated CD8+ T cells into 
CTL effectors. We adoptively transferred OVAI peptide-pulsed splenocytes that had been 
strongly labeled with CFSE (CFSEhigh), as well as the control peptide Mut1-pulsed splenocytes 
that had been weakly labeled with CFSE (CFSElow), into recipient mice that had been vaccinated 
with OVA-Texo cells. As expected, there was substantial loss (75%) of the CFSEhigh (OVAI 
peptide-pulsed) cells in the OVA-Texo-immunized mice, whereas no cytotoxicity was induced in 
mice immunized with ConA-stimulated CD8+ T (ConA T) cells without acquired exosomal 
molecules (Figure 2.4D), indicating that OVA-Texo vaccine efficiently stimulates CD8+ T cell 
differentiation into functional CTL effectors. In the above experiments, a positive control DCova 
vaccine similarly stimulated CD8+ effector CTL response as OVA-Texo. 
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Figure 2.4 OVA-Texo induces OVA-specific CD8+ T cell responses.  
(A) Naive OTI mouse CD8+ T cells (0.5×105 cells/well) were incubated with irradiated DCOVA and OVA-Texo 
(0.25×105 cells/well) and their 2 fold dilutions in a 3H-thymidine uptake assay. The ConA-stimulated C57BL/6 
CD8+ T (ConA T) cells were used as a control. (B) The immunized C57BL/6 mouse tail blood samples harvested at 
different days after the immunization of OVA-Texo were stained with PE-H-2Kb/OVAI peptide tetramer and 
FITC-anti-CD8 Ab, and then analyzed by flow cytometry. (C) The tail blood samples harvested at day 6 after the 
immunization of Iab-/- KO mice or DTR-CD11c transgenic mice (with a single dose treatment of DT) with 
OVA-Texo were stained with PE-H-2Kb/OVAI peptide tetramer and FITC-anti-CD8 Ab, and then analyzed by flow 
cytometry. The value in each panel represents the percentage of OVA-specific (tetramer-positive) CD8+ T cells vs 
the total CD8+ T cell population. The value in parenthesis represents the standard deviation (SD). (D) In vivo 
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cytotoxicity assay. Six days after immunization, the immunized mice were i.v. injected with 2×106 cells containing a 
1:1 mixture of CFSEhigh and CFSElow -labeled splenocytes that had been pulsed with OVAI or Mut1 peptides, 
respectively. After 16 hrs, the spleens of immunized mice were removed and the percentages of the residual 
CFSEhigh (H) and CFSElow (L) target cells remaining in the recipients' spleens were analyzed by flow cytometry. The 
value in each panel represents the percentage of CFSEhigh vs CFSElow target cells remaining in the spleen. The value 
in parenthesis represents the standard deviation (SD). One representative experiment of three is shown. 
 
2.4.5 OVA-Texo-stimulated CD8+ T cell responses are DC and CD4+ T cell independent 
 
To assess the potential involvement of the host DC and CD4+ T cells in OVA-Texo-induced 
CD8+ CTL responses, we performed OVA-Texo vaccination in both Iab-/- gene KO mice lacking 
the host CD4+ T cells and transgenic diphtheria toxin receptor (DTR)-CD11c mice with 
treatment of diphtheria toxin (DT) for depletion of the host DCs. Interesting, we found that the 
efficiency of OVA-Texo-stimulated CTL responses (1.17%) in DT-treated DTR-CD11c mice 
lacking the host DCs was maintained at the same level, whereas OVA-Texo-stimulated CTL 
responses (1.07%) in Iab-/- gene KO mice lacking the host CD4+ T cells declined slightly 
compared to those (1.13%) in wild-type C57BL/6 mice (Figure 2.4C), indicating that 
OVA-Texo vaccine stimulates CD8+ CTL responses which are DC and CD4+ T cell independent. 
In comparison, DCova failed in stimulation of CTL responses in Iab-/- KO mice lacking CD4+ T 
cells, indicating that DCova stimulated CD4+ T cell-dependent CTL responses. In addition, 
OVA-Texo-stimulated CTL in Iab-/- gene KO mice also displayed efficient killing activity to 
OVAI-pulsed CFSEhigh target cells in vivo (Figure 2.4D), indicating that they are also functional. 
 
2.4.6 Induction of CD8+ CTL-mediated antitumor immunity and long-term T cell memory 
by OVA-Texo  
 
Next, we assessed the potential antitumor immunity derived from OVA-Texo vaccine against 
OVA-expressing B16 melonoma. As shown in Exp I of Table 2.1, all the mice injected with 
PBS or CD8+ T cells without uptake of exosomal molecules had large numbers (> 100) of lung 
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metastatic BL6-10ova tumor colonies. OVA-Texo vaccine, however, induced a complete 
immune protection against BL6-10ova tumor cell challenge in all 8/8 (100%) mice, indicating 
that OVA-Texo induces efficient antitumor immunity. To study the immune mechanism, lab and 
H-2Kb gene KO mice were used for immunization. As shown in Exp 11 of Table 2.1, most (7/8, 
88%) of lab gene KO mice lacking CD4+ T cells were still tumor free, whereas all H-2Kb gene 
KO mice (8/8) lacking CD8+ T cells had numerous lung tumor metastases, indicating that 
OVA-Texo-induced antitumor immunity is relatively CD4+ T-cell independent, but completely 
mediated by CD8+ CTLs. To assess whether these OVA-Texo-stimulated CD8+ T cells can 
become long-lived memory CD8+ T (Tm) cells leading to long-term immunity. One month after 
the immunization, we challenged the immunized mice with BL6-10OVA tumor cells. As shown in 
Exp III of Table 2.1, all mice immunized with OVA-Texo were free of tumor, indicating that 
CD8+ aTexo vaccine can induce OVA-specific CD8+ memory T cell development leading to a 
long-term T cell memory.  
 
Table 2.1 OVA-Texo vaccine protects against lung tumor metastases VaccinesA	   Tumor	  cell	  challenge	   	   	   	   Tumor	  growth	  incidence	  (%)	   Median	  number	  of	  lung	  tumor	  colonies	  Exp.	  I.	   	   	   	  DCOVA	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0)	   0	  OVA-­‐TEXO	   	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0)	   0	  Con	  A	  T	   	   	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  8/8	  (100)	   >100	  PBS	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  8/8	  (100)	   >100	  OVA-­‐TEXO	   BL6-­‐10	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  8/8	  (100)	   >100	  PBS	   BL6-­‐10	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  8/8	  (100)	   >100	  	   	   	   	  Exp.	  II.	   	   	   	  OVA-­‐TEXO	  (B6)	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0)	   0	  OVA-­‐TEXO	  (Iab	  KO)	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0)	   0	  OVA-­‐TEXO	  (Kb	  KO)	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  8/8	  (100)	   >100	  	   	   	   	  Exp.	  III	   	   	   	  OVA-­‐TEXO	   	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0)	   0	  DCOVA	   	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0)	   0	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PBS	   BL6-­‐10OVA	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  8/8	  (100)	   >100	  
A. In experiment I, wild-type C57BL/6 (B6) mice were immunized with DCOVA, ConA-stimulated CD8+ T (ConA T) 
and OVA-TEXO cells or PBS. In experiment II, B6, Iab or Kb KO mice were immunized with aTEXO cells. Six days 
after the immunization, each mouse was challenged with BL6-10OVA or BL6-10 tumor cells. In experiment III, B6 
mice were immunized with OVA-TEXO. One month later, mice were challenged with BL6-10OVA tumor cells. The 
mice were sacrificed 3 weeks after tumor cell challenge and the numbers of lung metastatic tumor colonies were 
counted. One representative experiment of two is shown.  
 
2.4.7 Stimulation of gp120-specific CD8+ CTL responses and long-term immunity against 
gp120-expressing tumor by Gp120- Texo  
 
To assess whether HIV-1 gp120-specific EXO-targeted Gp120-Texo vaccine can stimulate CD8+ 
CTL responses leading to long-term immunity, we first transfected DC cell line DC2.4 with 
pcDNAgp120 by lipofectamin to form DCgp120. We demonstrated that DCgp120 displayed 
expression of CD11c, CD40, CD54, CD80 and Iab by flow cytometry (Figure 2.5A), indicating 
that they are mature DCs. To confirm expression of gp120, we performed RT-PCR and Western 
blotting analysis. We demonstrated that DCgp120, but not the control DCnull transfected with 
the control pcDNA vector expressed Gp120 molecule by RT-PCR (Figure 2.5B) and Western 
blotting (Figure 2.5C) analysis. We then purified EXOgp120 derived from culture supernatants 
of DCgp120 by differential ultracentrifugation. EXOgp120 were then subjected to electron 
microscopic, Western blot and flow cytometric analysis. As shown in Figure 2.1B, EXOgp120 
also had a typical exosomal characteristic of "saucer" or round shape with a diameter between 50 
to 90 nm. We also confirmed that EXO-associated proteins including CD54, CD80 and LAMP-1 
were abundant in EXOgp120 preparation by Western blot analysis (Figure 2.1E). EXOgp120 
displayed expression of all DCgp120 cell-surface molecules, but at a lower extent than DCgp120 
(Figure 2.5A). To assess the stimulatory effect on CD8+ T cell responses, we immunized 
C57BL/6 mice with Gp120-Texo and then performed flow cytometric analysis. Since no H-2Kb 
epitope of Gp120 was defined, we could not use Gp120-specific tetramer staining to detect 
Gp120-specific CD8+ T cells. Instead, we used FITC-anti-CD8 and ECD-anti-CD44 Ab as well 
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as PE-anti-IFN-γ Ab for double staining to assess Gp120-Texo-stimulated CD8+ T cell responses 
by flow cytometry as described by Shedlock et al [45]. We demonstrated that Gp120-Texo more 
efficiently stimulated upregulation of T cell activation marker CD44 on CD8+ T cells than ConA 
T cells (p<0.05) (Figure 2.5D), indicating that Gp120-Texo stimulates efficient Ag-specific 
CD8+ CTL responses. In addition, we also quantified the Ag-specific CD8+ T cell responses in 
Gp120-Texo-immunized mice by intracellular IFN-γ staining. We found that 3.21% CD8+ T 
cells from Gp120-Texo-immunized mice produced IFN-γ, which is significantly more than 
ConA T cells (p<0.05), indicating that Gp120-Texo stimulates efficient Ag-specific effector 
CD8+ CTL responses. In the above experiments, a positive control DCgp120 vaccine similarly 
stimulated CD8+ effector CTL response as OVA-Texo. To assess the short- and long-term 
immunity, we immunized C57BL/6 mice with Gp120-Texo and challenged the mice with 
Gp120-expressing BL6-10gp120 tumor cells (Figure 2.5B & 2.5C) at day 6 and 30 subsequent 
to the immunization, respectively. We found that all (8/8) of mice were tumor free in both Exp I 
and II of Table 2.2, indicating that Gp120-Texo vaccine can stimulate both efficient short- and 
long-term immunity against Gp120-expressing BL6-10gp120 tumor cells. In the above 
experiments, we used a positive control (DCgp120) vaccine showing a similar short- and 
long-term antitumor immunity as Gp120-Texo. 
	   71	  
	  
Figure 2.5 Phenotypic and functional analysis of Gp120-Texo. 
(A) DCgp120 and DCgp120-released EXOgp120 were stained with a panel of Abs (solid lines) or isotype-matched 
irrelevant Abs (dotted lines) and analyzed by flow cytometry. (B) RT-PCR and (C) Western blotting analysis of 
DCgp120 and BL6-10gp120 tumor cells. (D) C57BL/6 mice were i.v. immunized with DCgp120 and Gp120-Texo. 
Six days after the immunization, tail blood samples of the immunized mice were stained with ECD-anti-CD44 Ab or 
PE-anti-IFN-γ Ab and FITC-anti-CD8 Ab, and then analyzed by flow cytometry. The value in each panel represents 
the percentage of CD8+CD44+ T cells in the total cells analyzed or the percentage of CD8+ T cells producing IFN-γ 
in the total CD8+ T cell population. The value in parenthesis represents the standard deviation (SD). *P<0.05 versus 
cohorts of ConA T cells (Student t test). One representative experiment of two is shown. 
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Table 2.2 Gp120-Texo vaccine protects against lung tumor metastases VaccinesA	   Tumor	  cell	  challenge	   	   	   	   Tumor	  growth	  incidence	  (%)	   Median	  number	  of	  lung	  tumor	  colonies	  Exp.	  I.	   	   	   	  DCgp120	   BL6-­‐10gp120	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0) 0	  Gp120-­‐TEXO	   	   BL6-­‐10gp120	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0) 0	  ConA	  T	   	   	   BL6-­‐10gp120	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  8/8	  (100)	   >100	  PBS	   BL6-­‐10gp120	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  8/8	  (100)	   >100	  	   	   	   	  Exp.	  II	   	   	   	  aTEXO	   	   BL6-­‐10gp120	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0) 0	  DCgp120	   	   BL6-­‐10gp120	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  0/8	  (0) 0	  PBS	   BL6-­‐10gp120	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  8/8	  (100)	   >100	  
A. In experiment I, wild-type C57BL/6 (B6) mice were immunized with DCgp120, ConA-stimulated T (ConA T) 
and Gp120-TEXO cells or PBS. In experiment II, B6 mice were immunized with DCgp120 and Gp120-TEXO. Two 
months later, mice were challenged with BL6-10gp120 tumor cells. The mice were sacrificed 3 weeks after tumor 
cell challenge and the numbers of lung metastatic tumor colonies were counted. One representative experiment of 
two is shown.  
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2.5 Discussion  
 
Antigen (Ag)-specific naive T cells can absorb dendritic cell (DC) exosomes (EXO) via either 
TCR or CD28 [44] and LFA-1 [20]. Activation of specific G protein receptors, cytokine 
stimulation motility and TCR-mediated signals all induce a transient conformational change in 
LFA-1, thereby highly increasing T cell LFA-1 avidity for CD54 [46]. We previously 
demonstrated that Con A-stimulated polyclonal CD4+ T cells acquired OVA-specific 
DCova-released EXOova via LFA-1 [33]. Recently, it has been also shown that T cells recruit 
DC EXO by LFA-1 [1], indicating that CD54/LFA-1 interaction plays an important role in not 
only intercellular cell-to-cell interactions but also DC EXO uptake by T cells. Since the uptake of 
EXO by T cells was a saturable process that required close cell proximity, actin polymerization 
and a permissive temperature [47], internalization/recycling and the fusion of DC EXO onto 
CD8+ T cells may be the two major pathways of exosomal molecule acquisition[48]. In this 
study, we demonstrate that CD54 expressing DC can uptake active T cell-released EXO 
expressing LFA-1 and the anti-LFA-1 Ab can block the uptake of T cell EXO by DC, indicating 
that active T cells recruit DC EXO via exosomal LFA-1.  
 
In AIDS patients, severe immune suppression and dysfunction have been found [46] For 
example, HIV-1 viral cytopathic effect causes CD4+ T cell depletion after HIV-1 gp120 binds to 
CD4 molecule of the T cells [46]. Individuals with high viral loads had increased frequencies of 
CD4+ T cells producing only IFN-γ, but not IL-2, resulting CD4+ T cell death and depletion and 
disease progression [44, 46, 49]. The CD4+ Th cell depletion due to the viral cytopathic effect [1] 
also quantitatively and qualitatively decreases CD8+ CTL responses [50]. CD4+ T cells are 
required for the generation and maintenance of cytotoxic CD8+ T cells[51]. Clinically, the 
association between peripheral blood CD4+ Th cell counts and risk of disease becomes well 
established [4]. The loss of non-helped CD8+ T cells is particularly apparent during chronic 
HIV-1 infection [52, 53]. It has recently been demonstrated that the primary CD8+ T cell 
responses and short-term memory to HIV-1 Env and vesicular stomatitis virus (VSV) 
nucleocapsid protein were largely intact [54]. However, their long-term memory was largely or 
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completely lost in CD4-deficient mice. Importantly, the qualitative nature of CD8+ T cell 
responses is key to the control of HIV-1 infection [55]. DCs expressing C-type lectin DC-SIGN, 
the target protein for Gp120 have also been found to be impaired in individuals with progressive 
HIV-1 infection [56, 57]. Infected DC-released EXO-associated virons are also likely to be 
transmitted to CD4+ T cells through membrane binding and fusion, either within the infectious 
synapse or over longer distances [58].  
 
Administration of attenuated T cells to animals has been shown to stimulate immune suppression 
and to prevent the development of experimental autoimmune diseases. For example, vaccination 
using myelin-basic-protein autologous T cells has also been applied preventing the development 
of experimental autoimmune disease [59] and to clinical trial in multiple sclerosis [60]. Recently, 
we have shown that ConA-stimulated nonspecific polyclonal CD4+ T cells with uptake of 
Ag-specific DC-released EXO can stimulate Ag-specific CD8+ CTL responses and antitumor 
immunity [33]. CD8+ T cells have been originally defined as effector T cells with cytotoxic 
activity to tumor or virally infected cells [37]. Interestingly, it has also been demonstrated that 
CD8+ T cells have helper effects as CD4+ Th cells [61, 62]. In this study, we further show that 
non-specific active CD8+ T cells can uptake OVA- and Gp120-specific DC-released EXO via 
LFA-1 to form OVA- and Gp120-Texo vaccines. Antigen-presenting cells (APCs) stimulate 
CD8+ T cell responses via 3 signaling including peptide major histocompatibility complex 
(pMHC) I/TCR (signal 1), CD80/CD28 (signal 2) and IL-12 (signal 3) [50]. Our OVA- and 
Gp120-Texo vaccines stimulate OVA- and Gp120-specific CD8+ CTL responses also via 3 
signaling such as exosomal pMHC I/TCR (signal 1), CD40L/CD40 and exosomal CD80/CD28 
(signal 2) and IL-2 (signal 3) [50]. We demonstrate that OVA-Texo can stimulate DC- and CD4+ 
T cell-independent OVA-specific CD8+ CTL responses leading to antitumor immunity and CD8+ 
T cell long-term memory against OVA-expressing B16 melanoma. Importantly, Gp120-Texo 
vaccine can also stimulate Gp120-specific effector CD8+ CTL responses and long-term memory 
against Gpl20-expressing B16 melanoma.  
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Although DCs have also been found to be dysfunctional in HIV-1 patients [56, 57, 63], 
administration of monocyte-derived and Ag-loaded DCs from HIV-1 patients could still generate 
cellular immune responses leading to reduction in viremia [29] and partial control of viral 
replication [30]. Mature DCs can still be obtained by culturing peripheral blood monocytes from 
AIDS patients or HLA-A-matched donors in culture medium with GM-CSF, IL-4 and TNF-α [64] 
and transfected with a recombinant Gp120-expressing adenovirus (AdVgp120) to form 
Gp120-expressing DCgp120. Therefore, it is feasible to generate functional Gp120-Texo vaccine 
by using ConA-stimulated patient's peripheral blood CD8+ T cells with uptake of purified 
Gp120-specific EXOgp120 released from DCgp120.  
 
Taken together, this novel HIV-1 gp120-specific EXO-targeted CD8+ Gp120-Texo vaccine 
capable of stimulating efficient HIV-1-specific CD8+ CTL responses in absence of DC and CD4+ 
T cell help may represent a new strategy for immunotherapeutic vaccine in treatment of AIDS 
patients with DC dysfunction and CD4+ T cell deficiency.  	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3.1 Abstract 
 
Human immunodeficiency virus type-1 (HIV-1)-specific dendritic cell (DC) vaccines have been 
applied to clinical trials that show only induction of some degree of immune responses, 
warranting the search of other more efficient vaccine strategies. Since HIV-1-specific CD8+ 
cytotoxic T lymphocytes (CTLs) have been found to recognize some HIV-1 structural protein 
Gag conserved and cross-strain epitopes, Gag has become one of the most attractive target 
candidates for HIV-1 vaccine development. In this study, we generated HIV-1 Gag-specific 
Gag-Texo vaccine by using ConA-stimulated polyclonal CD8+ T-cells with uptake of 
Gag-expressing adenoviral vector AdVGag-transfected DC (DCGag)-released exosomes (EXOs), 
and assessed its stimulation of Gag-specific CD8+ CTL responses and antitumor immunity. We 
demonstrate that Gag-Texo and DCGag vaccines comparably stimulate Gag-specific effector 
CD8+ CTL responses. Gag-Texo-stimulated CTL responses result in protective immunity against 
Gag-expressing BL6-10Gag melanoma in 8/8 wild-type C57BL/6 mice. In addition, we show that 
Gag-Texo vaccine also induces CTL responses leading to protective and long-term immunity 
against Gag/HLA-A2-expressing BL6-10Gag/A2 melanoma in 8/8 and 2/8 transgenic HLA-A2 
mice, respectively. The average number of lung tumor colonies in mice with 30-days 
post-immunization is only 23, which is significantly less than that (>300) in control 
ConA-T-immunized HLA-A2 mice. Furthermore, Gag-Texo vaccine also induces some degree 
of therapeutic immunity. The average number (50) and size (1.02 mm in diameter) of lung tumor 
colonies in Gag-Texo-immunized HLA-A2 mice bearing 6-day-established lung BL6-10Gag/A2 
melanoma metastasis are significantly less than the average number (>300) and size (0.23 mm in 
diameter) in control ConA-T-immunized HLA-A2 mice. Taken together, HIV-1 Gag-Texo 
vaccine capable of stimulating Gag-specific CTL responses and therapeutic immunity may be 
useful as a new immunotherapeutic vaccine for viral control in HIV-1 patients. 
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3.2 Introduction 
 
Immune surveillance by CD8+ cytotoxic T lymphocytes (CTLs) represents a major mechanism 
for the detection and elimination of cells infected with intracellular pathogens, especially viruses. 
CTLs are also essential for effective immunity against human immunodeficiency virus type 1 
(HIV-1), and the induction of such responses using vaccines has become a major objective in the 
strategy to halt the pandemic [1]. HIV-1 structural proteins such as Gp120 and Gag are the major 
targets in vaccine development [2, 3]. Dendritic cells (DCs), the most potent antigen presenting 
cells (APCs), play an important role in inducing CD4+ T-cell dependent CTL responses [4]. DCs 
expressing HIV-1 Gp120 and Gag have been used as vaccines to stimulate HIV-1-specific CTL 
responses in animal models [5-8]. HIV-1-specific DC vaccines have been also applied to clinical 
trials [9-12]. However, they have been found to only induce some degree of immune responses 
in these clinical trials [13], warranting the search of other more efficient vaccine strategies.  
 
We previously developed a novel CD4+ T cell-based vaccine (OVA-Texo) using CD4+ T-cells 
with uptake of ovalbumin (OVA)-specific DC-released exosomes (EXO) [14-16]. We 
demonstrated that CD4+ OVA-Texo vaccine is capable of stimulating potent OVA-specific CTL 
responses and long term immunity via IL-2/CD80 and CD40L signaling and counteracting 
regulatory T cell-mediated immune suppression, and is also capable of inducing more efficient 
immunity than DC vaccine and [14-16]. In addition, we have recently demonstrated that 
ConA-stimulated mouse CD8+ T cells with uptake of HIV-1 Gp120-specific DC-released EXO 
(EXOGp120) can also be used as CD8+ Gp120-Texo vaccine capable of stimulating 
Gp120-specific CTL responses leading to therapeutic and long-term immunity against 
Gp120-expressing B16 melanoma in both wild-type C57BL/6 and transgenic HLA-A2 mice [17, 
18]. 
 
CD8+ CTLs capable of recognizing some conserved and cross-strain epitopes [19-21] play a 
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critical role in control of HIV-1 proliferation [22, 23], acute phase of infection and disease 
progression even in the absence of neutralizing Abs [3, 24]. Monkeys immunized with viral 
vectors developed cellular immune responses that did slow disease progression [25, 26]. Thus, 
CTLs become essential for effective immunity against HIV-1 infection [1]. Compared to HIV-1 
structural protein Gp120, HIV-1 Gag has the following advantages as a target antigen for 
developing HIV-1-specific vaccines. Gag as a viral antigen can enter the defective ribosomal 
product (Drip) pathway [27], leading to enhanced major histocompatibility complex (MHC)-1 
antigen presentation and CD8+ T-cell activation [28]. Gag vaccine thus stimulated persistent and 
broader CTL responses against conserved Gag epitopes in animal models [21, 29, 30]. HLA-B57 
HIV-1-infected individuals have also been found to have autologous CTL responses against four 
conserved Gag epitopes, leading to reducing virus replication and viral control [31]. In addition, 
effective CTL responses against Gag, but not other viral antigens, have been found to correlate 
with suppression of HIV-1 replication in HIV-1 patients [32-35]. Therefore, Gag has become one 
of the most attractive target candidates for HIV-1 vaccine development.  
 
In this study, we generated Gag-Texo vaccine by using ConA-stimulated mouse CD8+ T cells 
with uptake of Gag-specific DC-released EXOs, and assessed its stimulation of Gag-specific 
CTL responses and immunity against Gag-expressing B16 melanoma in both wild-type C57BL/6 
and transgenic HLA-A2 mice.  
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3.3 Materials and methods 
 
3.3.1 Reagents, cell lines and animals  
 
Biotin-labeled or fluorenscein isothiocyanate (FITC)-labeled antibodies (Abs) specific for H-2Kb, 
Iab, CD8, CD11c, CD40, CD54, CD80, CD86, 4-1BBL, OX40L and HLA-A2 antibodies (Abs), 
FITC-conjugated avidin and PE-anti-IFN-r and PE-anti-CD44 Abs were all obtained from BD 
Biosciences (Mississauga, Ontario, Canada). The rabbit anti-Gag polyclonal Ab was obtained 
from Fisher Scientific Inc, Waltham, MA. The Gag76-84 peptide (SLYNTVATL) and the 
irrelevant control human epidermal growth factor receptor-2 (HER2) peptide (ILHNGAYSL) 
were synthesized by Multiple Peptide Systems (San Diego, CA). Adenoviral vector AdVGag 
expressing HIV-1 Gag was constructed by insertion of Gag cDNA fragment of pcDNAGag into 
pShuttle vector (Stratagene, La Jolla, CA) by recombinant technology. The recombinant AdVGag 
vector was linealized by PacI digestion, and then transfected into 293 cells using Lipofectamine 
2000 (Invitrogene, Carlsbad, CA) to generate AdVGag expressing transgene Gag (Figure 3.1A). 
AdVGag was amplified in 293 cells, and purified by a series of cesium chloride 
ultracentrifugation gradients [36]. Vectors pcDNAHLA-A2 expressing α1 and α2 domains of 
HLA-A2 and α3 domain of H-2Kb and vector pcDNA-Gag/GFP expressing a fused gene 
Gag/GFP were previously constructed in our laboratory [15].  B16 melanoma cell line BL6-10 
was transfected with pcDNA-Gag/GFP by Lipofectamine 2000 (Invitrogene) to generate 
BL6-10Gag/GFP cells, which were then further transfected with pcDNAHLA-A2 to form 
Gag/HLA-A2-expressing BL6-10Gag/A2. Female C57BL/6 and transgenic (Tg) HLA-A2 mice 
(#3584) were obtained from the Jackson Laboratory (Bar Harbor, MA). All mice were treated 
according to animal care committee guidelines of the University of Saskatchewan. 
 
3.3.2 Dendritic cell and exosome preparations  
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Bone marrow-derived dendritic cells (DCs) were obtained by culturing the wild-type C57BL/6 or 
transgenic HLA-A2 mouse bone marrow cells in culture medium containing GM-CSF (20 ng/ml) 
and IL-4 (20 ng/ml) for six days as previously described [15]. DCs were infected with AdVGag 
and termed DCGag. DCGag-released exosomes (EXOGag) were then purified from DC culture 
supernatants by differential ultracentrifugation [15].  
 
3.3.3 Gag-Texo preparation  
 
The wild-type C57BL/6 or transgenic HLA-A2 mouse splenocytes were cultured in RPMI1640 
medium containing IL-2 (20 U/ml) and ConA (1 µg/ml) for 3 days [37]. ConA-activated CD8+ T 
(ConA-T) cells were enriched by passage through nylon wool columns (C&A Scientific, 
Manassas, VA), and then purified by negative selection using anti-mouse CD8 paramagnetic 
beads (DYNAL Inc, Lake Success, NY) [38]. Gag-Texo vaccine was generated by incubation of 
CD8+ ConA-T cells with EXOGag as previously described [17]. 
 
3.3.4 Electron microscopic analysis 
 
EXOs were fixed in 4% paraformaldehyde. The pellets were then loaded onto carbon-coated 
formvar grids. The EXO sample-loaded grids were stained with saturated aqueous uranyl, and  
then examined with a JEOL 1200EX electron microscope at 60 kV [39]. 
 
3.3.5 Western blot analysis 
 
Cell lysates (10 µg/well) were loaded onto 12% acrylamide gels, subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and subsequently transferred onto 
nitrocellulose membrane (Millipore, Bedford, MA). The membrane was blocked with 
ODYSSEY blocking buffer (LI-COR Bioscience, Lincoln, NE), immunoblotted with anti-gag 
	   88	  
Ab, incubated with anti-goat IRDyeR800CW Ab, and then scanned using ODYSSEY instrument 
according to manufacture’s instruction (LI-COR Bioscience) [39]. 
 
3.3.6 Flow cytometric analysis  
 
Cells and EXOs were stained with a panel of Abs and analyzed by flow cytometry [17]. To 
assess Gag-Texo stimulated CTL responses, the blood samples harvested from immunized mice 
were stained with FITC-conjugated anti-CD8 Ab (FITC-CD8) and PE-conjugated anti-CD44 Ab 
(PE-CD44), and analyzed by flow cytometry. In another set of experiments, the spleen cells were 
harvested from immunized mice, and depleted of erythrocytes. The splenocytes were cultured for 
4 hrs with 2 µM Gag peptide (SLYNTVATL), and then stained with FITC-anti-CD8 Ab. 
Subsequently, the T cells were fixed, and cell membranes were permeabilized with 
Cytofix/Cytoperm solution (BD Biosciences). The cells were stained with PE-conjugated 
anti-IFN-r Ab, and then analyzed by flow cytometry [40].  
 
3.3.7 Cytotoxicity assay  
 
The in vivo cytotoxicity assay was performed as previously described [41]. Briefly, splenocytes 
were harvested from naive C57BL/6 mouse spleens and incubated with either high (3.0 µM, 
CFSEhigh) or low (0.6 µM, CFSElow) concentrations of CFSE, to generate differentially labeled 
target cells. The CFSEhigh cells were pulsed with Gag peptide, whereas the CFSElow cells were 
pulsed with irrelevant HER2 peptide, and served as internal controls. These peptide-pulsed target 
cells (1×106 cells/mouse) were i.v. co-injected at 1:1 ratio into immunized mice six days after the 
immunization. Sixteen hrs later, the residual Gag-specific CFSEhigh and irrelevant control 
CFSElow target cells remaining in the recipients' spleens were analyzed by flow cytometry. 
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3.3.8 Animal studies  
 
To examine the protective antitumor immunity conferred by Gag-Texo vaccine, the wild-type 
C57BL/6 or transgenic HLA-A2 mice (n=8) were injected i.v. with DCGag, Gag-Texo and the 
control ConA-stimulated CD8+ T (ConA-T) cells (2×106 cells/mouse) respectively. The 
immunized mice were challenged i.v. with 0.5×106 BL6-10Gag/GFP or HLA-A2-expressing 
BL6-10Gag/A2 cells 6 or 30 days subsequent to the immunization. To examine the therapeutic 
antitumor immunity conferred by Gag-Texo vaccine, the transgenic HLA-A2 mice (n=8) were 
first injected i.v. with 0.5×106 BL6-10Gag/A2 cells. Six days after tumor cell inoculation, HLA-A2 
mice were then injected i.v. with Gag-Texo cells (2×106 cells/mouse). The mice were sacrificed 
3 weeks after tumor cell injection, and the lung metastatic tumor colonies were counted in a 
blind fashion. Metastases on freshly isolated lungs appeared as discrete black pigmented foci that 
were easily distinguishable from normal lung tissues and confirmed by histological examination. 
Metastatic foci too numerous to count were assigned an arbitrary value of >300 [15]. 
 
3.3.9 Statistic analyses  
 
Statistical analyses were performed using the Student t test or the Mann-Whitney U test for 
comparison of variables from different groups. A value of p<0.05 was considered to be 
statistically significant [16].   
	   90	  
3.4 Results  
 
3.4.1 Generation of Gag-Texo vaccine 
 
We previously prepared Gp120-specific CD8+ T cell-based vaccine (Gp120-Texo) by using 
ConA-stimulated CD8+ T cells with uptake of AdVGp120-infected DC (DCGp120)-released 
exosomes (EXOGp120), and showed that Gp120-Texo vaccine stimulated Gp120-specific CTL 
responses and therapeutic immunity [17, 18]. To assess whether HIV-1 Gag-specific T cell-based 
vaccine can also stimulate CTL responses and therapeutic immunity, we first constructed a 
recombinant adenoviral vector AdVGag expressing HIV-1 Gag (Figure 3.1A), and generated 
bone marrow-derived DCs which express CD11c, DC maturation markers such as Iab, CD40, 
CD80 and CD86 and other costimulatory molecules such as 41BBL and OX40L (Figure 3.1B), 
indicating that they are mature DCs. We then infected DCs with AdVGag to form DCGag. We 
showed that DCGag expressed HIV-1 Gag (55 KDa) assessed by Western Blotting analysis 
(Figure 3.1C). We also purified DCGag-released EXO (EXOGag) from DCGag culture supernatants 
by ultracentrifugation. We demonstrated that EXOGag showed a typical exosomal characteristic 
of “saucer” or round shape with a diameter between 50-90 nm (Figure 3.1D), and similarly 
expressed the above DC’s molecules, but at much less content than DCs (Figure 3.1E).  
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Figure 3.1 Phenotypic analysis of Gag-Texo.  
(A) Schematic representation of adenoviral (AdV) vector AdVGag. The E1/E3 depleted replication-deficient AdV is 
under the regulation of the cytomegalovirus (CMV) early/immediate promoter/enhancer. ITR, inverted terminal 
repeat. (B) DCGag were stained with a panel of Abs (solid lines) or isotype-matched irrelevant Abs (dotted lines) and 
analyzed by flow cytometry. (C) Western blot analysis of lysates of DCGag and DCs using the anti-gag Ab. (D) 
Electron micrograph of EXOGag. Bar, 100 nm. (E) EXOGag were stained with a panel of Abs (solid lines) or 
isotype-matched irrelevant Abs (dotted lines) and analyzed by flow cytometry. One representative experiment of 
two is shown. 
 
3.4.2 Gag-Texo vaccine stimulates Gag-specific effector CTL responses in C57BL/6 mice 
 
We then immunized C57BL/6 mice with Gag-Texo and DCGag, and then assessed CTL responses 
by flow cytometry using FITC-anti-CD8 and PE-anti-CD44 antibodies for double staining 6 days 
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after immunization [17, 18]. We demonstrated that both Gag-Texo and DCGag vaccines were 
capable of more efficiently stimulating proliferation of CTLs expressing T cell activation marker 
CD44 than ConA-T cells (p<0.05) (Figure 3.2A). In addition, we also quantified Gag-specific 
CTL responses in Gag-Texo- and DCGag-immunized mice by flow cytometry using 
FITC-anti-CD8 and PE-anti-IFN-γ antibodies for double staining after in vitro Gag peptide 
stimulation of splenocytes purified from the immunized mice. We found that 3.76% and 5.61% 
of CD8+ T-cells from Gag-Texo- and DCGag-immunized mice produced IFN-γ, which is 
significantly more than CD8+ T-cells (1.31%) from ConA-T-immunized mice (p<0.05) (Figure 
3.2B), indicating that both Gag-Texo and DCGag stimulate efficient Gag-specific CTL responses. 
Next, we assessed the ability of Gag-Texo to induce the differentiation of stimulated CD8+ 
T-cells into effector CTLs. We adoptively transferred Gag76-84 peptide-pulsed splenocytes that 
had been strongly labeled with CSFE (CFSEhigh), as well as the control HER2 peptide-pulsed 
splenocytes that had been weakly labeled with CFSE (CFSElow) at 1:1 ratio, into recipient mice 
that had been vaccinated with either Gag-Texo or DCGag cells 7 days after immunization. Sixteen 
hours after the cell transfer, mouse splenocytes were analyzed by flow cytometry. Thus, the loss 
of Gag-specific CFSEhigh target cells represents the Gag-specific killing activity of CTLs in 
immunized mice. As expected, there was substantial loss (72% and 80%) of the CFSEhigh cells in 
the Gag-Texo- and DCGag-immunized mice, respectively, whereas little cytotoxicity (3%) was 
induced in control ConA-T-immunized mice (Figure 3.2C), indicating that Gag-Texo- and 
DCGag -stimulated CTLs are effector CTLs with Gag-specific cellular cytotoxicity. 
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Figure 3.2 Gag-Texo stimulates Gag-specific functional effector CTL responses. 
(A, B) C57BL/6 mice were i.v. immunized with DCGag, Gag-Texo or active CD8+T cell (ConA T) without uptaking 
EXOGag. Six days after the immunization, tail blood samples of the immunized mice were stained with 
PE-anti-CD44 Ab and FITC-anti-CD8 Ab, and analyzed by flow cytometry. In another set of experiments, the 
splenocytes of immunized mice were first stimulated by Gag peptide in culture, and then stained with 
FITC-anti-CD8 Ab. After cell membrane permeabilization, the cells were stained with PE-anti-IFN-r Ab, and then 
analyzed by flow cytometry. The value in each panel represents the percentage of CD8+CD44+ T cells in the total 
cells analyzed or the percentage of CD8+ T cells producing IFN-r in the total CD8+ T cell population. (C) In vivo 
cytotoxicity assay. Six days after the immunization, the immunized mice were i.v. injected with a mixture of 
CFSEhigh and CFSElow -labeled splenocytes (at 1:1 ratio) that had been pulsed with Gag76-84 or irrelevant Mut1 
peptide, respectively. After 16 hrs, the spleens of immunized mice were removed and the percentages of the residual 
CFSEhigh (H) and CFSElow (L) target cells remaining in the recipients' spleens were analyzed by flow cytometry. The 
value in each panel represents the percentage of CFSEhigh vs CFSElow target cells remaining in the spleen. The value 
in parenthesis represents the standard deviation (SD). *p < 0.05 versus cohorts of ConA- T cells (Student t test). One 
representative experiment of two is shown. 
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3.4.3 Gag-Texo vaccine stimulates protective antitumor immunity in C57BL/6 mice 
 
Next, we transfected BL6-10 cells with pcDNA-Gag/GFP expression vector to form BL6-10Gag 
melanoma cells expressing a fluorescent fusion protein Gag/GFP (Figure 3.3A, panel a), but not 
HLA-A2 (Figure 3.3A, panel c) by flow cytometric analysis. Expression of Gag portion of 
Gag/GFP (82 KDa) was confirmed using anti-Gag antibody by Western blotting analysis (Figure 
3.3B). We then assessed the protective immunity derived from Gag-Texo vaccine against B16 
melanoma BL6-10Gag by i.v. injection of BL6-10Gag cells into immunized C57BL/6 mice 6 days 
after immunization. Three weeks after tumor cell injection, mice were sacrificed, and mouse 
lungs were checked for tumor metastasis colonies. As shown in Figure 3.3C, all mice injected 
with ConA-T cells without uptake of EXOGag had large numbers (>300) of lung metastatic 
BL6-10Gag tumor colonies. Gag-Texo or DCGag vaccine, however, induced a complete immune 
protection against BL6-10Gag tumor cell challenge in all 8/8 (100%) mice, indicating that 
Gag-Texo induces efficient protective immunity in wild-type C57BL/6 mice.  
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Figure 3.3 Gag-Texo stimulates preventive anti-tumor immunity.  
(A) Gag/GFP expression in BL6-10Gag (solid lines) or BL6-10 cells (dotted lines) was analyzed by flow cytometry 
(panel a). BL6-10Gag and BL6-10 cells were stained with the anti-HLA-A2 Ab and analyzed by flow cytometry 
(panels b and c). (B) Western blot analysis of lysates of BL6-10Gag and BL6-10 cells using the anti-Gag Ab. (C) 
C57BL/6 mice were immunized with PBS, ConA T, or Gag-Texo or DCGag. 6 days after the immunization, the 
immunized mice were i.v. injected with BL6-10Gag cells, then sacrificed 3 weeks subsequent to tumor challenge. The 
lung samples were collected and metastatic tumor colonies were counted. One representative experiment of two is 
shown. 
 
3.4.4 Gag-Texo vaccine induces protective and long-term antitumor immunity in 
transgenic HLA-A2 mice  
 
Next, we generated BL6-10Gag/A2 melanoma cells by transfection of BL6-10Gag/GFP cells with 
pcDNA-HLA-A expression vector, and showed that transfected BL6-10Gag/A2 melanoma cells 
expressed both HLA-A2 and Gag (Figure 3.4A, panels a/d and b/d). We then assessed the 
protective (6 days after immunization) and long-term immunity (30 days after immunization) 
derived from Gag-Texo vaccine against B16 melanoma BL6-10Gag/A2. As shown in Figure 3.4B, 
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all mice injected with ConA-T cells without uptake of EXOGag had a large number (>300) of 
lung metastatic BL6-10Gag/A2 tumor colonies. Gag-Texo vaccine, however, induced immune 
protection against BL6-10Gag/A2 tumor-cell challenge in 8/8 (100%) and 2/8 (25%) HLA-A2 mice 
with 6 and 30 days post immunization, respectively. The average number of lung tumor colonies 
in mice with 30 days post immunization is only 23, which is significantly less than that (>300) in 
control ConA-T-immunized mice (p<0.05). Our data indicate that Gag-Texo induces both 
protective and long-term immunity in HLA-A2 mice.  
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Figure 3.4 Gag-Texo induces preventive and therapeutic anti-tumor immunity in HLA-A2 mice.  
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(A) BL6-10Gag/A2 cells were stained with FITC-anti-HLA-A2 Ab (solid lines) or isotype-matched irrelevant Ab 
(dotted lines) and analyzed by flow cytometry (panel a). In addition, Gag/GFP expression in BL6-10Gag/A2 (solid 
lines) or BL6-10 cells (dotted lines) was analyzed with flow cytometry (panel b). BL6-10Gag/A2 cells were also 
stained with PE-anti-HLA-A2 Ab, and the cells were then analyzed for PE-HLA-A2 and GFP-Gag expression by 
flow cytometry (panels c and d). (B) To assess protective and long-term immunity, HLA-A2 mice were i.v. injected 
with BL6-10Gag/A2 6 or 30 days after PBS, ConA-T, or Gag-Texo immunization. (C) To assess therapeutic immunity, 
HLA-A2 mice were i.v. injected with BL6-10Gag/A2. Six days after tumor challenge, mice were then vaccinated with 
after ConA-T, or Gag-Texo. The mice were sacrificed 3 weeks after tumor cell challenge. The average number and 
diameter of lung metastatic tumor colonies were counted and measured using a caliper, respectively. *p < 0.05 
versus cohorts of ConA- T cells (Mann-Whitney U test) and **p < 0.05 versus cohorts of ConA- T cells (Student t 
test). One representative experiment of two is shown. 
 
3.4.5 Gag-Texo vaccine induces therapeutic immunity against Gag/HLA-A2-expressing 
tumor in transgenic HLA-A2 mice  
 
To assess the potential therapeutic effect of Gag-Texo, we first challenged HLA-A2 mice with 
BL6-10Gag/A2 tumor cells. Six days after tumor cell challenge, mice were then immunized with 
Gag-Texo. We found that, though all Gag-Texo-immunized mice (8/8) post 6-day tumor-cell 
challenge still carried lung tumor metastasis, the average number (50) and size (1.02 mm in 
diameter) of lung tumor colonies in Gag-Texo-immunized mice are significantly less than the 
average number (>300) and size (0.23 mm in diameter) in control ConA-T-immunized mice 
(p<0.05) (Figure 3.4C), indicating that Gag-Texo vaccine also induces some degree of 
therapeutic immunity against 6-day-established lung tumor metastasis in transgenic HLA-A2 
mice. 
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3.5 Discussion 
 
We previously generated Gp120-Texo vaccine using ConA-T-stimulated mouse polyclonal 
CD8+ T cells with uptake of HIV-1 Gp120-specific DC-released EXO (EXOGp120), and 
demonstrated that CD8+ Gp120-Texo vaccine is capable of stimulating CD4+ T cell-independent 
Gp120-specific CTL responses leading to protective and long-term immunity against 
Gp120/HLA-A2-expressing B16 melanoma (BL6-10Gp120/A2) in 8/8 transgenic HLA-A2 mice [17, 
18]. In addition, CD8+ Gp120-Texo vaccine also induced complete therapeutic immunity against 
6-day-established lung BL6-10Gp120/A2 melanoma metastasis in 2/8 HLA-A2 mice [17, 18]. Since 
Gag has become one of the most attractive target candidates for HIV-1 vaccine development, we 
generated Gag-Texo vaccine in this study. We demonstrate that both Gag-Texo and DCGag 
vaccines are capable of comparably stimulating Gag-specific effector CD8+ CTL responses. We 
also show that Gag-Texo-stimulated CTL response results in protective immunity against 
Gag-expressing BL6-10Gag melanoma in 8/8 wild-type C57BL/6 mice. In addition, we show that 
Gag-Texo vaccine also induces Gag-specific CTL responses leading to protective and long-term 
immunity against Gag/HLA-A2-expressing BL6-10Gag/A2 melanoma in 8/8 and 2/8 transgenic 
HLA-A2 mice, respectively. However, the average number of lung tumor colonies in the 
remaining 6 mice is only 23, which is significantly less than that (>300) in control 
ConA-T-immunized mice. In addition, Gag-Texo vaccine also induces some degree of 
therapeutic immunity against 6-day-established lung tumor metastasis in transgenic HLA-A2 
mice. Although all Gag-Texo-immunized mice (8/8) post 6-day tumor-cell challenge still carried 
lung tumor metastasis, the average number (50) and size (1.02 mm in diameter) of lung tumor 
colonies in Gag-Texo-immunized mice is significantly less than the average number (>300) and 
size (0.23 mm in diameter) in control ConA-T-immunized mice. Compared to Gp120-Texo 
vaccine inducing therapeutic immunity against 6-day-established lung BL6-10Gp120/A2 melanoma 
metastasis in 2/8 HLA-A2 mice, Gag-Texo vaccine induces a relatively less efficient therapeutic 
immunity in HLA-A2 mice bearing 6-day-established lung BL6-10Gag/A2 melanoma. It was 
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demonstrated that B16 melanoma expressing a low density of tumor antigen-specific pMHC-I 
complexes became less sensitive to CTL killing [42]. The less effectiveness of therapeutic 
immunity in Gag-Texo-immunized mice may be due to the lower density of Gag-specific 
peptide/MHC-I (pMHC-I) complexes presented on target BL6-10Gag/A2 cells expressing both Gag 
and irrelevant GFP, compared to the higher density of Gp120-specific pMHC-I complexes 
presented on BL6-10Gp120/A2 cells carrying only Gp120. Costimulatory molecule 41BBL has been 
shown to play important role in CTL priming and memory development, and in rescuing 
functionally impaired HIV-1-specific CTLs [43, 44]. To improve effectiveness of Gag-Texo 
vaccine, we are currently engineering Gag-Texo vaccine to express transgene-encoded 41BBL, 
and assessing its enhanced stimulatory effect on Gag-specific CTL responses and antitumor 
immunity in transgenic HLA-A2 mice. 
 
HIV-1 patients often have CD4+ T cell deficiency derived from the binding of HIV-1 gp120 to T 
cell CD4 molecules leading to T cell death by viral cytopathic effect [45]. Since CD4+ T cells are 
required for CD8+ CTL response and memory development [46], the quantitative and qualitative 
nature of HIV-1-specific CD8+ T cells has been greatly affected in HIV-1 patients [47]. 
HIV-1-specific DC vaccines have been also applied to clinical trials [9-12]. However, these DC 
vaccines which are capable of HIV-1-specific CTL responses in the presence of CD4+ T cells 
have been found to only induce some degree of immune responses in these studies [13]. 
Therefore, the quality of CTL responses may be the key to HIV-1 control [48]. Since 
HIV-1-specific CD8+ CTLs have been found to recognize some Gag conserved and cross-strain 
epitopes [21, 29, 30], Gag, but not Gp120 becomes one of the most attractive target candidates 
for HIV-1 vaccine development. Our HIV-1 Gag-specific DC-released exosome-targeted CD8+ 
T cell-based Gag-Texo vaccine may thus bypass the high mutation problem faced by preventive 
vaccines for induction of Abs [49], and become more efficient HIV-1 vaccine than our 
previously reported Gp120-Texo one [17, 18]. Our previous data showed that HIV-1 
Gp120-Texo, but not DCGp120 vaccine stimulated Gp120-specific CD8+ T cells in the absence of 
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CD4+ T cells [17, 18], indicating that our Gag-Texo vaccine may similarly stimulate CD4+ T 
cell-independent Gag-specific CTL responses. Although both Gag-Texo and DCGag vaccines 
stimulate comparable CTL responses, Gag-Texo vaccine may become more useful for treatment 
of HIV-1 patients with CD4+ T cell deficiency than DCGag. The assessment of Gag-specific CTL 
responses in patient’s blood samples, which are stimulated in vitro by Gag-Texo cells derived 
from patient’s autologous T cells with uptake of AdVGag-transfected autologous DC-released 
exosomes, is currently underway in our laboratory. 
 
Taken together, our novel CD8+ Gag-Texo vaccine capable of stimulating Gag-specific effector 
CTL responses and therapeutic immunity in transgenic HLA-A2 mice may be useful as a new 
immunotherapeutic vaccine for viral control in HIV-1 patients.  
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4.1 Abstract 
 
Human immunodeficiency virus type-1 (HIV-1)-specific dendritic cell (DC) vaccines have been 
applied to clinical trials. However, they have been found to only induce some degree of immune 
responses in clinical trial studies. We previously demonstrated HIV-1 Gag-specific Gag-Texo 
vaccine stimulated Gag-specific effector CD8+ cytotoxic T lymphocyte (CTL) responses leading 
to complete protective, but very limited therapeutic immunity. In this study, we constructed a 
recombinant adenoviral vector AdV4-1BBL expressing mouse 4-1BBL, and generated transgene 
4-1BBL-engineered OVA-Texo/4-1BBL and Gag-Texo/4-1BBL vaccines by transfection of 
ovalbumin (OVA)-Texo and Gag-Texo cells with AdV4-1BBL, respectively. We demonstrate that 
OVA-specific OVA-Texo/4-1BBL vaccine stimulates more efficient OVA-specific CTL responses 
(3.26%) compared to OVA-Texo-activated ones (1.98%) in wild-type C57BL/6 mice and the 
control OVA-Texo/Null vaccine without transgene 4-1BBL expression, leading to enhanced 
therapeutic immunity against 6-day established OVA-expressing B16 melanoma BL6-10OVA. 
OVA-Texo/4-1BBL-stimulated CTLs which show CD44+CD62LhighIL-7R+ phenotype are likely 
memory CTL precursors demonstrating prolonged survival and enhanced differentiation into 
memory CTLs with functional recall responses and long-term immunity against BL6-10OVA 
melanoma. In addition, we demonstrate that OVA-Texo/4-1BBL-stimulated CTLs up- and 
down-regulate expression of anti-apoptosis (Bcl2l10, Naip1, Nol3, Pak7 and Tnfrsf11b) and 
pro-apoptosis (Casp12, Trp63 and Trp73) genes, respectively, by RT2 ProfilerTM PCR array 
analysis. Importantly, Gag-specific Gag-Texo/4-1BBL vaccine also stimulates more efficient 
Gag-specific therapeutic and long-term immunity against HLA-A2/Gag-expressing B16 
melanoma BL6-10Gag/A2 than the control Gag-Texo/Null vaccine in transgenic HLA-A2 mice. 
Taken together, our novel Gag-Texo/4-1BBL vaccine capable of stimulating potent Gag-specific 
therapeutic and long-term immunity may represent a new immunotherapeutic vaccine for 
controlling HIV-1 infection.  
 
	   109	  
Key words: 4-1BBL, Gag, HLA-A2 mice, T-cell-based vaccine, Therapeutic immunity. 
	   110	  
4.2 Introduction 
 
CD8+ cytotoxic T lymphocytes (CTLs) are considered to be an important immune component for 
effective immunity against human immunodeficiency virus type 1 (HIV-1), and the induction of 
such responses using vaccines has become a major objective in the strategy to halt the pandemic 
[1, 2]. Dendritic cells (DCs), the most potent antigen presenting cells (APCs), expressing HIV-1 
structure proteins Gp120 and Gag have been used as vaccines and shown to stimulate 
HIV-1-specific CTL responses in animal models [3-6]. However, HIV-1-specific DC vaccines 
have been found to only induce some degree of immune responses in clinical trials [7], 
warranting the search of other more efficient vaccine strategies.  
 
We previously developed a novel T cell-based vaccine (OVA-Texo) using ConA-stimulated 
CD4+ T cells with uptake of ovalbumin (OVA)-specific DC-released exosomes (EXOs) [8-10]. 
We demonstrated that OVA-Texo vaccine induces more efficient immunity than DC vaccine, 
and is capable of stimulating potent CD4+ T-cell independent CTL responses and long-term 
antitumor immunity via IL-2/CD80 and CD40L signaling, and counteracting regulatory T 
cell-mediated immune suppression [8-10]. In addition, we also developed HIV-1 Gp120- and 
Gag-specific T cell-based (Gp120-Texo and Gag-Texo) vaccines using ConA-stimulated mouse 
CD8+ T cells with uptake of Gp120- and Gag-specific DC-released EXO [11, 12][13]. We 
demonstrated that Gp120-Texo and Gag-Texo stimulated Gp120- or Gag-specific CTL responses 
in transgenic HLA-A2 mice [11, 12][13]. However, their therapeutic efficacy was still very 
limited. For example, Gp120-Texo vaccine only cured 2/8 transgenic HLA-A2 mice bearing 6 
day-established HLA-A2/Gp120-expressing BL6-10Gp120/A2 B16 melanoma，though the vaccine 
cured 8/8 HLA-A2 mice bearing 3 day-established tumor [11, 12][13]. Gag-Texo vaccine could 
only induce some degree of therapeutic immunity by showing a decreased number and size of 6 
day-established HLA-A2/Gag-expressing BL6-10Gag/A2 B16 melanoma in transgenic HLA-A2 
mice [13].  
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4-1BB ligand (4-1BBL) is a member of the tumor necrosis factor family [14]. It is inducible on 
activated APCs, and can provide a CD28-independent signal leading to cell division, induction 
of effector function and enhancement of CD8+ T cell survival and memory development [15-19]. 
It synergizes with CD80 and PD-1 blockade for re-activation of anergic T cells [20], and for 
augmentation of CTL responses during chronic viral infection [21]. In addition, 4-1BBL 
signaling is also a critical component in the costimulation-dependent rescue of exhausted 
HIV-specific CTLs [22], and the combination of 4-1BBL and CD40L signaling enhances 
stimulation of HIV-1-specific CTLs [23]. Therefore, 4-1BBL becomes an attractive candidate 
signaling to improve efficacy of immunotherapy [19]. We assume that incorporation of 4-1BBL 
into our Gag-Texo vaccine may enhance its therapeutic effect against Gag-expressing tumor cell 
challenge. 
 
In this study, we generated transgene 4-1BBL-engineered OVA-Texo/4-1BBL and Gag-Texo/4-1BBL 
vaccines and assessed OVA- and Gag-specific CTL responses, therapeutic and long-term 
immunity against OVA- and Gag-expressing B16 melanoma in vaccinated-wild-type C57BL/6 
and -transgenic HLA-A2 mice, respectively.  
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4.3 Materials and methods 
	  
4.3.1 Reagents, cell lines and animals  
 
Biotin-labeled or fluorescein isothiocyanate (FITC)-labeled antibodies (Abs) were obtained from 
BD Biosciences (Mississauga, Ontario, Canada). Gag/HLA-A2-expressing BL6-10Gag/A2 tumor 
cell line was generated by transfection of BL6-10 tumor cells with two expression vectors 
pcDNANeoGag and pcDNAHygroHLA-A2 expressing Gag and HLA-A2, respectively, in our lab 
[13]. Female C57BL/6 and transgenic (Tg) HLA-A2 mice (#003475) carrying the transgene 
Tg(HLA-A2.1)1Enge were obtained from the Jackson Laboratory (Bar Harbor, MA). All mice 
were treated according to animal care committee guidelines of the University of Saskatchewan. 
 
4.3.2 Recombinant adenovirus construction 
 
The construction of recombinant adenovirus (AdV) expressing 4-1BBL (AdV4-1BBL) was 
performed by insertion of mouse 4-1BBL gene cloned from bone marrow-derived DCs into 
pShuttle vector (Stratagene Inc, La Jolla, CA) using the cloned 4-1BBL cDNA to form 
pLpA4-1BBL expressing 4-1BBL gene. The PmeI-digested shuttle vector was then co-transformed 
into BJ5183 E. coli cells that already containing the backbone vector for homologous 
recombination to form the recombinant vector AdV4-1BBL as described previously (Figure 4.1A) 
[13]. Adenoviral vector AdVGag expressing HIV-1 Gag and the control AdVNull without any 
transgene expression were previously constructed in our laboratory (Figure 4.1A) [13].  
 
4.3.3 Preparation of engineered OVA-Texo/4-1BBL and Gag-Texo/4-1BBL vaccines 
 
Ovalbumin (OVA)- and Gag-specific OVA-Texo and Gag-Texo vaccines were generated by 
incubation of ConA-activated CD8+ T (ConA-T) cells with OVA protein-pulsed bone 
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marrow-derived dendritic cell (DCOVA)- and AdVGag-transfected DC (DCGag)-released exosomes 
(EXOOVA and EXOGag) as previously described [13]. CD8+ OVA-Texo/4-1BBL and 
Gag-Texo/4-1BBL or the control CD8+ OVA-Texo/Null and Gag-Texo/Null vaccines were then 
generated by transfection of CD8+ OVA-Texo and Gag-Texo cells with AdV4-1BBL or the control 
AdVNull as previously described [13]. 
 
4.3.4 Flow cytometric analysis  
 
To assess CTL responses, blood samples of C57BL/6 mice i.v. immunized with 
OVA-Texo/4-1BBL or OVA-Texo/Null cells (2×106 cells/mouse) 6 or 10 days after the 
immunization were doubly stained with FITC-conjugated anti-CD8 Ab (FITC-CD8) and 
PE-conjugated H-2Kb/OVA257-264  tetramer (PE-Tetramer) or triply stained with FITC-CD8 Ab, 
PE-tetramer and PE-Cy5-conjugated anti-CD44, CD62L and IL-7R Abs, respectively, and then 
analyzed by flow cytometry [8-10]. To assess intracellular expression of granzyme B and IFN-γ, 
spenocytes of immunized mice were stimulated with 2 µM OVAI (SIINFEKL) peptide in vitro 
in presence of 2 µM monensin (GolgiStop) for four hours, and stained with FITC-anti-CD8 
antibody. The cells were then fixed, and the cell membranes were permeabilized in 
Cytofix/Cytoperm solution (BD Biosciences) and stained with PE-anti-granzyme B antibody or 
PE-anti-IFN-γ antibody for flow cytometric analysis [24]. To assess recall responses, immunized 
mice were i.v. boosted with DCOVA (1×106 cells/mouse) 30 days after immunization. CTL 
responses were analyzed by flow cytometry. The absolute numbers of OVA-specific 
tetramer-positive CD8+ T cells in each spleen of immunized mice in primary and recall responses 
were calculated as we previously described [24].    
 
4.3.5 Cytotoxicity assay  
 
The in vivo cytotoxicity assay was performed in immunized mice with transfer of both 
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OVA-specific CFSEhigh-labeled (H) and the control irrelevant CFSElow-labeled (L) target 
splenocytes at ratio of 1:1 (each 1×106 cells) as previously described [13]. Sixteen hrs after cell 
transfer the residual CFSEhigh and CFSElow target cells remaining in the recipients' spleens were 
analyzed by flow cytometry. 
 
4.3.6 RT2 profiler PCR array analysis 
 
T cells were enriched from splenocytes of C57BL/6 mice immunized with OVA-Texo/4-1BBL and 
OVA-Texo/Null vaccines by using nylon wool-column [8-10]. OVA-specific CTLs were then 
purified from enriched T cell population by using PE-tetramer staining followed by using 
anti-PE microbeads (Miltenyi Biotec) [25]. A highly purified population of OVA-specific CTLs 
was obtained by positive selection through passing in 2 separate MACS columns sequentially. 
The expression of pathway-focused panel of 84 genes related to apoptosis in the above two 
groups of CTLs was examined using RT2 ProfilerTM PCR Array Mouse Apoptosis (SuperArray 
Bioscience) [25].  
 
4.3.7 Animal studies  
 
To examine the therapeutic antitumor immunity conferred by Gag-Texo/4-1BBL vaccine, the 
wild-type C57BL/6 and transgenic HLA-A2 mice (n=8) were first injected i.v. with 0.5×106 
BL6-10OVA and BL6-10Gag/A2 cells. Six days after tumor cell inoculation, C57BL/6 and HLA-A2 
mice were then injected i.v. with OVA-Texo/4-1BBL and Gag-Texo/4-1BBL cells (2×106 cells/mouse), 
respectively. OVA-Texo/Null and Gag-Texo/Null cells (2×106 cells/mouse) were used as vaccine 
controls. To assess the long-term antitumor immunity, C57BL/6 mice immunized with 
OVA-Texo/4-1BBL vaccine and HLA-A2 mice immunized with Gag-Texo/4-1BBL vaccine were i.v. 
challenged with a large dose of BL6-10OVA cells (1×106 cells/mouse) and a regular dose of 
BL6-10Gag/A2 cells (0.5×106 cells/mouse), respectively, 30 days after immunization. The mice 
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were sacrificed 3 weeks after tumor cell injection, and the lung metastatic tumor colonies were 
counted in a blind fashion. Metastases on freshly isolated lungs appeared as discrete 
black-pigmented foci that were easily distinguishable from normal lung tissues and confirmed by 
histological examination. Metastatic foci too numerous to count were assigned an arbitrary value 
of >300 [9]. 
 
4.3.8 Statistic analyses  
 
Statistical analyses were performed using the Student t test or the Mann-Whitney U test for 
comparison of variables from different groups. A value of p<0.05 was considered to be 
statistically significant [10].  
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4.4 Results  
 
4.4.1 Generation of AdV4-1BBL-infected OVA-Texo (OVA-Texo/4-1BBL) vaccine expressing 
transgene 4-1BBL 
 
We first constructed a recombinant 4-1BBL-expressing adenoviral vector AdV4-1BBL by 
recombinant DNA technology (Figure 4.1A). We generated OVA-Texo vaccine by using 
ConA-stimulated CD8+ T cells with uptake of OVA-pulsed DC (DCOVA)-released EXO 
(EXOOVA) [11]. We then generated transgene 4-1BBL-engineered and the control OVA-Texo 
vaccines (OVA-Texo/4-1BBL and OVA-Texo/Null) by transfection of OVA-Texo cells with 
AdV4-1BBL and the control AdVNull, respectively, followed by phenotypical assessment of 
OVA-Texo/4-1BBL and OVA-Texo/Null by flow cytometry. We demonstrated that OVA-Texo/4-1BBL 
expressed comparable amount of T cell CD8, CD25, CD28, CD44, CD40L, CD62L, IL-7R, 
inhibitory PD-1 and exosomal costimulatory CD80, but enhanced amount of costimulatory 
4-1BBL compared to the control OVA-Texo/Null and OVA-Texo (Figure 4.1B), indicating that 
OVA-Texo/4-1BBL expresses transgene-encoded cell-surface 4-1BBL.  
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Figure 4.1 Phenotypic analysis of OVA-Texo/4-1BBL.  
(A) Schematic representation of adenoviral (AdV) vectors AdVNull, AdVGag and AdV4-1BBL. The E1/E3 depleted 
replication-deficient AdV is under the regulation of the cytomegalovirus (CMV) early/immediate 
promoter/enhancer. ITR, inverted terminal repeat. (B) The engineered OVA-Texo/4-1BBL and the control 
OVA-Texo/Null and OVA-Texo cells were stained with a panel of Abs (solid lines) or isotype-matched irrelevant 
Abs (dotted lines), and then analyzed by flow cytometry. One representative experiment of two is shown. 
 
4.4.2 OVA-Texo/4-1BBL stimulates enhanced OVA-specific CD8+ effector CTL responses in 
wild-type C57BL/6 mice 
 
To assess whether OVA-Texo/4-1BBL vaccine stimulates enhanced CTL responses, we immunized 
wild-type C57BL/6 mice with OVA-Texo/4-1BBL, and then assessed OVA-specific CTL responses 
using FITC-CD8 and PE-tetramer antibody staining by flow cytometry. We demonstrated that 
OVA-Texo/4-1BBL vaccine was able to more efficiently stimulate OVA-specific CTL responses 
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[3.26%, equivalent to 0.33×106 cells per spleen [24]] than OVA-Texo vaccine (1.98%, 
equivalent to 0.20×106 cells per spleen) (p<0.05) (Figure 4.2A). To assess their phenotypes, the 
splenocytes of immunized mice were in vitro stimulated with OVAI peptide and CD8+ T cells 
were examined for their intracellular expression of INF-γ and Granzyme B by flow cytometry. 
We demonstrated that 2.69% and 1.98% of IFN-γ- and Granzyme B-expressing CD8+ T cells 
were found in OVA-Texo/4-1BBL-immunized mice (Figure 4.2B), which are more than those in 
either OVA-Texo- or OVA-Texo/Null-immunized mice. Next, we assessed the ability of 
OVA-Texo/4-1BBL vaccine to induce the differentiation of stimulated CD8+ T cells into effector 
CTLs. We adoptively transferred OVA257-264 peptide-pulsed splenocytes that had been strongly 
labeled with CSFE (CFSEhigh), as well as the control peptide Mut1-pulsed splenocytes that had 
been weakly labeled with CFSE (CFSElow), into recipient mice that had been vaccinated with 
OVA-Texo/4-1BBL or OVA-Texo/Null. Thus, the loss of CFSEhigh target cells represents the killing 
activity of CTLs in immunized mice. As expected, there was substantial loss (90%) of the 
CFSEhigh (OVA peptide-pulsed) cells in the OVA-Texo/4-1BBL-immunized mice, whereas 
significantly less cytotoxicity (77%) was induced in mice immunized with the control 
OVA-Texo/Null vaccine (p<0.05) (Figure 4.2C), indicating that OVA-Texo/4-1BBL efficiently 
stimulates OVA-specific CD8+ T cell differentiation into functional effector CTLs with 
OVA-specific cytotoxicity.  
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Figure 4.2 OVA-Texo/4-1BBL stimulates potent OVA-specific effector CTL responses and therapeutic 
immunity.  
(A) C57BL/6 mice (3-4 per group) were immunized with OVA-Texo/4-1BBL, OVA-Texo/Null and OVA-Texo. Six 
days after the immunization, tail blood samples of the immunized mice were stained with FITC-anti-CD8 Ab and 
PE-tetramer, and then analyzed by flow cytometry. The value in each panel represents the percentage of 
OVA-specific CD8+ T cells in the total CD8+ T cell population. The value in parenthesis represents the standard 
deviation (SD). *p<0.05 versus cohorts of the control OVA-Texo/Null and OVA-Texo groups (Student t test). (B) 
Intracellular staining. To assess intracellular expression of granzyme B and IFN-γ, spenocytes of immunized mice 
were stimulated with OVAI peptide in vitro in presence of monensin, followed by FITC-anti-CD8 antibody staining. 
After permeabilization, cells were further stained with PE-anti-granzyme B antibody or PE-anti-IFN-γ antibody. 
CD8 positive T cells were gated for assessment of granzyme B and IFN-γ expression by flow cytometry. (C) In vivo 
cytotoxicity assay. Six days after the immunization, the immunized mice (3-4 per group) were i.v. injected with a 
mixture of CFSEhigh- and CFSElow-labeled splenocytes (at 1:1 ratio) that had been pulsed with OVA257-264 
(SIINFEKL) peptide and the control Mut1 (FEQNTAQP) peptide of an irrelevant 3LL lung carcinoma antigen, 
respectively. After 16 hrs, the spleens of immunized mice were removed and the percentages of the residual 
CFSEhigh (H) and CFSElow (L) target cells remaining in the recipients' spleens were analyzed by flow cytometry. The 
value in each panel represents the percentage of CFSEhigh vs CFSElow target cells remaining in the spleen. The value 
in parenthesis represents the standard deviation (SD). *p<0.05 versus cohorts of the control OVA-Texo/Null and 
OVA-Texo groups (Student t test). (C) C57BL/6 mice (8 per group) were first i.v. injected with BL6-10OVA tumor 
cells (0.5×106 cells/mouse) followed by immunization of the mice with OVA-Texo/Null and OVA-Texo/4-1BBL (2×106 
cells/mouse) for assessment of the therapeutic immunity against 6 day-established tumor. The mice were sacrificed 
3 weeks after tumor cell challenge. The numbers of black lung metastatic tumor colonies were counted. *p<0.05 
versus cohorts of OVA-Texo/4-1BBL group (Mann-Whitney U test). (D) H&E staining of lung tissues. The lung 
tissues of immunized mice were fixed in 10% neutral-buffered formalin and then embedded in paraffin. Tissue 
sections were stained with H&E and examined by microscopy. Tumor colonies were marked with arrows. 
Magnification × 150. One representative experiment of two is shown. 
 
4.4.3 OVA-Texo/4-1BBL vaccine stimulates enhanced therapeutic immunity against 
OVA-expressing BL6-10OVA melanoma in wild-type C57BL/6 mice 
 
To assess the potential therapeutic effect of OVA-Texo/4-1BBL, we first challenged wild-type 
C57BL/6 mice with BL6-10OVA tumor cells. Six days after tumor cell challenge, mice bearing 6 
day-established tumor were then immunized with OVA-Texo/4-1BBL. We demonstrated that both 
OVA-Texo/Null and OVA-Texo vaccines were able to significantly reduce average number of 
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lung tumor metastatic colonies (p<0.05) compared to the control mice with PBS injection, 
though they failed in curing any mice bearing 6 day-established tumor (Figure 4.2D). However, 
OVA-Texo/4-1BBL vaccine was able to cure 8/8 mice (Figure 4.2D), indicating that 
OVA-Texo/4-1BBL vaccine induces an excellent therapeutic immunity against 6-day established 
lung tumor metastasis in C57BL/6 mice. The presence and absence of lung tumor metastatic 
colonies in OVA-Texo/Null- and OVA-Texo/4-1BBL-immunized mouse lungs were confirmed by 
histopathologic analysis (Figure 4.2E). 
 
4.4.4 OVA-Texo/4-1BBL-stimulated CD8+ T cells are likely CD62LhighIL-7R+ memory CTL 
precursors  
 
To assess the phenotypic characteristics of OVA-Texo/4-1BBL-stimulated CD8+ T cells, we first 
gated OVA-Texo/4-1BBL- or OVA-Texo/Null- or OVA-Texo-stimulated CD8+ T cells for further 
analysis of the expression of CD44, CD62L and IL-7R 10 days after immunization. We 
demonstrated that all vaccine-stimulated CD8+ T cells expressed these molecules 10 days after 
immunization (Figure 4.3A). However, OVA-Texo/4-1BBL-stimulated CD8+ T cells showed a 
higher amount of CD62L and IL-7R expression than OVA-Texo/Null- or OVA-Texo-stimulated 
CD8+ T cells, indicating that they are likely CD62LhighIL-7R+ memory CTL precursors [26].  
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Figure 4.3 Characterization of OVA-Texo/4-1BBL-stimulated CTLs.  
(A) The tail blood samples were harvested from the immunized C57BL/6 mice 10 days after immunization and 
triply stained with FITC-anti-CD8 and PE-tetramer and PE-Cy5-anti-CD44, CD62L and IL-7R Abs, respectively, 
for flow cytometric analysis. The value in each panel represents the percentage of OVA-specific CD8+ T cells in the 
total CD8+ T cell population. The value in parenthesis represents the standard deviation (SD). *p<0.05 versus 
cohorts of the control OVA-Texo/Null and OVA-Texo groups (Student t test). OVA-specific CD8+tetramer+ CTLs 
were sorted for assessment of expression of CD44, CD62L and IL-7R by flow cytometry (solid lines). Irrelevant 
isotype-matched Abs were used as controls (dotted lines). (B) Apoptosis real-time PCR (RT-PCR) array were 
performed to compare apoptosis-related gene expression differences between OVA-Texo/4-1BBL-stimulated and 
OVA-Texo/Null-stimulated CTLs. Total RNA was isolated from purified OVA-specific CTLs using RNeasy 
extraction kit (Qiagen) and reversely transcribed using RT2 First Strand kit (SuperArray Bioscience). The mRNA 
expression of each gene in array system was performed using StepOnePlus thermocycler (Applied Biosystem) and 
analyzed using Hprt1, Gapdh and β-actin as interal controls in web-based software as per manufacturer’s 
instructions.  Only genes with mRNA fold changes of more than 3 are shown. (C) Recall responses. The tail blood 
samples were harvested from the immunized C57BL/6 mice 30 days after immunization or 4 days after the boost, 
and then doubly stained with FITC-anti-CD8 and PE-tetramer for flow cytometric analysis. The value in each panel 
represents the percentage of OVA-specific CD8+ T cells in the total CD8+ T cell population. The value in 
parenthesis represents the standard deviation (SD). *p<0.05 versus cohorts of the control OVA-Texo/Null and 
OVA-Texo groups on day 30 after immunization or day 4 after the boost (Student t test). One representative 
experiment of two is shown. 
 
4.4.5 OVA-Texo/4-1BBL-stimulated CD8+ T cells show up- and down-regulation of anti- and 
pro-apoptosis genes 
 
To assess expression of anti- and pro-apoptosis genes, we extracted RNA from mouse 
OVA-specific CTLs purified from immunized mouse splenic T cell population 10 days after 
immunization using RNeasy extraction kit. Apoptosis real-time PCR (RT-PCR) arrays were then 
performed to compare apoptosis-related gene expression between OVA-Texo/4-1BBL-stimulated 
and OVA-Texo/Null-stimulated CTLs by using their RNA samples and RT2 ProfilerTM PCR Array 
Mouse Apoptosis. We demonstrated that anti-apoptosis-related genes such as Bcl2l10 (3.3-fold), 
Naip1 (14.6-fold), Nol3 (3.0-fold), Pak7 (7.1-fold) and Tnfrsf11b (7.2-fold) were found to be 
up-regulated in OVA-Texo/4-1BBL-stimulated CTLs compared to OVA-Texo/Null-stimulated CTLs 
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(Figure 4.3B). In contrast, pro-apoptosis-related genes such as Casp12 (-4.5-fold), Trp63 
(-4.5-fold) and Trp73 (-14.1-fold) were found to be down-regulated in 
OVA-Texo/4-1BBL-stimulated CTLs (Figure 4.3B). Our results indicate that compared to 
OVA-Texo/Null-stimulated CTLs, OVA-Texo/4-1BBL-stimulated CTLs up- and down-regulate 
expression of anti- and pro-apoptosis related genes, respectively.   
 
4.4.6 OVA-Texo/4-1BBL vaccine stimulates enhanced long-term immunity against 
OVA-expressing BL6-10OVA melanoma in wild-type C57BL/6 mice 
 
To assess whether OVA-Texo/4-1BBL-stimulated CD8+ T cells differentiate into memory CD8+ T 
cells, we harvested blood samples from immunized C57BL/6 mice 30 days after the primary 
immunization, when OVA-Texo/4-1BBL-stimulated effector CD8+ T cells should become memory 
CD8+ T cells. We then stained the blood samples with FITC-conjugated anti-CD8 Ab and 
PE-conjugated H-2Kb/OVA257-264 tetramer, and analyzed them by flow cytometry. We 
demonstrated that CD8+ T cells (0.27%) in OVA-Texo/4-1BBL-vaccinated group became memory 
CD8+ T cells, which are significantly more than that (0.15%) in OVA-Texo/Null-vaccinated group 
(p<0.05) (Figure 4.3C). To assess whether these memory CD8+ T cells are functional, we then 
i.v. boosted the immunized mice with DCOVA cells 30 days after the primary immunization. Four 
days after the boost, we assessed OVA-specific CTL responses by flow cytometry. We 
demonstrated that more recall responses (2.98%, equivalent to 0.30×106 cells per spleen) were 
seen in OVA-Texo/4-1BBL-vaccinated group than OVA-Texo/Null-immunized group (0.73%, 
equivalent to 0.07×106 cells per spleen) (p<0.05) (Figure 4.3C), indicating that OVA-specific 
CTLs in OVA-Texo/4-1BBL-vaccinated group become 4-fold more than those in 
OVA-Texo/Null-vaccinated group after the boost stimulation. To assess the potential long-term 
protective immunity, we also i.v. challenged the immunized mice with BL6-10OVA tumor cells 30 
days after the primary immunization, when vaccine-stimulated CTLs should have become 
memory CTLs. We demonstrated that OVA-Texo/4-1BBL-immunized, but not OVA-Texo/Null- or 
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OVA-Texo-immunized C57BL/6 mice obtained long-term immunity efficiently against 
challenge with a large dose of BL6-10OVA tumor cells (1×106/mouse) in all 8/8 mice (Figure 4.4), 
indicating that OVA-Texo/4-1BBL vaccine also induces enhanced long-term immunity against 
OVA-expressing BL6-10OVA tumor in C57BL/6 mice.  
	  
Figure 4.4 OVA-Texo/4-1BBL vaccine stimulates efficient long-term immunity in C57BL/6 mice.  
To assess long-term immunity, C57BL/6 mice (8 per group) were first i.v. immunized with OVA-Texo, 
OVA-Texo/Null and OVA-Texo/4-1BBL (2×106 cells/mouse), 30 days after vaccination, mice were then i.v. injected 
with a large dose of OVA-expressing BL6-10OVA tumor cells (1×106 cells/mouse). The mice were sacrificed 3 weeks 
after tumor cell challenge. The numbers of black lung metastatic tumor colonies were counted. *p<0.05 versus 
cohorts of the control PBS group (Mann-Whitney U test). One representative experiment of two is shown. 
 
4.4.7 Gag-Texo/4-1BBL vaccine induces enhanced preventive, therapeutic and long-term 
immunity against Gag/HLA-A2-expressing BL6-10Gag/A2 melanoma in transgenic HLA-A2 
mice  
 
To assess preventive immunity, we first immunized transgenic HLA-A2 mice with 
Gag-Texo/4-1BBL or Gag-Texo/Null followed by challenging the immunized mice with 
HLA-A2/Gag-expressing BL6-10Gag/A2 tumor cells 6 days after immunization. We demonstrated 
that both Gag-Texo/4-1BBL and Gag-Texo/Null vaccines were able to protect all 8/8 mice from 
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tumor challenge (Figure 4.5A), indicating that Gag-Texo/4-1BBL vaccine stimulates potent 
preventive immunity. To assess the potential therapeutic effect of Gag-Texo/4-1BBL, we first 
challenged transgenic HLA-A2 mice with BL6-10Gag/A2 tumor cells. Six days after tumor cell 
challenge, mice were then immunized with Gag-Texo/4-1BBL or Gag-Texo/Null. We demonstrated 
that Gag-Texo/Null vaccine was able to significantly reduce the average number of lung tumor 
metastatic colonies (p<0.05) compared to the control mice with PBS injection, but they failed in 
curing any mice bearing 6 day-established tumors (Figure 4.5B). However, Gag-Texo/4-1BBL 
vaccine was still able to cure all 8/8 mice (Figure 4.5B), indicating that Gag-Texo/4-1BBL vaccine 
stimulates potent therapeutic immunity. Next, we assessed long-term immunity by challenging 
immunized mice with a regular dose of BL6-10Gag/A2 tumor cells (0.5×106/mouse) 30 days after 
immunization. We demonstrated that Gag-Texo/4-1BBL, but not Gag-Texo/Null vaccine was able to 
protect all 8/8 mice from tumor challenge 30 days after immunization, though Gag-Texo/Null 
vaccine significantly reduced the average number of lung tumor metastatic colonies (p<0.05) 
compared to the control mice with PBS injection (Figure 4.5C), indicating that Gag-Texo/4-1BBL 
vaccine also stimulates efficient long-term immunity in HLA-A2 mice. 
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Figure 4.5 Gag-Texo/4-1BBL vaccine stimulates potent immunity in transgenic HLA-A2 mice.  
(A) Transgenic HLA-A2 mice (8 per group) were first i.v. immunized with Gag-Texo/Null and Gag-Texo/4-1BBL 
(2×106 cells/mouse) followed by i.v. injection of HLA-A2/Gag-expressing BL6-10Gag/A2 tumor cells (0.5×106 
cells/mouse) 6 days after immunization for assessment of the preventive immunity. (B) Transgenic HLA-A2 mice (8 
per group) were first i.v. injected with BL6-10Gag/A2 tumor cells (0.5×106 cells/mouse) followed by immunization of 
the mice with Gag-Texo/Null and Gag-Texo/4-1BBL (2×106 cells/mouse) for assessment of the therapeutic immunity 
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against 6 day-established tumor. (C) HLA-A2 mice (8 per group) were first i.v. immunized with Gag-Texo/Null and 
Gag-Texo/4-1BBL (2×106 cells/mouse) followed by i.v. injection of BL6-10Gag/A2 tumor cells (0.5×106 cells/mouse) 30 
days after immunization for assessment of the long-term immunity. The mice were sacrificed 3 weeks after tumor 
cell challenge. The numbers of black lung metastatic tumor colonies were counted. *p<0.05 versus cohorts of the 
control PBS group (Mann-Whitney U test). One representative experiment of two is shown. 
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4.5 Discussion 
 
We previously developed a novel OVA-specific T cell-based vaccine (OVA-Texo) capable of 
stimulating efficient CTL responses and protective immunity via counteracting regulatory T 
cell-mediated immune suppression, and inducing long-term antitumor immunity via IL-2/CD80 
and CD40L signaling [8-10]. To assess its therapeutic effect, C57BL/6 mice bearing 6 
day-established OVA-expressing B16 melanoma BL6-10OVA were immunized with OVA-Texo 
in this study. We demonstrate that OVA-Texo vaccine is unable to cure any mice bearing 6 day 
tumor though OVA-Texo vaccination significantly reduces the average number of lung tumor 
colonies compared to the control PBS. To improve its therapeutic efficacy, we generated an 
engineered OVA-Texo/4-1BBL vaccine expressing transgene 4-1BBL. We demonstrate that 
OVA-Texo/4-1BBL vaccine stimulates more efficient OVA-specific effector CTL responses 
leading to potent therapeutic immunity curing 8/8 C57BL/6 mice bearing 6 day-established 
BL6-10OVA melanoma. In addition, we also demonstrate that OVA-Texo/4-1BBL-stimulated CTLs 
are more likely the memory CTL precursors with preferential differentiation into 
CD44+CD62LhighIL-7R+ central memory CTLs [26] since  OVA-Texo/4-1BBL-stimulated mice 
demonstrated enhanced recall responses and more efficient long-term immunity against 
challenge of a large dose of OVA-expressing B16 melanoma BL6-10OVA cells. 
 
Several apoptosis-related molecules that play key roles in regulating apoptosis in T cells have 
been identified [27, 28], including the Bcl-2 family with either anti-apoptotic or pro-apoptotic 
effects. It has been reported that 4-1BBL signaling promotes the survival of CD8+ T cells via 
4-1BB-mediated NF-κB activation leading to up-regulation of Bcl-XL and Bfl-1 [17], and inhibits 
T cell apoptosis via phosphatidylinositol 3-kinase (P13K)-AKT/protein kinase-B 
(PKB)-mediated up-regulation of Bcl-XL and c-FLIPshort [29]. Recently, it has been shown that 
41BB signaling enhances T cell survival via cooperation of TNF receptor-1 (TNFR1) and 
leukocyte-specific protein-1 (LSP1) leading to activation of ERK and Bcl-2-interacting mediator 
	   130	  
of cell-death (Bim) [30]. In this study, we demonstrated that 4-1BBL signaling up- and 
down-regulates expression of anti-apoptosis (Bcl2l10, Naip1, Nol3, Pak7 and Tnfrsf11b) and 
pro-apoptosis (Casp12, Trp63 and Trp73) genes, respectively, in CD8+ CTLs with prolonged 
survival. It has also been reported that 4-1BBL can interact with Toll-like receptors (TLRs) to 
sustain tumor necrosis factor (TNF) production [31]. Active CD8+ T cells express TLRs, and 
TLR signaling has been shown to play a role in T cell survival independently of APCs [32-34]. 
TNF receptor-2 (TNFR2) is also present on active CD8+ T cells and TNF/TNFR2 interaction is 
important in sustaining their survival [35, 36]. Therefore, it is possible that the transgene 4-1BBL 
expression on OVA-Texo/4-1BBL cells interacts with TLRs of CD8+ T cells leading to enhanced 
TNF production and prolonged survival of activated CD8+ T cells via TLR signaling. Enhanced 
TNF production may also induce prolonged survival of activated CD8+ T cells via its auto-crime 
TNF/TNFR2 loop [35, 36].  
 
Gag vaccine has been shown to stimulate persistent and broader HIV-1-specific CTL responses 
against conserved Gag epitopes in animal models [37-40]. HLA-B57 HIV-1-infected individuals 
have been found to have autologous CTL responses against four conserved Gag epitopes, leading 
to reducing virus replication and viral control [41]. In addition, clinically, effective CTL 
responses against Gag, but not other viral antigens, have been found to correlate with a 
significant suppression of HIV-1 replication in patients [42-45]. We have recently generated 
Gag-specific exosome-targeted Gag-Texo vaccine and demonstrated that Gag-Texo could 
stimulate Gag-specific CTL responses, but only induce some degree of therapeutic immunity 
against Gag/HLA-A2-expressing B16 melanoma BL6-10Gag/A2 in transgenic HLA-A2 mice [13]. 
To improve its vaccination efficacy, we incorporated 4-1BBL into Gag-Texo vaccine to generate 
an engineered Gag-Texo/4-1BBL vaccine expressing transgene 4-1BBL. We demonstrate that 
Gag-Texo/4-1BBL vaccine stimulates potent preventive immunity leading to protection of 8/8 
transgenic HLA-A2 mice from challenge of BL6-10Gag/A2, and induces potent therapeutic 
immunity leading to curing 8/8 transgenic HLA-A2 mice bearing 6 day-established BL6-10Gag/A2. 
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In addition, Gag-Texo/4-1BBL vaccine also induces an enhanced long-term immunity against 
BL6-10Gag/A2 challenge in transgenic HLA-A2 mice. Since HIV-1-specific CTLs are essential for 
effective immunity against HIV-1 [1, 2], Gag-Texo-stimulated Gag-specific CTLs which showed 
their killing effects to Gag-expressing tumor cells in HLA-A2 mice in this study should also play 
important roles in controlling HIV-1 infection by their cytolytic effects to virus-infected T cells 
or DCs in HIV-1 patients. Assessment of Gag-Texo/4-1BBL vaccination efficacy in controlling 
Gag-specific viral infection in wild-type C57BL/6 mice infected by a recombinant 
replication-competent poxvirus rTTV-luc-gag expressing Gag [46] is underway in our 
laboratory. 
 
In this study, we also demonstrated that Gag-Texo/4-1BBL vaccine cells express PD-1 which was 
originally reported to be a T cell activation antigen [47], and later found to be an inhibitory 
regulator promoting immune exhaustion [48] and suppressing T cell responses [49, 50]. PD-1 
blockade with its antibody could restore T cell’s function [51]. It has been reported that the 
HIV-1 early regulatory protein Tat can broaden T cell responses to HIV-1 envelope proteins [52, 
53]. To enhance the therapeutic efficacy of Gag-Texo/4-1BBL vaccine, the construction and the 
assessment of Gag-Tat-Texo/4-1BBL vaccine expressing both late HIV-1 Gag and early HIV-1 Tat 
proteins, and the examination of Gag-Texo/4-1BBL vaccine cells with its PD-1 blocked by 
anti-PD-1 antibody in our transgenic HLA-A2 mouse model are also underway in our laboratory.       
 
Taken together, our novel engineered Gag-Texo/4-1BBL vaccine capable of stimulating potent 
therapeutic and long-term immunity may represent a new immunotherapeutic vaccine for 
controlling HIV-1 infection.  
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CHAPTER 5  Novel exosome-targeted T cell-based vaccine counteracts T cell 
anergy/tolerance and converts CTL exhaustion via CD40L signaling the mTORC1 
pathway in chronic infection 
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5.1 Abstract 
 
CD8+ cytotoxic T lymphocytes (CTL) are important effector cells providing protection against 
various viral infections, while T cell exhaustion is probably a chief reason for the ineffective 
virus elimination in chronic infectious diseases, such as human immunodeficient virus type 1 
(HIV-1) infection. We have recently generated novel HIV-1 Gag-specific exosome 
(EXO)-targeted T cell-based vaccine (Gag-Texo) capable of activation of Gag-specific CTL 
responses and immunity in transgenic HLA-A2 mice. To assess the potential therapeutic 
immunity derived from Gag-Texo vaccination in chronic infection, we developed a chronic 
infection model by injecting of C57BL/6 mice with an ovalbumin (OVA)-expressing 
recombinant adenoviral vector AdVova. We found that OVA-specific memory CTLs expressing 
inhibitory PD-1 and LAG-3 are inflated and functionally exhausted (defective in T cell 
proliferation, IFN-γ expression, cytotoxicity and recall responses, and in tumor suppression) in 
mice with AdVova-induced chronic infection. In addition, we also demonstrate that during 
chronic infection, naïve CD8+ T cells increase expression of inhibitory PD-L1 and BTLA 
molecules, and of T cell anergy-associated genes (Grail and Itch), and reduce in vitro T cell 
proliferation. Remarkably, OVA-specific OVA-Texo vaccine efficiently counteracts T cell 
anergy/tolerance and converts CTL exhaustion during chronic infection. Its effect on converting 
memory CTL exhaustion is also synergistic with PD-L1 blockade. Furthermore, our work reveals 
that CD40L signaling of OVA-Texo vaccine plays a critical role in counteracting T cell 
anergy/tolerance and CTL exhaustion, and that in vivo OVA-Texo-treated CTLs up-regulate 
mTORC1 pathway-related molecules including Akt, S6, elF4E and T-bet. Importantly, 
Gag-Texo vaccine is capable of inducing a strong protective and therapeutic immune responses 
in the course of AdV-induced chronic infection. Therefore, this study is likely to have a serious 
impact on the development of therapeutic vaccines for treatment of HIV-1 and other chronic 
infectious diseases. 
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5.2 Introduction 
 
CD8+ cytotoxic T lymphocytes (CTLs) are important effector cells actively involved in the 
immune response against various viral infections. After acute viral infection, CTL immunity 
develops in the three phases of expansion, contraction and memory [1]. In brief, initial encounter 
with viral antigens (Ags) derived from an infectious agent triggers activation and proliferation of 
Ag-specific CTLs [2, 3].  CTL responses often peak 7 days after an infection followed by the 
contraction-phase when majority (>90%) of effector CTLs (eCTLs) die of activation-induced 
cell death (AICD) [4, 5]. Remaining 5-10% of CTLs go on to seed the memory pool, and become 
long-term memory CTLs (mCTLs) [6]. These mCTLs are capable of responding robustly upon 
re-encounter with the same viral Ags. In contrast, during chronic viral infections with 
lymphocytic choriomeningitis virus (LCMV) and human immunodeficiency virus (HIV), 
Ag-specific CD8+ T cells initially acquire effector function, but gradually become less functional 
as the infection progresses. This loss of function, known as “exhaustion”, is hierarchical, with 
properties such as proliferative potential and production of IL-2 affected early and IFN-γ later in 
the course [7, 8]. T cell exhaustion is probably a chief issue leading to the ineffective virus 
control in these chronic infectious diseases.  
 
Dendritic cells (DCs) are the most potent antigen-presenting cells (APC). They have been used 
as vaccines to stimulate HIV-specific CTL responses in vitro and in animal models [9-11], as 
well as in clinical trials in acquired immunodeficiency syndrome (AIDS) patients [12-16]. In 
these trials, the safety profile has been excellent with minor local side-effects found.  However, 
dendritic cell vaccine-induced HIV-specific CTL responses and immunotherapeutic efficacy 
were relatively poor in AIDS patients and usually were associated with a deficiency in helper 
CD4+ T cell. Nevertheless, some inhibitory effects on viral titers and disease progression have 
been found [14-16], warranting a search for more potent HIV-specific therapeutic vaccines.   
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We previously developed a new “T-APC” concept by demonstrating that CD4+ helper T cells 
became “T-APCs” capable of directly stimulating CD8+ CTL responses after acquiring 
Ag-specific DC membrane molecules [17]. Based upon this concept, we also developed 
ovalbumin (OVA)-specific DC (DCOVA)-released exosome (EXO)-targeted T cell-based 
(OVA-Texo) vaccine, while demonstrating that non-specific or Ag-specific T cells were able to 
uptake Ag-specific DC-released EXO via CD54/LFA-1 interaction [18, 19]. The OVA-Texo 
vaccination is of more potent immunogenicity than the DCOVA approach, inducing CD4+ T 
cell-dependent CTL responses, and capable of directly stimulating potent OVA-specific CTL 
responses and memory even in the absence of the host CD4+ T cell help, and counteracting 
CD4+25+FoxP3+ regulatory T (Treg) cell suppression [18, 19]. To develop an HIV-specific T 
cell-based vaccine, we constructed recombinant HIV Gp120-expressing adenoviral vectors 
(AdVGp120), and generated a Gp120-specific Gp120-Texo vaccine by using AdVGp120 [20]. We 
found that Gp120-Texo vaccine stimulated Gp120-specific CTL responses leading to therapeutic 
immunity in both wild-type (WT) C57BL/6 and transgenic HLA-A2 mice [20, 21]. Since HIV-1 
Gag is more suitable [22], we thus developed an HIV Gag-specific EXO-targeted T cell-based 
(Gag-Texo) vaccine by using AdVGag, and showed that the Gag-Texo vaccine was capable of 
activation of Gag-specific CTL responses and immunity [23]. To enhance its immunogenicity, 
we generated a 4-1BBL-expressing Gag-Texo vaccine, and demonstrated that it assured more 
efficient Gag-specific CTL responses and therapeutic immunity against Gag-expressing tumor 
challenges than Gag-Texo vaccine, while also inducing enhanced long-term Gag-specific CTL 
memory in WT C57BL/6 and transgenic HLA-A2 mice [24].     
 
In this study, we established a mouse AdV-induced chronic infection model by i.v. inoculation of 
WT C57BL/6 mice with OVA- or beta galactosidase-expressing adenoviruses (AdVova or 
AdVLacZ) [18, 25, 26]. We found OVA-specific memory CTLs expressing inhibitory 
programmed cell death protein-1 (PD-1) and lymphocyte-activation gene 3 (LAG3) molecules 
were inflated and became functionally exhausted, while naïve CD8+ T cells expressed inhibitory 
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programmed death-ligand 1 (PD-L1) and B- and T-lymphocyte attenuator (BTLA) molecules [27] 
and became anergic in mice with the AdVova-induced chronic infection. Interestingly, our work 
also revealed that the OVA-Texo vaccine stimulated potent CTL responses and immunity in the 
AdVLacZ- and AdVova-induced chronic infection models by counteracting naïve CD8+ T cell 
anergy/tolerance and converting CTL exhaustion via the CD40L-activated mammalian target of 
rapamycin complex-1 (mTORC1) pathway. To examine whether the Gag-Texo vaccine is 
capable of effectively stimulating Gag-specific CTL immunity in chronic infection, we 
performed animal studies by immunizing C57BL/6 mice in the AdVova-induced chronic 
infection model with the HIV-1-specific Gag-Texo vaccine, and this vaccination induced 
therapeutic immunity against Gag-expressing tumors.  	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5.3 Materials and Methods 
	  
5.3.1 Reagents, cell lines and animals  
	  
Ovalbumin (OVA) was obtained from Sigma (St. Louis, MO). OVAI (OVA257-264, SIINFEKL) 
peptide specific for H-2Kb and Mut1 (FEQNTAQP) peptide specific for H-2Kb of an irrelevant 
3LL lung carcinoma were synthesized by Multiple Peptide Systems (San Diego, CA). 
Biotin-labeled antibodies (Abs) specific for CD44 (IM7) and CD40 (3/23) and Phycoerythrin 
(PE)-IFN-γ (XMG1.2) and PE-CD45RA (14.8) Abs were obtained from BD Biosciences 
(Mississauga, ON, Canada). Biotin anti-CD62L (MEL-14), IL-7R (SB/199), 
lymphocyte-activation gene 3 (LAG-3) (C9B7W) Abs, purified anti-Histone H3 (Poly6019), 
T-bet (Poly6235) Abs, phycoerythrin/Cy5 (PE/Cy5)-conjugated streptavidin were obtained from 
Biolegend (San Diego, CA, USA). PE/Cy5-CD8 (53-6.7), biotin-programmed cell death protein 
1 (PD-1) (J43), programmed death-ligand 1 (PD-L1) (1-111A), B- and T-lymphocyte attenuator 
(BTLA) (8F4), and Ki67 (SolA15) Abs were obtained from eBioscience (San Diego, CA). 
Purified anti-pAkt 1/2/3 (Ser 473) was obtained from Santa Cruz Biotechnology, Inc. (Dallas, 
TX). Purified anti-phospho-eukaryotic translation initiation factor 4E (eIF4E) (Ser209), and 
anti-phospho-S6 ribosomal protein (Ser235/236) (D57.2.2E) were obtained from Cell Signaling 
Technology, Inc. (Danvers, MA, USA). PE-labeled H-2Kb/OVA257-264 tetramer (YTS 169.4) was 
obtained from Beckman Coulter (Miami, FL). Fluorenscein isothiocyanate (FITC)-labeled CD8 
(53-6.7) was obtained from Caltag (Burlingame, CA). FITC-conjugated AffiniPure goat 
anti-rabbit IgG (H+L) was obtained from Jackson ImmunoResearch Laboratories, Inc. (West 
Grove, PA). Carboxyfluorescein succinimidyl (CFSE) was obtained from Molecular Probes 
(Eugene, OR). The depleting anti-CD4 antibody was purified from ascites of hybridoma cell 
lines GK1.5. Rat anti-mouse PD-L1 (10F.9G2) was obtained from BioXCell Inc  (West 
Lebanon, NH) [28]. Adenoviral vector AdVova, AdVLac Z, and AdVGag expressing OVA, 
β-galactosidase, HIV-1 Gag respectively were previously constructed in our laboratory [23][24, 
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26]. Recombinant Listeria mono-cytogenes rLmOVA [29] expressing OVA was obtained from 
Dr. Hao Shen, University of Pennsylvania, Philadelphia, PA. The highly lung metastatic 
OVA-expression BL6-10OVA and Gag-expressing BL6-10Gag tumor cell lines were generated in 
our lab [17, 26]. Female WT C57BL/6 (B6), OVA-specific T cell receptor (TCR)-transgenic (Tg) 
OTI or OTII mice and various gene knockout (KO) mice were obtained from the Jackson 
Laboratory (Bar Harbor, MA). All mice were treated according to animal care committee 
guidelines of the University of Saskatchewan. 	  
5.3.2 Dendritic cell and exosome preparations  
 
Bone marrow-derived dendritic cells (DCs) were obtained by culturing bone marrow cells of WT 
B6 in culture medium containing GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) for six days as 
previously described [19]. DCs were pulsed with OVA (0.5 mg/ml) for overnight or infected 
with AdVGag and termed DCOVA or DCGag, respectively. DCOVA or DCGag-released exosomes 
(EXOOVA or EXOGag) were then purified from DC culture supernatants by differential 
ultracentrifugation [19].  
	  
5.3.3 T cell preparation 
 
Naïve or memory CD8+ T cells were isolated from naïve or AdVLacZ-infected WT B6 and 
OVA-specific TCR transgenic OT I mouse spleens, enriched by passage through nylon wool 
columns (C&A Scientific, Manassas, VA), and then purified by negative selection using 
anti-mouse CD4 paramagnetic beads (DYNAL Inc, Lake Success, NY). To generate active CD8+ 
T cells, the spleen cells from naïve C57BL/6 mice were cultured in RPMI1640 medium 
containing IL-2 (20 U/ml) and ConA (1 µg/ml) for 3 days [30].  CD8+ T cells were then 
purified from ConA-activated T cells using MACS anti-CD8 microbeads (Miltenyi Biotech 
GmBH, Germany) to yield T cell populations that were >98% CD8+ T (ConA-T) cells [17].  
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ConA-T cells derived from IL-2, IL-6, TNF-α and CD40L KO mice were termed  (IL-2-/-), 
(IL-6-/-), (TNF-α-/-) and (CD40L-/-) ConA T cells, respectively. 	  
5.3.4 Preparation of OVA-Texo and Gag-Texo vaccines 	  
OVA- and Gag-specific OVA-Texo and Gag-Texo vaccines were generated by incubation of 
CD8+ ConA-T cells with EXOOVA and EXOGag [23]. OVA-Texo and Gag-Texo cells were then 
transfected with AdV4-1BBL as previously described [24]. OVA-Texo derived from (IL-2-/-), 
(IL-6-/-), (TNF-α-/-) and (CD40L-/-)ConA-T cells were termed OVA-Texo(IL-2-/-), 
OVA-Texo(IL-6-/-),  OVA-Texo(TNF-α -/-) and OVA-Texo(CD40L-/-), respectively. 
	  
5.3.5 Chronic and acute infection animal model 
B6 mice and OTI mice were i.v. injected with AdVova (2.5×106 pfu) or AdVLacZ (2.5×106 pfu) 
for over 60 days to establish an chronic infection. B6 mice were i.p. injected with anti-CD4 Ab 
(GK1.5; 400 µg) to deplete endogenous CD4+ T cells one day before adenoviral infection. For 
acute infection, B6 mice were i.v. injected with rLmOVA (2,000 cfu). To generate long-lasting 
CD8+ memory T cells during the acute infection, naive CD8+ and CD4+ T (0.25×106) cells 
derived from OT I and OTII mice were i.v.  injected into B6 mice, one day after transfer, mice 
were i.v. immunized with rLmOVA (2,000 cfu) [29]. Seven or nine, fourteen, thirty and sixty 
days after immunization, mice tail blood was harvested for detecting OVA-specific CD8+ T cells 
by flow cytometry. 
	  
5.3.6 Cytotoxicity assay  
The in vivo cytotoxicity assay was performed in immunized mice with transfer of both 
OVAI-pulsed CFSE (3.0 µM CFSEhigh)-labeled (H) and the control irrelevant Mut1-pulsed CFSE 
(0.6 µM CFSElow)-labeled (L) target splenocytes at ratio of 1:1 (each 4×106 cells) as previously 
described [17]. Sixteen hrs after cell transfer, the residual CFSEhigh (H) and CFSElow (L) target 
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cells remaining in the recipients' spleens were analyzed by flow cytometry. 	  
5.3.7 T cell proliferation assays 
In in vitro T-cell proliferation assay, the purified CD8+ T cells from naïve and chronically 
AdVLacZ-infected B6 mice were labeled with CFSE (3 mM). CFSE-labeled CD8+ T cells were 
then incubated with CD3/CD28-microbeads in presence of IL-2 (40 U/mL) and 
beta-mercaptoethanol (2-ME; 50 µM). Three days after incubation, active CD8+ T cells were 
harvested, and analyzed for determination of the number of CFSE-labeled T cell divisions by 
flow cytometry. In in vivo T-cell proliferation assay, naïve CD8+ T cells were purified from 
naïve OTI mice or OTI mice chronically infected with AdVLacZ, labeled with CFSE (4 mM), and 
then adoptively transferred (1×106/mouse) into naïve B6 recipients. DCova or OVA-Texo 
vaccines were injected on the following day to active OTI-CD8+ T cells in vivo. Seventy two 
hours later, splenocytes were collected and analyzed by flow cytometry.  
	  
5.3.8 RNA array analysis 
Naïve CD8+ T cells from naïve or chronically infected WT B6 mice spleens were purified by 
using EasySep™ Mouse CD8+ T Cell Isolation Kit (STEMCELL Technologies Inc, Vancouver, 
BC, Canada), followed by Biotin-CD45RA (BD Biosciences, Mississauga, ON, Canada) and 
MACS anti-biotin microbeads (Miltenyi Biotech GmBH, Germany). RNA isolation was 
performed using RNeasy Plus Mini Kit (QIAGEN Inc, Toronto, ON, Canada), cDNA was 
synthesized immediately using RT² First Strand Kit (QIAGEN Inc.). Real-time PCR was carried 
out with RT² SYBR Green qPCR Mastermix (QIAGEN Inc.) using a StepOnePlus Real-time 
PCR system (Applied Biosystems, Burlington, ON, CANADA). A panel of primers specific for 
T-cell anergy-associated genes were synthesized [31]. Expression of each gene was normalized 
to β-actin. The primers were as follows: β-actin: F-GTGAC GTTGA CATCC GTAAA GA; 
R-GCCGG ACTCA TCGTA CTCC; Grail: F-GCGCA GTCAG CAAAT GAA; R-TGTCA 
ACATG GGGAA CAACA; Ikaros: F-GCTGG CTCTC GGAGG AG; R-CGCAC TTGTA 
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CACCT TCAGC; Casp3: F-ACGCG CACAA GCTAG AATTT; R-CTTTG CGTGG AAAGT 
GGAGT; EGR2: F-TCAGT GGTTT TATGC ACCAG C; R-GAAGC TACTC GGATA 
CGGGA G; Grg4 F-TCACT CAAGT TTGCC CACTG; R-CACAG CTAAG CACCG ATGAG; 
Itch: F-GTGTG GAGTC ACCAG ACCCT; R-GCTTC TACTT GCAGC CCATC. The fold 
induction represents the ratio of mRNA expression in CD8+ T cells from chronically infected 
mice spleens to that in naive mice spleens. 
	  
5.3.9 Conversion of CTL exhaustion by PD-L1 blockade and OVA-Texo vaccine 
	  
To assess the conversion of memory CTL (mCTL) exhaustion by OVA-Texo vaccine, 
chronically AdVova-infected WT B6 mice with CTL exhaustion were given i.v. OVA-Texo 
vaccine (2×106 cells/mouse) or OVA-Texo vaccines with defect of various molecules such as 
IL-2, IL-6, TNF-α and CD40L. Four days after vaccination, OVA-specific CD8+ T cell 
proliferation was assessed at day 4 post vaccination by cytometry. For in vivo PD-L1 blockade, 
chronically AdVova-infected WT B6 mice with CTL exhaustion were given two hundred 
micrograms of rat anti-mouse PD-L1 (10F.9G2) or rat IgG2b isotype control (BioXCell) every 
third day intraperitoneally, five times in total [32]. OVA-specific CD8+ T cell proliferation was 
analyzed on the following day after the last treatment by flow cytometry. To assess the 
synergistic effect on conversion of CTL exhaustion, OVA-Texo (2×106 cells/mouse) was given 
intravenously on day 14 (one day post the last PD-L1 blockade treatment), and OVA-specific 
CD8+ T cell proliferation was assessed at day 4 post vaccination by flow cytometry.  
	  
5.3.10 Flow cytometric analysis  	  
For OVA-specific CD8+ T cell response kinetic study, periphery blood samples of B6 mice i.v. 
infected with AdVova (1×108 pfu/mouse) or rLmOVA (2,000 cfu/mouse) were collected at 
different time points. Mouse blood samples were then stained with FITC-anti-CD8 antibody 
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(FITC-CD8) and PE-H-2Kb/OVA257-264 tetramer (PE-tetramer), and then analyzed by flow 
cytometry. To phenotypically analyze mCTLs or naïve CD8+ T cells, mouse blood samples of 
B6 mice i.v. infected with AdVova (1×108 pfu/mouse) or rLmOVA (2,000 cfu/mouse) were 
triply stained with FITC-CD8, PE-tetramer or PE-CD45RA and biotin-CD44, CD62L, IL-7R, 
PD-1, PD-L1, LAG-3, CD40, and BTLA, respectively, followed by staining of 
PE/Cy5-streptavidin, and then analyzed by flow cytometry. To assess CTL recall responses, 
mouse splenic T cell populations containing mCTLs from B6 mice with rLmOVA-induced acute 
infection or AdVova-induced chronic infection were adoptively transferred into naïve B6 mice, 
and then the mice were i.v. boosted with DCova (1×106 cells/mouse). Four days after the boost, 
OVA-specific CTL responses were analyzed by flow cytometry. To assess OVA-specific CD8+ 
T cell responses, B6 mice were i.v. infected chronically with AdVLacZ (2.5×106 pfu/mouse), or 
AdVova (2.5×106 pfu/mouse) were i.v. immunized with  DCova, OVA-Texo and OVA-Texo 
cells (2×106 cells/mouse) derived from various gene KO mice, respectively. Mouse blood 
samples or cell suspensions prepared from mouse spleens and lungs were then stained with 
FITC-CD8 and PE-tetramer, and then analyzed by flow cytometry [18, 19, 33]. The chronically 
AdVLacZ-infected B6 mice were first i.v. immunized with DCova or OVA-Texo (2×106 
cells/mouse), and the vaccinated mice were then i.v. boosted with rLmOVA (1,000 cfu) 30 days 
after immunization. To assess conversion of CTL exhaustion, chronically AdVova-infected B6 
mice were i.v. vaccinated with OVA-Texo (2×106 cells/mouse). Four days after the 
immunization, mouse splenocyte samples were intracellularly stained with PE/Cy5-CD8, 
PE-tetramer and polyclonal rabbit anti-pAKT, pelF4E, pS6, NFAT, T-bet, Histone H3 Abs, and 
biotin-Ki67, respectively, followed by FITC-anti-rabbit IgG and FITC-streptavidin, and then 
analyzed by flow cytometry. To analyze OVA-specific CD8+ T cell proliferation inanti-PD-L1 
Ab or rat IgG2b isotype control-treated, OVA-Texo-vaccinated B6 mice with AdVova chronic 
infection, mouse blood samples were stained with FITC-CD8 and PE-tetramer, and then 
analyzed by flow cytometry. For intracellular staining, the splenocytes samples were collected, 
re-stimulated with 2 µM OVAI peptide and subjected to intracellular staining (BD Biosciences) 
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of IFN-γ, as described previously [34].  	  
5.3.11 Animal studies  
To assess functional effect of mCTLs in chronic infection, splenocytes from chronically 
AdVova-infected mice or rLmova-infected mice 60 days after primary infection were transferred 
into naive B6, the recipient mice (n=4) were injected with 0.5×106 BL6-10OVA cells on the 
following day. The mice were sacrificed 3 weeks after tumor cell challenge, and the lung 
metastatic tumor colonies were counted in a blind fashion. To examine the protective antitumor 
immunity conferred by Gag-Texo vaccine, B6 mice (n=8) with AdVova-induced chronic 
infection were i.v. injected with Gag-Texo or DCGag cells (2×106 cells/mouse). The immunized 
mice were i.v. challenged with 0.5×106 BL6-10Gag cells 6 days subsequent to the immunization. 
To examine the therapeutic antitumor immunity conferred by Gag-Texo vaccine, B6 mice (n=8) 
with chronic infection were first i.v. injected with 0.5×106 BL6-10Gag cells. Six days after tumor 
cell inoculation, B6 mice were then i.v. injected with Gag-Texo or DCGag cells (2×106 
cells/mouse). The mice were sacrificed 3 weeks after tumor cell challenge, and the lung 
metastatic tumor colonies were counted in a blind fashion. Metastases on freshly isolated lungs 
appeared as discrete black-pigmented foci that were easily distinguishable from normal lung 
tissues and confirmed by histological examination. Metastatic foci too numerous to count were 
assigned an arbitrary value of >300 [19]. 
	  
5.3.12 Statistic analyses  
Unless stated otherwise, data are expressed as mean (with SD). Statistical analyses were 
performed using the Student t test or the Mann-Whitney U test for comparison of variables from 
different groups. Probability values of p > 0.05 and p < 0.01 are considered statistically not 
significant and very significant, respectively [33].   	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5.4 Results 
 
5.4.1 OVA-expressing adenoviral vector induces mouse chronic infection: 
 
Distinctive CD8+ T cell responses ranging from immunogenic CTL responses to CTL exhaustion 
or depletion were reported to be elicited post vaccination with adenoviral vectors (AdVs) 
expressing different antigens and after immunization with AdVs at various doses or through 
different routes [35-41]. For example, mice i.v. injected with β-galactosidase-expressing AdVLacZ 
induced mouse chronic infection with CTL exhaustion and deletion [36]. To assess whether a 
replication-deficient transgene OVA-expressing AdVova [26] also induces mouse chronic 
infection, C57BL/6 (B6) mice were i.v. injected with AdVova. Our further analysis demonstrated 
that 60 days later, AdVova injection resulted in a dose-dependent OVA-specific memory CD8+ T 
cell inflation (Figure 5.1A and sFig 5.1). Inflated memory CTLs down-regulated their cell 
surface markers for T cell memory, CD62L and IL-7R, compared to memory CTLs developed in 
rLmOVA-immunized mice (Fig 5.1B). Interestingly, we found that inflated CTLs expressed 
CD40. Importantly, we also demonstrated that inflated CTLs up-regulated inhibitory molecules, 
such as PD-1, PD-L1 and LAG-3 (Fig 5.1B), indicating that these CTLs may be exhausted. To 
assess the functional traits (capacity for Ag-specific cell killing and CTL recall responses) of 
these potentially “exhausted” CTLs, we performed flow cytometric analyses to measure cellular 
IFN-γ expression, cytolytic effectiveness and CTL recall responses following antigen boost, and 
performed animal studies to analyze protective immunity against OVA-expressing tumor 
(BL6-10OVA) challenge.  We found that only 17% of these CTLs possessed intracellular IFN-γ 
in comparison to nearly 75% of of IFN-γ-positive CTLs observed in rLmOVA-immunized 
control (Fig 5.1C). This observation clearly indicates that CTLs in chronic infection display a 
significant reduction in the expression of an effector cytokine, IFN-γ. In addition, these CTLs 
also showed defects in the cytolytic response against OVA-specific highly CFSE-labeled (H) 
target cells (Fig 5.1D), in CTL recall responses upon DCOVA boost (Fig 5.1E), and in the 
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immunity against OVA-expressing BL6-10OVA tumors (Fig 5.1F), indicating that the 
OVA-specific inflated CTLs are functionally exhausted in AdVova-induced chronic infection 
model. Taken together, our observations implicate that OVA-expressing AdVova-infected mice 
represent a new chronic infection mouse model with memory CTL inflation and exhaustion.   
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Figure 5.1 Figure 1. AdVova induces chronic infection in mice.  
(A) Periphery blood samples harvested at peak days (Day 9 and Day 7) and up to Day 120 after i.v. injection of 
C57BL/6 mice with AdVova (2.5×106 pfu) or rLmOVA (2,000 cfu) were stained with the PE-H-2Kb/OVAI peptide 
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tetramer (PE-tetramer) and FITC-anti-CD8 Ab (FITC-CD8), and analyzed by flow cytometry. The value in each 
panel represents the percentage of OVA-specific (tetramer-positive) CD8+ T cells vs total CD8+ T cell population. 
Sixty days after the infection, mouse periphery blood samples from each group were stained with the PE-tetramer, 
FITC-CD8, and PE-Cy5-labeled Abs, and analyzed by flow cytometry. (B, C) Assessment of phenotype and 
intracellular IFN-γ of CTLs in chronic infection. OVA-specific CD8+ T cells with positive PE-tetramer and 
FITC-CD8 staining (B) were gated, and assessed for expression of the indicated molecules (solid lines). Dotted lines 
represent isotype-matched controls. In (C), cells were permeabilized for assessment of intracellular IFN-γ by flow 
cytometry. The value in each panel represents the percentage of CD8+ T cells producing IFN-γ. (D) In vivo 
cytotoxicity assay. Sixty days after the infection, mice were i.v. injected with a mixture of CFSEhigh and CFSElow 
-labeled splenocytes (at 1:1 ratio) that had been pulsed with OVAI or irrelevant Mut1 peptide, respectively. After 16 
hrs, the residual CFSEhigh (H) and CFSElow (L) target cells remaining in the recipients' spleens were analyzed by 
flow cytometry. The value in each panel represents the percentage of CFSEhigh vs CFSElow target cells remaining in 
the spleen. (E) Sixty days after the infection, splenocytes of AdVova- or rLmOVA-infected mice were adoptively 
transferred into naïve C57BL/6 mice, and 1 day after the transfer, the mice were boosted with DCova. Four days 
after the boost, their periphery blood samples were analyzed for OVA-specific memory CTL recall responses by 
flow cytometry. The value in each panel represents the percentage of PE-tetramer-positive CD8+ T cells vs total 
peripheral CD8+ T cells. (F) One day after the transfer, the mice were i.v. injected with BL6-10OVA tumor cells, and 
were euthanized 3 weeks later. The numbers of lung metastatic tumor colonies were counted. **P < 0.01. Error bars 
represent standard deviation (SD). One representative experiment of two to three is shown. 
 
5.4.2 CD8+ T cell anergy/tolerance in chronic infection: 
 
The bystander chronic infection associated with some level of immune tolerance often enhances 
susceptibility of chronically infected hosts to a variety of co-infections [42]. To assess a potential 
immune tolerance in our chronic infection model, we assessed OVA-specific CTL responses 
derived from vaccination of DCova and OVA-Texo, respectively, in WT B6 and chronically 
AdVLacZ-infected B6 mice. This analysis demonstrated that DCova stimulated significantly less 
OVA-specific CTL and memory CTL recall responses in mice with chronic infection, compared 
to WT B6 mice (Fig 5.2A), indicating that some immune tolerance occurs in the presence of the 
AdVLacZ-induced chronic infection. In contrast, only slightly decreased CTL and memory CTL 
recall responses were found in OVA-Texo-immunized mice with chronic infection (Fig 5.2A), 
indicating that OVA-Texo vaccine can counteract T cell tolerance caused by chronic infection. 
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To assess whether the immune tolerance involves CD8+ T cells, we performed an in vitro T cell 
proliferation assay. In the assay, naïve CD8+ T cells purified from chronically infected-B6 mice 
or WT B6 mice were labeled with CFSE, and were activated with anti-CD3/CD28 beads, and 
IL-2 in vitro. Three days later, these T cells were analyzed by flow cytometry. We demonstrated 
that naïve CD8+ T cells derived from chronically AdVLacZ-infected B6 mice underwent less cell 
divisions (Fig 5.2B, panel c) than those from WT B6 mice (Fig 5.2B, panel b), indicating that 
naïve CD8+ T cells in chronic infection are tolerogenic. In addition, we also performed an in vivo 
T cell proliferation assay. In the assay, naïve CD8+ T cells purified from OTI mice or 
AdVLacZ-infected OTI mice were labeled with CFSE and then, transferred into WT B6 mice. One 
day after the cell transfer, the mice were immunized with DCova, and mouse splenocytes were 
analyzed by flow cytometry. We demonstrated that CFSE-labeled OTI CD8+ T cells derived 
from AdVLacZ-infected OTI mice passed through less cell divisions (Fig 5.2C, panel e) than 
those derived from uninfected OTI mice (Fig 5.2C, panel b), thus confirming that naïve CD8+ T 
cells with chronic infection background are indeed tolerogenic. It has been shown that naïve 
splenocytes representing B and T cells and DCs up-regulated inhibitory PD-L1 in the course of 
chronic infection [32]. To assess the phenotype of the tolerogenic CD8+ T cells, we performed 
flow cytometric analysis. Interestingly, we found that naïve CD8+ T cells in AdV-induced 
chronic infection up-regulated inhibitory PD-L1 and BTLA, compared to cells derived from 
rLmOVA-infected mice (Fig 5.2D), suggesting that the inhibitory PD-L1 and BTLA may be 
responsible for CD8+ T cell tolerance. In addition, we also performed RT-PCR analysis, and 
showed that naïve CD8+ T cells in AdV-induced chronic infection model up-regulated T cell 
anergy-associated genes Grail and Itch (Fig 5.2E), implicating that naive CD8+ T cell tolerance 
in chronic infection is associated with T cell anergy. Interestingly, OVA-Texo vaccine induced 
proliferation of CD8+ T cells transferred from AdVLacZ-infected OTI mice at a level similar to 
proliferation of cells transferred from WT OTI mice (Fig 5.2C), thus further confirming that 
OVA-Texo vaccine is capable of counteracting CD8+ T cell tolerance in chronic infection.  
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Figure 5.2 T cell anergy/tolerance in chronic infection. 
(A) Naive C57BL/6 mice or C57BL/6 mice chronically infected with AdVLacZ were immunized with DCova or 
OVA-Texo. Six days after the immunization, mouse periphery blood samples were stained with the PE-tetramer and 
FITC-CD8, and analyzed by flow cytometry. Thirty days after immunization, mice were boosted. The periphery 
blood samples were analyzed 4 days after the boost for OVA-specific memory CTL recall responses by flow 
cytometry. (B, C) Cell division was monitored by levels of CFSE dilution. Histograms show the FACS profiles of 
(B) CD8+CFSE+ T cells from the in vitro proliferation assay or (C) PE-tetramer+ (Tet+) CFSE+ T cells from the in 
vivo proliferation assay. Numbers of cell division (n) are indicated on top of each peak. (D) Periphery blood samples 
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from mice with rLmOVA-induced acute infection or mice with AdVova-induced chronic infection were stained with 
PE-CD45RA, FITC-CD8, and PE-Cy5 labeled Abs, respectively, and then analyzed by flow cytometry. Naive CD8+ 
T cells with positive PE-CD45RA and FITC-CD8 staining were gated, and assessed for expression of co-stimulatory 
or inhibitory molecules (solid lines). Dotted lines represent isotype-matched controls. (E) Expression of 
anergy-associated genes was assessed by RT-PCR using mRNA purified from naïve CD8+ T cells derived from 
naïve or chronically infected mice. (F) C57BL/6 mice chronically infected with AdVLacZ were immunized with 
OVA-Texo or with OVA-Texo with indicated molecule defects. Six days after the immunization, cells from 
periphery blood samples were stained with PE-tetramer and FITC-CD8, and analyzed by flow cytometry. The value 
in each panel represents the percentage of PE-tetramer-positive CD8+ T cells vs total peripheral CD8+ T cells. *p < 
0.05, **P < 0.01.  Error bars represent SD. One representative experiment of two to three is shown. 
 
5.4.3 OVA-Texo-induced counteraction of CD8+ T cell anergy/tolerance depends upon 
CD40L signal: 
 
It has been demonstrated that IL-2, IL-6, TNF-α as well as CD40L counteract T cell anergy and 
tolerance [43-45]. To assess a potential molecular mechanism for OVA-Texo-mediated 
counteraction of CD8+ T cell tolerance, we generated a panel of OVA-Texo vaccines with 
various gene defects, such as OVA-Texo(IL-2-/-), OVA-Texo(IL-6-/-),  OVA-Texo(TNF-α-/-) 
and  OVA-Texo(CD40L-/-) lacking expression of IL-2, IL-6, TNF-α and CD40L, respectively. 
Mice with AdVLacZ-induced chronic infection were then immunized with each of these vaccines, 
respectively, followed by assessing by flow cytometry OVA-specific CTL responses at day 6 
after immunization. This approach demonstrated that CD40L deficiency alone reduced 
OVA-Texo-stimulated OVA-specific CTL responses in chronic infection by 85%, though CTL 
responses were also slightly to moderately down-regulated when using OVA-Texo(TNF-α-/-), 
OVA-Texo(IL-2-/-) and OVA-Texo(IL-6-/-) vaccines (Fig 5.2F), indicating that 
OVA-Texo-induced counteraction of CD8+ T cell anergy/tolerance in chronic infection is 
mediated mainly by CD40L signaling.    
 
5.4.4 OVA-Texo vaccine converts T cell exhaustion in chronic infection: 
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In our further work, we examined whether OVA-Texo vaccine would enhance responses of 
CD8+ T cells primed in the absence of CD4+ T cell help. This is a more stringent model of 
chronic infection, in which the ‘helpless’ CD8+ T cells demonstrated stronger functional defects 
[46]. Mice with AdVova-induced chronic infection were boosted with the OVA-Texo vaccine. 
Four days after the boost, the proliferation, IFN-γ expression and cytolytic avtivity of 
OVA-specific CTLs were analyzed by flow cytometry. These experiments demonstrated that, 
though no significant change in expression of inhibitory molecules (PD-1 and PD-L1) on CTLs 
could be observed, there were around 3-fold more of OVA-specific CTLs in OVA-Texo-boosted 
mouse peripheral blood (Fig 5.3A), spleen (Fig 5.3B), and non-lymphoid tissues, including lungs 
(Fig 5.3B). We next measured by intracellular staining the effect of the OVA-Texo vaccine on 
the stimulation-induced expression of the effector cytokine IFN-γ in exhausted CTLs on a 
‘per-cell’ basis. We determined that there was nearly 4.5-fold increase in IFN-γ-producing 
OVA-specific CTLs (nearly 90% of IFN-γ+ cells) in OVA-Texo-treated mice, compared to 
untreated (PBS) control mice (only ~20% of IFN-γ+ cells) (Fig 5.3C). Since in chronic infection, 
exhausted CTLs have a functional defect in their ability to lyse target cells (Fig 5.1D) [7], we 
attemted to determine whether OVA-Texo-converted CTLs resume their cytolytic effectiveness. 
To achieve this, we performed an in vivo cytotoxicity assay by transferring highly and lowly 
CFSE-labeled OVA-specific (H) and non-specific (L) target cells in 1:1 ratio into 
OVA-Texo-immunized mice, and monitoring the lysis of OVA-specific (H) target cells by flow 
cytometry. This showed a significant increase in OVA-specific cytolytic response  (93.5% lysis) 
in OVA-Texo-treated mice, compared to weak (13.5%) target cell lysis in untreated mice (Fig 
5.3D).   
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Figure 5.3 OVA-Texo converts OVA-specific exhausted CD8+ T cells. 
(A) AdVova-infected C57BL/6 mice were immunized with OVA-Texo. Before the immunization and 4 days after 
the immunization, cells from periphery blood samples were stained with PE-tetramer, FITC-CD8, and 
PE-Cy5-labeled Abs, and analyzed by flow cytometry. The value in each panel represents the percentage of 
PE-tetramer-positive CD8+ T cells vs total peripheral CD8+ T cells. PBS was used as control treatment. The 
OVA-specific CD8+ T cells with positive PE-tetramer and FITC-CD8 staining were gated, and assessed for 
expression of inhibitory molecules (solid lines). Dotted lines represent isotype-matched controls. (B) Total numbers 
of PE-tetramer+/FITC-CD8+ T cells in spleens and lungs of immunized mice were measured by flow cytometry. (C) 
Percentage of IFN-γ producing cells in PE-tetramer+/FITC-CD8+ T cell population was analyzed. (D) In vivo 
cytotoxicity assay was performed in OVA-Texo-treated mice with AdVova-induced chronic infection as described 
in figure 1D. The value in each panel represents the percentage of CFSEhigh vs CFSElow target cells remaining in the 
spleen. *p < 0.05, **P < 0.01. Error bars represent SD. One representative experiment of two is shown. 
 
5.4.5 OVA-Texo-induced conversion of CTL exhaustion is triggered through the 
CD40L-induced activation of the PI3K/Akt/mTORC1 pathway: 
 
Since CD40L signaling of OVA-Texo vaccine was found to be important for the counteraction of 
CD8+ T cell tolerance, we examined whether CD40L plays any role in the conversion of CTL 
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exhaustion by the OVA-Texo vaccine. Chronically AdVova-infected B6 mice with CTL 
exhaustion were immunized with the OVA-Texo(CD40L-/-) vaccine, lacking CD40L signaling. 
Interestingly, CD40L deficiency alone caused a significant decrease in its activity to enhance T 
cell proliferation (Fig 5.4A), indicating that OVA-Texo-induced conversion of CTL exhaustion 
occurs  mainly via its CD40L signaling. In addition, there was also no increase in OVA-specific 
CTLs in spleens and lungs in OVA-Texo(CD40L-/-)-stimulated mice with chronic infection (Fig 
5.4B). It has been shown that CD40L signaling assures T cell activation via the 
PI3K/Akt/mTORC1 pathway [47]. To assess whether OVA-Texo vaccine activates the 
PI3K/Akt/mTORC1 pathway, we analyzed CTLs by flow cytometry for the phosphorylation 
status and intracellular expression of a panel of molecules associated with the 
PI3K/Akt/mTORC1 pathway, including Akt, mTORC1-regulated S6, elF4E and T-bet. We 
determined that OVA-specific CTLs up-regulated levels of pAkt, pS6, pelF4E and T-bet as well 
as T cell proliferation marker Ki67 in B6 mice with the AdVova-induced chronic infection 
following the OVA-Texo vaccination (Fig 5.4C). This indicates that the OVA-Texo vaccine 
stimulates proliferation of exhausted CTLs at least in part by activating the PI3K/Akt/mTORC1 
pathway. In addition, we also measured expression of diacetylated histone H3 (diAcH3) 
molecule, which is a useful marker for memory T cell activation and functionality [48]. These 
experiments revealed that OVA-specific CTLs up-regulated expression of diAcH3 after the 
OVA-Texo vaccination (Fig 5.4C). 
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Figure 5.4 OVA-Texo vaccine converts T cell exhaustion via CD40L signaling. 
(A) AdVova-infected C57BL/6 mice were immunized with OVA-Texo or OVA-Texo with CD40L deficiency 60 
days after primary infection. Prior to 4 days post-immunization, periphery blood samples were analyzed for 
OVA-specific CTL responses by flow cytometry. The value in each panel represents the percentage of 
PE-tetramer-positive CD8+ T cells vs the total peripheral CD8+ T cell population. (B) Total number of 
PE-tetramer+/FITC-CD8+ T cells in spleens and lungs following OVA-Texo or OVA-Texo(CD40L-/-) immunization. 
(C) Four days after immunization, mouse splenocytes were triply stained with PE-tetramer, PE/Cy5-CD8, and 
FITC-labeled Abs, and analyzed by flow cytometry. The OVA-specific CD8+ T cells with positive PE-tetramer and 
PE/Cy5-CD8 staining were gated, and assessed for the presence of various markers (solid lines). Dotted lines 
represent isotype-matched controls. *p < 0.05, **P < 0.01. Error bars represent SD. One representative experiment 
of two to three is shown. 
 
5.4.6 OVA-Texo vaccine and PD-L1 blockade synergistically converts CTL exhaustion: 
 
To assess a potential synergistic effect of the OVA-Texo vaccine on the PD-L1 blockade, we 
initially measured OVA-specific CTL proliferation in mice with chronic infection treated 
anti-PD-L1 antibody (Fig 5.5A), and then, assessed OVA-specific CTL proliferation in mice 
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with anti-PD-L1 antibody treatment followed by the OVA-Texo vaccination (Fig 5.5B). In this 
experiment, OVA-specific CTLs slightly and gradually proliferated with each individual 
treatment, and OVA-specific CTL population increased nearly 2.5-fold after the fifth treatment 
(Fig 5.5A).  Remarkably, a dual (both anti-PD-L1 antibody and OVA-Texo vaccine) treatment 
resulted in almost 6-fold CTL increase, compared to the untreated exhausted CTLs (1.90%) in 
the chronic infection model (Fig 5.5B). To assess whether CTLs were functional, we measured 
intracellular production of IFN-γ by flow cytometry. This showed that around 50% of CTLs in 
mice with the PDL-1 blockade and nearly 90% of CTLs in mice with the dual treatment 
expressed the IFN-γ effector cytokine, indicating a synergistic effect of the PD-L1 blockade and 
the OVA-Texo vaccine in converting CTL exhaustion.  
	   163	  
 
Figure 5.5 OVA-Texo vaccine synergizes with the PD-L1 blockade. 
(A) AdVova-infected C57BL/6 mice were treated with anti-PD-L1 Ab five times in total at three day intervals. (B) 
OVA-Texo was administrated one day subsequent to the last anti-PD-L1 Ab treatment. Peripheral blood samples 
were collected at the indicated days, stained with the PE-tetramer and FITC-CD8, and then analyzed by flow 
cytometry. The value in each panel represents the percentage of PE-tetramer-positive CD8+ T cells vs total 
peripheral CD8+ T cells. (C) Percentage of IFN-γ producing cells in PE-tetramer+ and FITC-CD8+ T cell population 
was analyzed in each treatment group. *p < 0.05, **P < 0.01. Error bars represent  SD. One representative 
experiment of two is shown. 
 
5.4.7 Gag-Texo vaccine induces Gag-specific therapeutic immunity in chronic infection 
model: 
 
To assess the preventive immunity, chronically AdVova-infected B6 mice were immunized with 
Gag-Texo and DCGag vaccines, respectively, and six days after immunization, the mice were 
challenged with Gag-expressing BL6-10Gag melanoma cells. Our analysis showed that the 
Gag-Texo, but not the DCGag vaccine completely protected all challenged mice from tumor 
growth even in the presence of chronic infection (Fig 5.6A).  To assess a potential therapeutic 
immunity in this model, mice with chronic infection were initially inoculated with 
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Gag-expressing BL6-10Gag melanoma cells, and six days later, were immunized with the 
Gag-Texo or the DCGag vaccine. Excitingly, we observed significantly less BL6-10Gag lung tumor 
colonies in mice immunized with Gag-Texo than in experimental animals immunized with DCGag 
(Fig 5.6B), indicating that our Gag-Texo vaccine is capable of inducing some degree of 
therapeutic immunity against established tumors even in the presence of chronic infection.  
 
Figure 5.6 Gag-Texo vaccine induces protective, and therapeutic antitumor immunity in chronically infected 
mice. 
AdVova-infected mice were i.v. injected with BL6-10Gag cells at day 6 post Gag-Texo or DCGag immunization (A), 
or 6 days prior to immunization (B). The mice were sacrificed 3 weeks after tumor cell challenge, and 
lung-metastatic tumor colonies were counted in lungs. *p < 0.05, **P < 0.01. Error bars represent SD. One 
representative experiment of two is shown. 
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5.5 Discussion 	  
Vaccines based on the recombinant human E1/E3-depleted adenovirus (AdV)-5 vector are well 
characterized and proved to be effective in inducing CD8+ CTL responses due to their strong 
immunogenicity [49]. Adenoviral vectors which are easy to manipulate infect different types of 
cells, and their safety is well defined since vector genome does not integrate into cellular DNA 
[50]. However, transgene expression could persist in a host at low levels for a long time post 
AdV infection [35, 37]. Depending upon a nature of a transgene (Gag, LacZ and Luc) used, the 
dose of vector, the route of immunization, and the persistency of transgene expression, 
distinctive memory CTL responses ranging from effective CTL immunity to CTL exhaustion or 
depletion were reported [35-41]. Chicken ovalbumin (OVA)-expressing adenoviral vector 
(AdVova) has been assessed for AdVova-stimulated OVA-specific CTL trafficking in vivo, but 
not for CTL’s phenotype and functional effect [39]. Exhausting CTLs, resulting from excessive 
or persistent Ag stimulation, often poses a significant barrier to the immune responses and 
managing chronic infection [51]. For example, in the exhausted state of LCMV-infected mice, 
LCMV-specific CTLs become subject to multiple inhibitory signals, such as PD-1, LAG-3, 
CD160 and 2B4, and lose their functional effectiveness in a stepwise fashion [8, 52]. In this 
study, we i.v. immunized C57BL/6 mice with our OVA-expressing AdVova, and phenotypically 
and functionally characterized OVA-specific CTLs 60 days following immunization. In line with 
previous reports, we observed inflated memory CTLs with defects in proliferation, IFN-γ 
expression and cytotoxicity in the presence of AdVova-induced chronic infection, indicating that 
these OVA-specific mCTLs are functionally exhausted. In addition, these exhausted mCTLs 
up-regulated expression of inhibitory PD-1, PD-L1 and LAG-3. Therefore, our data implicate 
that AdVova-immunized mice represent an OVA-specific mouse model of chronic infection.   
 
A chronic infection with persisting pathogens can impair immune responses to unrelated 
pathogens and vaccines, and a dysfunctional immunity (a bystander immunity in chronic 
infection) might be responsible for increased susceptibility to various coinfections [42]. However, 
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our current understanding of the bystander chronic infection is mainly based upon 
epidermiological evidence with limited insights into molecular mechanisms. DC defects in 
maturation, cytokine production and antigen-presentation have been reported in chronic infection 
models [53-55]. Defects in T cell proliferation have also been demonstrated in both animal 
models and humans with chronic infection [56-58]. However, it is not clear whether T cell 
proliferation defect is intrinsic to T cells themselves or is derived from the functional deficiency 
of DCs.  The inhibitory PD-1 molecule was previously found on naive CD4+ T cells in chronic 
HCV infection [58], whereas up-regulation of inhibitory PD-L1 was originally observed on 
splenocytes of chronically LCMV-infected mice [32]. Later, reports confirmed that PD-L1 
expression was high in spleen tissues, especially on spleen CD11b+F4/80+ macrophages and 
B220+CD19+ B cells, but low in bone marrows [59]. In our work, we demonstrate that naïve 
CD8+ T lymphocytes up-regulate expression of inhibitory PD-L1 and immunoglobulin-like 
co-inhibitory receptor BTLA [60], and overexpress T cell anergy-associated genes Grail and Itch 
[61], indicating that they may become anergic in the presence of chronic infection. Anergy of 
naïve CD8 T cells in our chronic infection model is further confirmed by showing that these 
naïve CD8+ T cells have some degree of proliferation defect both in in vitro and in vivo.  
Interestingly, our OVA-Texo, but not DCova vaccine is capable of counteracting T cell 
anergy/tolerance associated with chronic infection. It has been demonstrated that IL-2, IL-6, 
TNF-α as well as CD40L counteract T cell anergy and tolerance [45]. To assess a potential 
molecular mechanism of counteraction of T cell tolerance by OVA-Texoe, we prepared a panel 
of OVA-Texo vaccines, OVA-Texo(IL-2-/-), OVA-Texo(IL-6-/-), OVA-Texo(TNF-α-/-) and 
OVA-Texo(CD40L-/-), deficient in IL-2 or IL-6 or TNF-α or CD40L, and  compared 
OVA-specific CTL responses in mice with chronic infection vaccinated with these preparations. 
We demonstrate here, that the deficiency in CD40L alone, but not in other signaling components 
of the OVA-Texo vaccine almost completely abolishes its stimulatory effect on CTL responses 
in our model of chronic infection, indicating that CD40L signaling plays a central role in 
counteracting CD8+ T cell anergy/tolerance induced by chronic infection conditions.   
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A member in the CD28 superfamily, PD-1 is a negative regulator of activated T cells [62, 63]. It 
is markedly up-regulated on the surface of exhausted CTLs in mice with chronic viral infection 
[64]. Blocking the PD-L1-PD-1 pathway in vivo by using anti-PD-L1 antibody converts CTL 
exhaustion, increases virus-specific CTL responses and decreases the viral load [32]. Apart from 
cytokine milieu, one of the most critical factors regulating CTL responses is the balance between 
positive and negative co-stimulations [63]. While the PD-1 negative co-stimulatory molecule is 
over-expressed on exhausted CTLs, the positive co-stimulatory proteins, members of the TNF-α 
receptor (TNFR) superfamily, including OX40, 4-1BB and CD27, have been demonstrated to 
suppress CTL exhaustion [65-67]. In this study, we demonstrate that during chronic infection, 
exhausted CTLs express CD40, and the OVA-Texo vaccine is capable of converting CTL 
exhaustion by enhancing their proliferation, cytokine production and cytolytic responses.  In 
addition, we also measured expression of a conventional marker of memory T cell activation and 
functionality, diacetylated histone H3 (diAcH3) [48]. Interestingly, the OVA-specific CTLs 
appeared to up-regulate expression of diAcH3 in response to the OVA-Texo vaccination, thus 
confirming that OVA-Texo efficiently stimulates exhausted CTLs leading to not only the cell 
proliferation but also the resume of cell functionality.  
 
To assess a potential role of CD40L-initiated signaling in OVA-Texo-induced conversion of 
CTL exhaustion, we have immunized mice with chronic infection with the OVA-Texo(CD40L-/-) 
lacking CD40L expressiong, and we demonstrate that CD40L absence strongly decreases its  
stimulatory effect on CTL proliferation, indicating that CD40L signaling by the OVA-Texo 
vaccine also plays a critical role in converting CTL exhaustion. CD40L signaling has been 
reported to play an important role in suppressing CTL exhaustion via the up-regulation of T-bet 
and IL-21 and the down-regulation of PD-1 [68-70]. However, our study is the first report 
demonstrating that CD40L signaling by the OVA-Texo vaccine is directly involved in converting 
CTL exhaustion in chronic infection. It has been shown that CD40L stimulates T cell activation 
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by inducing recruitment of the adaptor proteins known TRAF, leading to the activation of the 
PI3K/Akt/mTORC1 pathway [47]. To assess whether the OVA-Texo vaccine activates the 
PI3K/Akt/mTORC1 pathway, we analyzed CTLs for the intracellular expression of molecules 
associated with this signaling cascade. Our experiments demonstrate that after immunization of 
chronically infected mice with the OVA-Texo vaccine, the OVA-specific CTLs up-regulate 
expression or phosphorylation status of pI3K, mTORC1-regulated pS6, pelF4E and T-bet that 
controls T cell activation, and of a protein associated with cell cycle progression, Ki67, 
indicating that the conversion of CTL exhaustion by the OVA-Texo vaccine may occur via the 
activation of the PI3K/Akt/mTORC1 pathway.  
 
LAG-3 is known to negatively regulate T cell activation and proliferation [71-73]. The blockade 
of LAG-3 by its antagonistic antibody suppressed CTL exhaustion, and the dual blockade of 
PD-1 and LAG-3 resulted in a synergistic effect on conversion of CTL exhaustion in chronic 
infection [8].  In addition, the dual blockade of PD-L1 and TNFR superfamily members also 
exerts similar synergistic effect [65, 67]. Interesting, our data show that the OVA-Texo vaccine 
also synergizes with the PD-L1 blockade in converting CTL exhaustion, indicating that 
mechanisms derived from the OVA-Texo vaccine and PD-L1 blockade most likely impart 
distinct regulatory effects on exhausted CTLs. The exhausted CTLs expressed both PD-1 and 
LAG-3 in the AdVova-induced chronic infection. We, therefore, speculate that a triple therapy 
using the OVA-Texo vaccine and a dual blockade of PD-1 and LAG-3 with anti-PD-L1 and 
anti-LAG-3 antibodies may assure even more efficient conversion of CTL exhaustion than the 
dual blockade of PD-1 and LAG-3. 
 
Taken together, our data demonstrate that our novel exosome-targeted T cell-based vaccine is 
capable of counteracting CD8+ T cell anergy/tolerance and converting CTL exhaustion by 
inducing CD40L-triggered signaling through the mTORC1 pathway, thus efficiently inducing 
therapeutic immunity in the presence of chronic infection. Therefore, this study is likely to 
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produce a strong impact on the development of new therapeutic vaccines against HIV-1 and 
other chronic infectious diseases. 
 
 
 
Figure s5.1 AdVova injection resulted in a dose-dependent OVA-specific memory CD8+ T cell response. 
Periphery blood samples harvested at Day 60 after i.v. injection of C57BL/6 mice with different dose of AdVova  
were stained with the PE-H-2Kb/OVAI peptide tetramer (PE-tetramer) and FITC-anti-CD8 Ab (FITC-CD8), and 
analyzed by flow cytometry. 
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CHAPTER 6  GENERAL DISCUSSION AND CONCLUSIONS 
 
Combined antiretroviral therapy (cART) dramatically improves HIV-1 patient lifespan and life 
quality. It has also been confirmed that ART significantly reduces the risk of viral transmission 
due to the considerably low level of HIV copies in the blood and genital fluid. This is termed 
“treatment as prevention”[1, 2]. Despite all the remarkable success of ART, it is not the means to 
the end. Without eradicating the infection, strict adherence to lifetime treatment is required. In 
addition, the persistent inflammation and drug toxicity are associated with progressive immune 
dysregulation and impaired B and T cell restoration. This results in higher risk of many 
non-AIDS related diseases such as neurocognitive abnormalities, bone disorders, cardiovascular 
disease and so on[3]. Facing the reality of approximately 35 million people infected with HIV-1 
worldwide, the need for finding a cure is greater now than even before.  
 
No “sterilizing cure” has been discovered yet with antiretroviral drugs. Development of a 
universal prophylactic vaccine seems to be extremely unlikely at this time. The RV144 Thai trial, 
using a heterologous prime/boost protocol with a canarypox vector encoding HIV-1 Gag, Pol, 
Gp120, followed by boosting with Gp120 protein from clade B and C is so far the only HIV-1 
vaccine efficacy trial in which some level of protection (31%) from acquisition of infection was 
achieved[4].  
  
“Functional cures” are most likely to be achieved by incorporating therapeutic strategies to 
restore HIV-1-specific CTL responses and restrain viral replication. This has been the focus of 
numerous research endeavors in recent years. Elite controllers, who are HIV-1 seropositive, but 
able to maintain HIV-1 RNA level under the detect limit without ART treatment, represent a 
natural functional cure model of HIV-1 infection[5]. Many studies have been focused on probing 
into unique host factors that contribute to viral control. Two protective MHC class I molecule 
alleles HLA-B27 and 57 are found to be highly overrepresented among elite controllers[6-8]. Of 
note, the superior HIV-1 CD8+ T cell responses mediated by these MHC I alleles are restricted to 
immunodominant conserved HIV-1 Gag epitopes[9, 10]. Viral mutations mapping to conserved 
regions are associated with a major fitness cost. Therefore, in the rapid expanding field of 
therapeutic vaccines, finding relevant epitopes with superior immunogenicity is of equal 
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importance as finding an effective therapeutic vaccine strategy.  
 
Early studies employed classic approaches, including whole inactivated virus[11] and 
recombinant protein subunits[12]. These exhibited limited capacity in evoking HIV-specific T 
cell responses and reducing viral load. More innovational approaches such as recombinant viral 
vectors and DC-based therapeutic vaccines have had more promising results[13, 14]. Although 
the stimulation of viral related immune response was observed, their impacts over viral 
replication were weak and inconsistent, necessitating the exploration of alterative novel vaccine 
strategies.  
 
Immature DCs residing at the mucosal surfaces are one of the earliest immune cells to meet 
invading HIV-1 viruses. The initial encounter could either serve as an effective priming of 
HIV-specific T cell responses, or on the contrary, facilitating the viral dissemination to CD4+ T 
cells, especially HIV-specific ones[15]. Furthermore, impaired DC function is largely associated 
with chronic HIV infections[16, 17]. Most DC vaccines adopt in vitro generation methods to 
avoid these issues – loading autologous DCs with various forms of HIV-related antigens. 
However, immune-suppressive factors released by HIV chronic infection can still compromise 
the fitness and immunogenicity of in vitro generated DCs, resulting in suppression, deletion, and 
failure in stimulating an ideal immune response. One intriguing alternative approach is to use 
DC-derived exosomes. As inner vesicles, exosomes are much more resistant to surrounding 
milieu. Hence, in the present work, autologous bone marrow DCs from C57BL/6 mice were 
culture and stimulated to become mature DCs in vitro and then pulsed by OVA protein, or 
infected with recombinant adenovirus vector encoding HIV-1 Gag. These two methods are well 
documented to be effective and well-tolerated in loading DCs with desired antigens[18-21]. Next, 
exosomes derived from those antigen-loaded DCs carrying pMHC I and II, costimulatory 
molecules and adhesion molecules were purified from culture supernatants. Non-specific 
polyclonal CD8+ T cells capturing exosomes via ICAM-1 and LFA-1 interaction, display DC 
originated antigen-presenting machinery, and become the exosome-targeted activated CD8+ T 
cell (aTexo) vaccine.  
 
Our work in Chapters 2 and 3 demonstrated that: (1) Non-specific active CD8+ T cells are able to 
	   178	  
uptake DC-derived exosomes carrying DC molecules and exogenous antigens. (2) OVA-Texo 
and Gag-Texo vaccines stimulate in vitro antigen-specific CD8+ T cell proliferation. (3) They are 
competent at inducing in vivo DC and CD4+ T cell independent, functional antigen-specific 
CD8+ T cell responses. (4) These vaccines efficiently promote CD8+ T cell differentiation into 
functional CTL effectors. (5) They induce CD8+ CTL-mediated antitumor immunity and 
long-term T cell memory in wild-type C57BL/6 and transgenic HLA-A2 mice. Those 
encouraging results provide early evidence of this novel T cell-based vaccine in stimulating HIV 
Gag-specific CTL responses and inducing some degree of therapeutic immunity against tumor 
cells bearing the Gag immunogen. Moreover, the desirable feature of priming CTL responses in 
the absence of assistance from DC and CD4+ Th cells make the CD8+ Gag-Texo vaccine an 
appealing immunotherapeutic strategy.   
 
In Chapter 4, experiments were performed to elucidate if 4-1BBL overexpression could improve 
the outcome of the CD8+ Texo vaccine. Many groups have reported positive adjuvant effect of 
costimulatory molecule 4-1BBL in HIV-specific T cell responses. 4-1BBL enhanced 
Gag-specific cellular immune responses of a HIV-1 Gag DNA vaccine[22]. A recombinant 
replication-defective adenovirus expressing 4-1BBL converted autologous monocytes into 
efficient APCs, and led to an expansion of antigen-specific CD8+ effector cells, elevating 
effector cytokine generation in both acute and chronic viral infections[23]. Co-expression of 
4-1BBL with a recombinant fowlpox virus vector expressing HIV Gag significantly boosted 
Gag-specific CD8+ T cell memory responses[24]. Loading of mRNA encoding 4-1BBL in 
addition to HIV antigen to HIV-1 infected patient derived DCs reinforced HIV-specific CD8+ T 
cell responses by promoting proliferation, effector functions, survival, and resistance to 
Treg-mediated immune suppression[25]. In line with those studies, our work in Chapter 4 
illustrated: (1) OVA-Texo/4-1BBL vaccine induces enhanced in vivo OVA-specific effector CD8+ 
CTL response. (2) OVA-Texo/4-1BBL vaccine stimulates efficient protective and therapeutic 
immunity against OVA-expressing tumor cells in C57BL/6 mice. (3) OVA-Texo/4-1BBL vaccine 
is capable of inducing CD44+62LhighIL-7R+ central memory CTLs formation. (4) 
OVA-Texo/4-1BBL vaccine evokes functional CD8+ memory CTLs and long-term antitumor 
immunity. (5) OVA-Texo/4-1BBL vaccine improves CTLs survival via regulating apoptosis 
pathway. (6) Gag-Texo/4-1BBL vaccine exhibits improved therapeutic and long-term antitumor 
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immunity in transgenic HLA-A2 mice. These improvements mediated by 4-1BBL are 
particularly meaningful for the Gag-Texo/4-1BBL vaccine, in consideration of the profoundly 
impaired expression of CD28 on defective T cells during HIV-1 infection. 4-1BBL may serve as 
a compensative costimulation signal pathway. Additionally, it has been proposed that strong 
CD8+ T cell responses are critical for control and eradication of HIV infection[26]. Furthermore, 
4-1BBL can efficiently promote the generation of more mature CD27- effectors and induce 
effector T cell expansion. This is of great importance as HIV-specific effector T cells are usually 
difficult to mature with down-regulated perforin expression[27, 28]. 
 
During chronic infection with HIV-1, HIV-1-specific CD8+ T cells show progressive impairment 
of effector functions[29]. Recent studies showed that 4-1BBL could increase HIV-1-specific T 
cells expansion with restored functions in chronically HIV-infected subjects[30]. Current work in 
Chapter 5 shows that: (1) adenovirus is able to induce a long lasting chronic infection with high 
percentage of antigen-specific CTL persistency. (2) Those CTLs expressing a variety of 
up-regulated inhibitory molecules are functionally exhausted with impaired proliferation, 
cytotoxic effect, effector cytokine production as well as defective memory response. (3) Naïve T 
cells exhibit increased inhibitory markers and compromised proliferation. (4) OVA-Texo vaccine 
is able to stimulate antigen specific primary and memory recall CTL responses, inducing CTL 
proliferation during bystander chronic infection. (5) OVA-Texo vaccine is able to convert 
exhausted OVA-specific CD8+ T cells during chronic infection, reversing CTL dysfunction. (6) 
Blockage of inhibitory PD-1-PD-L1 pathways is a novel “non-specific” therapeutic approach 
that has shown encouraging results[31, 32]. In this study, a dual treatment combining 
OVA-Texo/4-1BBL vaccine with PD-L1 blockage resulted in a synergistic effect – rescuing CTLs 
exhaustion in chronic infection. (7) Gag-Texo vaccine could stimulate effective antitumor 
immunity in chronic infected transgenic HLA-A2 mice. A number of molecular mechanism 
studies are conducted in this part as well – via the usage of T cells derived from gene knockout 
mouse, and detection of expression level changes of molecules in certain pathways. Those 
molecular mechanisms provide some valuable insight into understanding our novel T cell-based 
vaccine. It highlights key molecules that are indispensable, and offer ideas regarding how we can 
further engineer or manipulate the vaccine for desired outcomes.    
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The two primary goals of a therapeutic vaccine is to provoke de novo HIV-specific CD8+ T cell 
responses from naïve T cells, as well as restore functionality of existing HIV-specific CD8+ T 
cells - ideally suppressing viral replication to below the detection level, and thus delay or 
minimize ART providing “drug holidays”.  Despite all the exciting and inspiring results 
achieved so far, there is still a long way ahead on optimizing the exosome-target activated CD8+ 
T cell aTexo vaccine before it is at our disposal as an effective “cellular adjuvant”. 
 
It is a consensus that the selection of relevant epitopes plays a critical part in vaccine design. We 
have constructed adenovirus vector expressing Gp120 and/or Tat in addition to Gag. HIV Tat 
protein as a key HIV virulence factor has been proposed as an ideal candidate to target. It is 
referred as “pathogenic-driven” intervention since Tat promotes the spreading of HIV to DCs 
and T cells. Recent evidence also indicates that Tat protein displays immunomodulatory 
activities which can be exploited for the development of combined subunit vaccines[33-35]. 
More importantly, Tat protein can enhance T cell responses against cryptic OVA epitopes and 
broaden T cell responses to HIV-1 envelope proteins (Gag and Env)[36]. This is possibly due to 
the cationic region of Tat being capable of increasing Env and Gag epitope expression on DCs 
with uptake of DNA plasmids expressing Env and Gag[37]. In addition, Tat vaccine strategies 
have also proven to be safe and immunogenic in mice, in non-human primates, and in humans. In 
addition, they have been shown to be effective in protecting from pathogenic challenge in 
monkeys[38-43]. It will be interesting to assess if Gp120 and/or Tat incorporation would 
enhance the magnitude and breadth of HIV-specific immunity in the future.  	  
Lymphocytic choriomeningitis virus (LCMV) induced chronic infection in adult mice is a 
well-characterized model system[44, 45]. Abundant studies on altered immune responses and the 
underlying molecular mechanisms have been conducted in LCMV persistent infection 
established by Clone 13 strain[46-48]. To further explore the potential converting of exhausted 
CTLs by this novel T cell-based vaccine, we constructed LCMV glycoprotein (gp) 33- specific 
GP-Texo. Influence on effector functions of CTLs and viral control post our therapeutic 
GP-Texo vaccine will be evaluated in a LCMV chronic infection.  
 
Although Clone 13 of LCMV represents an ideal mouse model that largely recapitulates T cell 
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dysfunction and immune tolerance seen in human persistent viral infection, more direct and 
convicting studies are achieving through Simian immunodeficiency viruses (SIVs) infected 
non-human primates. Strong evidence suggest HIV-1, HIV-2 evolved from chimpanzees 
infecting SIVcpz and sooty mangabeys infecting SIVsmm via cross-species infections[49, 50]. 
SIV-infected Chinese rhesus macaques develop simian AIDS[51], which is remarkably similar to 
HIV-1 infection in human. Viral load and severity of infection after SIVmac239 challenge in 
Chinese rhesus macaques were closer to that observed in untreated human HIV-1 infection, 
serving as a more suitable AIDS model[52]. Thus, it is considered as one of the most valuable 
animal models for HIV research over the last two decades[53, 54]. One prophylactic vaccine 
study in rhesus monkeys showed large protection against SIVMAC251 infection using SIVSME543 
Gag, Pol and Env antigens expressing, adenovirus/poxvirus vector-based vaccines[55]. In 
another report, SIV protein-expressing rhesus cytomegalovirus vectors (RhCMV) vaccine 
elicited SIV-specific effector memory T-cell responses, 50% of rhesus macaques exhibited 
durable viral control after a highly pathogenic strain SIVmac239 infection[56]. There is no doubt 
that performance and mechanism evaluation of SIV Gag-specific Gag-Texo vaccine in Chinese 
rhesus macaques will provide more integrated, insightful knowledge of exosome-target CD8+ T 
cell-based Texo vaccine. 	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